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Abstract 
 
Transglutaminase 2 (TGase 2) is a multifunctional calcium dependent enzyme that 
catalyzes protein modifications. TGase 2 is essential in neuronal cell differentiation and it 
has been reported that certain organophosphates are able to inhibit this process, and the 
organophosphate phenyl saligenin compound also disrupts TGase 2 activity. It has also 
been shown that the organophosphates chlorpyrifos (CPF) and chlorpyrifos oxon (CPFO), 
which cause developmental neurotoxicity, provoke several changes in differentiating rat 
C6 glioma cells at different levels. The aims of this thesis were to analyse the effects of 
CPF and CPFO on the TGases present in differentiating rat C6 glioma cells, to develop a 
new method for the purification of TGase 2 from guinea pig liver, to study possible direct 
interactions between TGase 2 and esterase inhibitors and to analyze a possible pathway 
for the externalisation of TGase 2. 
In the presence of sodium butyrate, rat C6 glial cells differentiated into an astrocyte 
phenotype. Differentiation of the cells was associated with an increase in the activity, 
protein levels and gene expression of TGase 2. Differentiation in the presence of CPF or 
CPFO generated an increase in the activity of TGase 2, a decrease in its levels of gene 
expression but had no effect on the protein levels. These effects could be associated with a 
direct interaction between the organophosphates and TGase 2. 
Chromatographic methods were developed to purify TGase 2 from guinea pig liver and 
the most effective one was a combination of ion exchange chromatography, protamine 
sulfate precipitation and hydrophobic interaction chromatography (HIC). The level of 
purity and yield obtained were superior to that of previously published methods. 
Furthermore, the final step of HIC could be applied directly to commercially available 
TGase 2 for the production of a highly purified TGase 2 sample.  
When TGase 2 purified in this manner was assayed in the presence of CPF and CPFO, 
enzyme activity was observed to increase significantly, suggesting a direct interaction 
with TGase 2. By contrast, phenyl saligenin phosphate was found to inhibit TGase activity 
in vitro, which suggests a direct effect that may involve a different binding site and/or 
mechanism to CPF or CPFO. The aspartyl protease inhibitor pepstatin A was also able to 
inhibit directly TGase activity in vitro. 
The final part of the project involved a short study of the potential association of TGase 2 
with exosomes, in order to determine whether the latter might present a means of 
externalization of this enzyme. Exosomes purified from mouse N2a neuroblastoma cells 
were found to contain TGase 2, but its localization within the vesicles remains unclear.  
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1. INTRODUCTION 
1.1. Transglutaminases 
In 1957 a Ca
2+
 dependent protein, which catalysed the incorporation of amines into 
proteins was described in guinea pig liver, kidney and brain by Heinrich Waelsch 
and his colleagues (Sarkar et al., 1957). They also considered that the amine 
incorporation process had a biological significance due to the metabolism of amines 
and the possible modification of proteins. Additional studies showed an increase in 
the liberation of ammonia in the presence of Ca
2+
 during amine incorporation (Clarke 
et al., 1957). In 1959, Waelsch and his group defined this protein as transglutaminase 
(TGase, protein-glutamine gamma-glutamyltransferase, polyamine transglutaminase, 
glutaminylpeptide gamma-glutamyltransferase, EC 2.3.2.13) and described the amine 
incorporation through a possible transamidation reaction, where the amide group of 
the protein was replaced by an amine, involving the release of ammonia (Clarke et 
al., 1959). Later in 1965, Folk and Cole corroborated the idea of the transamidation 
reaction (Folk and Cole, 1965). Waelsch‟s group also demonstrated the possibility 
that the Ca
2+
 dependent protein could play an important role in the cross-linking of 
proteins (Neidle et al., 1958). Later studies on the polymerisation of human fibrin 
catalysed by factor XIIIa during blood clotting showed that the protein cross-link 
involves an ε-(γ-glutamyl)lysine bond (Pisano et al., 1968). The covalent cross-
linking reaction is described in Figure 1.1. 
    
 
      ε-(γ-glutamyl)lysine bond 
 
Figure 1. 1: Cross-link interaction through an acyl-transfer reaction 
ε-(γ-glutamyl)lysine bond between γ -carboxamide group of peptide-bound 
glutamine and the ε -amino group of peptide-bound lysine. 
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Since the introduction of the term transglutaminase, its presence has been 
demonstrated in several organisms including micro-organisms such as 
Streptoverticillium S-8112 and bacillus subtilis in which the enzyme molecular 
weight is around 30 - 40 kDa (Ando et al., 1989, Nonaka et al., 1989; Zilhao et al., 
2005); plants, as it has been found in pea seeds (Icekson and Apelbaum, 1987) and in 
different plant sub-cellular compartments (Serafini-Fracassini and Del Duca, 2008), 
arthropods (Chen et al., 2005) and strongly suggested in nematodes (Singh & Mehta, 
1994), amphibia (Zhang & Masui, 1997), fish (Yasueda et al., 1994), birds (Puszkin 
& Raghuraman, 1985) and mammals (Sarkar et al., 1957). In most organisms, 
TGases are intracellular enzymes with Ca
2+
 dependent activity, but the microbial 
TGases are extracellular and Ca
2+
 independent (Taguchi et al., 2002). TGase 
functions are related with tissue stabilization and with the prevention and protection 
of bodily injury, but they are inappropriately activated in some pathologies (Kim et 
al., 2002). The main studies have been carried out on mammalian TGases, which are 
present in several tissues and in distinct forms (Griffin et al., 2002). 
1.2. Reactions catalysed by TGases 
TGases are involved in post-translational protein modifications through acyl-transfer 
reactions, where the peptide-bound glutamine residue act as an acyl donor and either 
a peptide-bound lysine residue or a low-molecular mass amine act as an acceptor, 
forming protease resistant isopeptide bonds (Griffin et al., 2002). The most common 
post-translational modification is the formation of isopeptide links between the γ-
carboxamide group of the peptide-bound glutamine residue and the ε-amino group of 
the peptide-bound lysine residue, generating cross-linked protein aggregates 
(Aeschlimann and Paulson, 1994).  
The enzyme reaction involves „ping-pong‟ kinetics as described by Folk for guinea 
pig liver transglutaminase (Folk, 1969). Later studies with plasma transglutaminase 
corroborated the idea of the „ping-pong‟ enzymatic mechanism (Chung and Folk, 
1972). 
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A. Thioester formation 
                        
         
B. Protein cross-link  
 
   
 
C. Polyamine incorporation  
 
                  
 
D. Deamidation                       
 
                                
 
Figure 1. 2: Reactions catalysed by transglutaminases 
A; first step of the reaction is the thioester formation, B; acyl transfer to a ε-amino 
group of a protein-bound lysine, C; acyl transfer to a polyamine, D; deamidation of 
the protein-bound glutamine. Adapted from Esposito and Caputo (2005).
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The rate-limiting step in the reaction is the binding of the enzyme to the protein-
bound glutamine (Esposito and Caputo, 2005). In this step, the active site of the 
TGase performs a nucleophilic attack directed to the γ-carboxamide group of the 
peptide-bound glutamine, forming a thioester intermediate molecule and releasing 
ammonia (Cleary & Maurer, 2006; Figure 1. 2A).  
In the protein cross-linking reaction (Figure 1. 2B) a second nucleophilic substrate, 
which usually is the ε-amino group of the peptide-bound lysine residue, attacks the 
thioester intermediate forming an isopeptide ε-(γ-glutamyl)lysine bond. In the last 
step, the active site of the TGase is restored and the enzyme is released (Folk, 1983). 
The cross-linked protein products generated are insoluble, rigid and very resistant to 
cleavage by proteolytic attack (Folk and Finlayson, 1977). 
Amines, diamines or polyamines can also perform a nucleophilic attack to the 
thioester intermediate resulting in an amine incorporation reaction (Figure 1. 2C) 
forming a N-mono(γ-glutamyl)(mono/di/poly)amine bond (Folk et al., 1980). After 
the amine incorporation, if a second reactive glutamine residue is present, the 
reaction can continue to form a secondary covalent cross-link between two different 
polypeptides forming a N,N-bis(γ-glutamyl)polyamine bond (Folk & Finlayson, 
1977). In the absence of a suitable amine, water can act as an acyl acceptor 
performing a deamidation (Figure 1. 2D) of the protein-bound glutamine residues to 
glutamate residues (Folk & Finlayson, 1977). The protein cross-linking and the 
polyamine incorporation have been shown to be relevant in vivo, playing important 
roles in physiological functions, enabling TGases to act as a „biological glue‟ (Kim et 
al., 2002). 
1.3. Structure and activity regulation of transglutaminase  
At the genetic level all of the TGases show high sequence homology, particularly in 
the sequences near the active site (Esposito and Caputo, 2005). All TGase isoforms 
have a very conserved four domain structure (Lorand and Graham, 2003), consisting 
of N-terminal β-sandwich, catalytic core and two C-terminal β-barrel domains 
(Figure 1. 3A). TGase 2 structure is the most studied and is further explained in 
section 1.6.2.  
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Figure 1. 3: Three dimensional structure of tissue transglutaminase 
(A) Three dimensional structure of TGase 2 bound to GTP. Domains I-IV (β-
sandwich, catalytic core, β-barrel1 and β-barrel2) are coloured as magenta, yellow, 
blue and green, respectively. (B1) TGase 2 structure bound to GTP and (B2) bound 
to Ca
2+
 ions. (B3) Closed and opened structures of TGase 2 superimposed. Obtained 
from Griffin et al., (2002) and Pinkas et al., (2007). 
 
GTP interaction site 
(A) Three dimensional structure of TGase 2 bound to GTP 
(B1) TGase 2 bound to GTP 
Ca
2+
 
Active site 
Ca
2+
 binding site 
(B2) TGase 2 bound to Ca
2+
 ions 
(B3) Closed and opened structures of TGase 2 superimposed 
Regulatory loop 
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The active site is a catalytic triad constituted by Cys277, His335 and Asp358 residues, 
the thiol group of Cys277 being the one with the highest reactivity. Thus, irreversible 
inhibitors of TGase activity target this residue (Griffin et al., 2002). 
Ca
2+
 is essential for the activation of mammalian TGases. TGases are activated at 
physiological Ca
2+
 concentrations (Griffin et al., 2002; Jeitner et al., 2009), although 
it was previously thought that the enzyme needed supraphysiological concentrations 
(Hand et al., 1985), due to the need for millimolar Ca
2+
 concentrations in the in vitro 
TGase activity assays. 
The interaction of some molecules such as sphingosylphosphocholine with TGase 2 
reduces the Ca
2+
 levels required for the activation of the enzyme (Lai et al., 1997).  
In the absence of Ca
2+
, TGase 2 and human factor XIII adopt their inactive 
conformation where the reactive Cys277 is bound to the phenolic hydroxy group of 
Tyr516 residue from β-barrel1 by a hydrogen bond (Griffin et al., 2002; Nemes et al., 
2005). It seems that in the inactive TGase 5 isoform, a similar hydrogen bond 
interaction exists between aminoacid residue Cys277 and His550 (Candi et al., 2004; 
Liu et al., 2002). This conformation (Figure 1. 3B) avoids the interaction between the 
substrate and the active site of the enzyme. When the enzyme binds Ca
2+
, it 
undergoes a conformational change, where the β-barrel domains are displaced away 
from the catalytic core, thus breaking this hydrogen bond and increasing both the 
accessibility and the reactivity of the active site towards its substrates (Figure 1. 3B) 
(Griffin et al., 2002; Candi et al.,2004). In TGase 2, various residues in the catalytic 
core (and especially Trp241) are very important for the transamidating activity, as 
they help to stabilise the transition state structure (Griffin et al., 2002). TGase 3 has 
one Ca
2+ 
ion permanently bound that helps to stabilize the local structure. To become 
active, a flexible solvent exposed loop constituted by residues 462-471, that connects 
the last α-helycal segment from the catalytic core domain with the first β-strand of 
the β-barrel1 domain has to be proteolysed so that the enzyme can bind two more 
Ca
2+
 ions that trigger the conformational change (Ahvazi et al., 2003). The cleavage 
site in the loop is the residue Ser 469 (Ahvazi et al., 2003). The cleavage of this loop 
in TGase 2 and Factor XIIIa leads to their inactivation (Pinkas et al., 2007). In TGase 
2 this loop is very important for the regulation of the activity as it acts as the hinge 
across which the spatial position of the domains vary (Griffin et al., 2002). 
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GTP can inhibit the transamidating activity of TGase 2, TGase 3, TGase 4 and 
TGase 5 in a dose-dependent manner, although only TGase 2 and 5 are able to 
hydrolyze the nucleotide (Candi et al., 2004; Liu et al., 2002). GTP induced 
inhibition can be suppressed by increasing the concentration of Ca
2+
, showing an 
inverse relationship between the calcium dependent activity and the nucleotide 
signalling activity and indicating that these two molecules can modulate the activity 
of TGases. Neither TGase 1 nor factor XIIIa are affected by GTP (Pinkas et al., 
2007).  
TGase 2 can also bind and hydrolyze ATP molecules, but its GTPase activity 
becomes inhibited (Achyuthan and Greenberg, 1987; Lai et al., 1998). ATP can also 
interact with TGase 5, inhibiting its activity in a non-competitive manner (Candi et 
al., 2004). 
Studies have indicated that GTP is important for the stabilization and promotion of 
the transamidating activity of TGase 2, suggesting that this activity could be 
associated with G-protein signalling system (Jeon et al., 2002), but when the enzyme 
is bound to GDP/GTP, its transamidating activity is inhibited (Fesus and Piacentini, 
2002). 
Calreticulin is a 50 kDa Ca
2+
 binding protein that is able to inhibit the interaction of 
GTP and the transamidating activity of TGase 2 (Feng et al., 1999). It has been also 
reported that TGase 2 activity can be inhibited by zinc ions, which interfere with 
calcium binding (Hand et al., 1985). 
Another system for the regulation of GTP-hydrolizing and transamidating activity of 
TGase 2 is the compartmentalization of the enzyme; as TGase 2 present in the 
cytosol shows a higher crosslinking activity while TGase 2 in the cell membrane has 
a predominant GTPase function (Park et al., 2001; Esposito and Caputo, 2005). 
1.4. Substrate requirements for TGases 
TGases do not interact with a free form of glutamine aminoacids, instead they target 
the γ-carbonylamide group present in the side chain of glutamine residues in protein 
substrates (Mehta and Eckert, 2005). TGases can recognise with high specificity the 
glutamine protein residues, however the mechanism by which TGase recognize the 
substrates is not fully understood (Griffin et al., 2002; Sugimura et al., 2006). 
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Although there is no clear consensus sequences around the reactive glutamine 
residues, investigations have indicated that in unfolded protein areas, if adjacent 
residues to the glutamine target are positively charged, the TGase reaction will be 
unfavourable. However, if the positively charged residues are located two or four 
residues away from the glutamine, the reaction will be encouraged, suggesting that 
the spacing between neighbouring residues is a crucial factor in TGase recognition 
(Esposito and Caputo, 2005).  
Studies on gliadin peptides, which are excellent TGase 2 substrates have reported 
that TGase 2 shows a preference of deamidation for QxP sequences instead than QP 
or QxxP sequences (Mehta and Eckert, 2005; Piper et al., 2002). Prolines seem to be 
important in the recognition of the glutamine residue, but if this glutamine residue is 
located between prolines, TGases will not recognize it as a substrate (Pastor et al., 
1999). Glutamine targets located at the N-terminal or C-terminal of the protein are 
not recognized by TGases (Pastor et al., 1999); but it appears that to be possible 
targets, glutamine residues have to be situated on accessible extensions or at the 
surface of the protein (Aeschlimann et al., 1992; Esposito and Caputo, 2005). Thus, 
it seems that the site where the crosslinking occurs is established by the secondary or 
tertiary structure of the protein rather than the location of the glutamine residue in the 
aminoacid sequence (Coussons et al., 1992; Esposito and Caputo, 2005). 
TGases can recognise with high specificity the glutamine protein residues, but they 
show a lower specificity for the acyl acceptor amine group (Griffin et al., 2002). 
In the case of a cross-linking reaction, residues flanking the lysine target residue can 
interfere in the reactivity or interaction of the enzyme with the lysine residue. Thus, 
small aliphatic, uncharged or basic polar residues will improve the reactivity whereas 
glycine, proline, histidine and aspartic acid residues will diminish the reactivity 
(Grootjans et al., 1995; Groenen et al., 1994). But, this is not an exact rule, as 
observations on the glyceradehyde-3-phosphate dehydrogenase (GAPDH) molecules 
have shown that lysine residues located within sequences that should enhance their 
reactivity do not act as amine donors. This suggests that conformational changes in 
the native protein induced by protein-protein interactions and steric resistance 
between the enzyme and the substrate, prevents the recognition of the lysine residues 
(Esposito and Caputo, 2005). 
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1.5. Transglutaminase family   
In mammals, nine different TGases have been identified at the genomic level 
(Grenard et al., 2001). The studied enzymes (Table 1. 1.) are the active factor XIIIa 
that is involved in wound healing; TGase 1, which is involved in the differentiation 
of keratinocytes; the ubiquitous TGase 2, which has several functions; TGase 3, 
which is involved in the differentiation of keratinocytes; the prostatic TGase 4, which 
is associated with fertility; TGase 5, which is mainly expressed in epithelia; TGase 6 
and 7, which are not yet well characterised; and the inactive erythrocyte-bound 4.2, 
which is an important component of the erythrocyte membrane skeleton. 
 
Name Synonyms Characteristics and location 
Activity 
regulator 
kDa 
Band 4.2 
Erythrocyte protein 
band 4.2 
Bone marrow, foetal spleen, foetal 
liver. Inactive form. 
- ~ 72 
Factor 
XIIIa 
Plasma 
transglutaminase 
Plasma, platelets Calcium ~ 83 
TGase 1 
Keratinocyte 
transglutaminase, 
TG K 
Membrane bound, epithelia, many 
other tissue 
Calcium ~ 106 
TGase 2 
Tissue 
transglutaminase, 
TG2, tTGase, TG C 
Multifunctional, ubiquitous 
although highly active in brain and 
liver. 
Calcium, GTP ~ 80 
TGase 3 
Epidermal 
transglutaminase, 
TG E 
Epithelia, widely expressed Calcium, GTP ~ 77 
TGase 4 
Prostate 
transglutaminase, 
TG P 
Many secretory fluids Calcium, GTP ~ 77 
TGase 5 TG X Epithelia, widely expressed Calcium, GTP ~ 81 
TGase 6 TG Y Unknown Calcium? ~ 80 
TGase 7 TG Z 
Ubiquitous, but predominantly in 
lung and testis 
Calcium ~ 80 
 
Table 1. 1: Mammalian transglutaminases. Adapted from Esposito and Caputo, 
(2005) and Griffin et al., (2002).  
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1.5.1. Erythrocyte protein band 4.2 
Protein 4.2 gene EPB42 is located in chromosome 15q15 (Najfeld et al., 1992) from 
which two cDNA sequences are obtained, one with 691 aminoacid residues that 
raises a 72 kDa protein, and another with 721 aminoacid residues that generates a 
74 kDa protein (Sung et al., 1990; Korsgren et al., 1990). Protein 4.2 is present in 
the erythroblasts and erythrocytes, where it is a major protein, representing 5 % of 
the total protein in the human red blood cell membrane (Steck, 1974). Although 
protein 4.2 shows a high homology with TGases especially around the active site, it 
is an inactive isoform due to a switch in the cysteine residue present in the active site 
for an alanine residue (Sung et al., 1990). The N-terminal glycine of the protein is 
myristoylated (Risinger et al., 1992) and the Cys203 is palmitoylated (Das et al., 
1994), which may permit an interaction with the inner side of the plasma membrane. 
The function of protein 4.2 remains unclear, although it is known that it is important 
in the maintenance of red cell membrane integrity by interacting with the N-terminal 
cytoplasmatic domain of band 3, with ankyrin (Korsgren and Cohen 1986, 1988), 
spectrin (Gondal et al., 1996; Mandal et al., 2002) and protein 4.1 (Korsgren and 
Cohen, 1988) in solution. Protein 4.2 is also related with the survival of the 
circulating red blood cells through its binding with CD47 protein (Bruce et al., 2002; 
Mouro-Chanteloup et al., 2003), a member of the Rhesus complex. It is now more 
evident that the association with CD47 protein is important for the integrity of the B3 
macrocomplex and the red cells (Satchwell et al., 2009). 
The possibility of protein 4.2 being phosphorylated has not been elucidated yet as 
studies by Fennell et al. suggested that protein 4.2 is in a highly phosphorylated state 
(Fennell et al., 1992), but other studies suggested that in normal conditions it is 
phosphorylated at low levels (Suzuki et al., 1985). 
Complete or partial absence of Band 4.2 is related with hereditary spherocytosis 
(Yawata, 1994; Bruce et al., 2002; Dahl et al., 2004), which is a type of haemolytic 
anaemia. This disease is also related with mutations in some other erythrocyte 
membrane proteins like spectrin, ankyrin and B3 (Satchwell et al., 2009). The 
disease is characterized by jaundice, reticulocytosis, haemolysis with anaemia and 
the presence of spherocytes in the peripheral blood (An and Mohandas, 2008).  
                                                                       CHAPTER I. INTRODUCTION 
 
 12 
1.5.2. Plasma transglutaminase  
Also identified as Factor XIIIa, was first described by Barkan and Gaspar in 1923, 
when they observed the formation of fibrin clots in presence of calcium (Barkan and 
Gaspar, 1923). Factor XIII is released as a zymogen that needs the presence of Ca
2+
 
and thrombin to become active. Plasma Factor XIII circulates in the blood as a 
heterotetramer (326 kDa) composed of two catalytic A-subunits (83 kDa) and two 
non-catalytic B-subunits (80 kDa) (A2B2), while the cellular Factor XIII is present 
in the placenta and in the cytoplasm of megakaryocytes, monocytes-macrophages 
and platelets as a homodimer (166 kDa) form composed by two catalytic A-
subunits (Lorand and Graham, 2003; Carrell et al., 1989; Bishop et al., 1990). 
Subunit A shows a TGase structure, containing the catalytic core and calcium 
binding sites (Muszbek et al., 1999); it is mainly synthesized in cell populations of 
bone marrow origin (Wolpl et al., 1987; Poon et al., 1989) and the encoding gene is 
localised in chromosome 6p24-25 (Board et al., 1988). Subunit B is a glycoprotein 
that is synthesized in the hepatocytes (Muszbek et al., 1999) and the encoding gene is 
confined to chromosome 1q31-32.1 (Webb et al., 1989). Subunits A from the cellular 
and plasma Factor XIII show identical structure (Muszbek et al., 1999). In normal 
conditions, A subunits travel in the plasma as a complex, while 50 % of B subunits 
do it in an unclomplexed form (Yorifuji et al., 1988; Kroll, 1989). 
Plasma Factor XIII binds fibrinogen noncovalently and independently of calcium 
(Greenberg and Shuman, 1982), but binds fibrin with a higher affinity (Achyuthan et 
al., 1996).  
The activation of the plasma Factor XIII occurs in two steps. In the first, the peptide 
bond between Arg37-Gly38 in the Factor XIII A subunit is cleaved by thrombin, 
generating a 37 aminoacid activation peptide that remains attached to the subunit 
(Yee et al., 1995). In the second step, the A subunits detach from the B subunits in 
the presence of Ca
2+
, exposing the active site cysteine. The first step of the 
proteolysis is accelerated by the presence of fibrinogen. The release of the activation 
peptide from one A subunit is enough to obtain the full transglutaminase activity in 
presence of Ca
2+
 (Muszbek et al., 1999; Hornyak et al., 1989; Yee et al., 1995). 
Factor XIII can also be activated without the proteolytic step when at 
supraphysiological concentrations of Ca
2+
 (>50 mM), the homotetramer disassociates 
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spontaneously and the homodimer A generated becomes active (Credo et al., 1978; 
Polgar et al., 1990; Muszbek et al., 1993). When Factor XIII A is activated without 
cleavage, the binding with fibrin(ogen) is weaker than when activated by proteolysis 
(Hornyak and Shafer, 1991). Several studies have suggested that cellular Factor XIII 
in platelets can be activated due to increases in the intracellular Ca
2+
 concentration 
that also activate calpain. In this activation process, there is no proteolysis because 
thrombin is unable to penetrate the membrane (Polgar et al., 1990; Ando et al., 
1987b). 
Once plasma Factor XIII A subunits are activated, the enzyme is known as factor 
XIIIa and catalyses the formation of γ-γ dimers of fibrin(ogen) between the Glu398 or 
Glu399 residue of one γ chain and the Lys406 residue of another γ chain from a 
different fibrin molecule. Consecutively, the enzyme cross-links the lysine and 
glutamine residues from the α and γ chains from the fibrin molecules, in order to 
stabilize the blood clot (Ritchie et al., 2000). It also protects the clot from lysis by 
cross-linking α2-antiplasmin and α2-macroglobulin to a fibrin molecule (Mortensen et 
al., 1981). The cross-linking of fibrin, fibronectin (FN) and collagen catalysed by the 
enzyme, improves wound healing by forming a scaffold for fibroblasts (McDonagh 
et al., 1981; Akagi et al., 2002). 
Plasma Factor XIIIa interacts with other plasma and tissue proteins such as 
thrombospondin, von Willebrand factor, lipoprotein, platelet vinculin and vitronectin 
(Lynch et al., 1987; Skorstengaard et al., 1990; Ichinose, 2002; Serrano and Devine, 
2002). 
Due to all these reactions, it is known that factor XIIIa is important in haemostasis 
and wound healing as well as in the maintenance of pregnancy as it is expressed in 
placenta and uterus (Bohn and Schwick, 1971; Chung, 1972). Also, experiments with 
factor XIIIa knock-out mice have shown that they suffer severe placental 
haemorrhage and subsequent spontaneous miscarriages (Koseki-Kuno et al., 2203).  
Factor XIIIa is also expressed in the prostate gland (Chung, 1972). 
Recent studies have shown that the in vitro inhibition of factor XIIIa decreases clot 
firmness, delays the formation of the clot and increases the rate of fibrinolysis in 
whole blood (Jambor et al., 2009) and its absence in pregnant woman, leads to 
miscarriage (Lorand et al., 1980).  
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1.5.3. Keratinocyte transglutaminase 
Keratinocyte transglutaminase, also known as TGase 1 or TG K, is a 106 kDa 
enzyme formed by 814 aminoacid residues (Kim et al., 1991) and encoded by the 
gene TGM1 located on chromosome 14q11.2 (Yamanishi et al., 1992). TGase 1 is 
the largest member of the family, due to the addition of N- / C- terminal extensions 
of residues in the amino and carboxyl terminal ends (Kim et al., 1991, Yamanishi et 
al., 1991), and it is usually associated with membranes (Thacher and Rice, 1985; 
Lichti et al., 1985). TGase 1 is present in keratinocytes, and shows an increased 
activity when the cells are in the last stage of differentiation (Rice and Green, 1978). 
The enzyme activity is important in the formation of an insoluble specialized 
structure known as the cell envelope (CE) beneath the plasma membrane of the 
keratinocytes (Thacher and Rice, 1985; Kalinin et al., 2001). The CE is very 
important in the barrier roles of the skin (Simon and Green, 1985; Greenberg et al., 
1991). 
Four members of the transglutaminase family (TGase 1, TGase 2, TGase 3 and 
TGase 5) are present in epithelia; but only TGase 1, TGase 3 and TGase 5, which are 
expressed in the upper layers (spinous and granular) (Candi et al., 2001) are involved 
in the formation of the CE, playing consecutive and complementary roles (Kalinin et 
al., 2001). In the initial stage of keratynocyte differentiation, TGase 5 cross-links the 
key substrates loricrin, involucrin and small proline rich protein 3 (SPR 3) (Candi et 
al., 2001). Loricrin is an insoluble protein and is the major component of the CE in 
the epidermis (Steven and Steinert, 1994). SPRs are very soluble proteins and are 
proposed to act as bridges to link together other precursors (Steinert et al., 1998) and 
involucrin, which have been hypothesized to be involved in the formation of a 
scaffold for subsequent cross-linking of additional molecules (Nemes and Steinert, 
1999). 
The oligomers formed by the activity of TGase 5 are then cross-linked to the CE by 
the cytosolic TGase 3 and, in the final stage of differentiation by the membrane 
bound TGase 1 (Candi et al., 2001). TGase 1 also catalyses the formation of an ester 
link between specialized ceramides and CE proteins (Nemes et al., 1999a). TGases 
present in the epithelia also cross-link a variety of CE proteins such as filaggrin, 
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elafin, desmoplakin, keratin intermediate filaments (Steinert and Marekov, 1995), 
cornifin (Marvin et al., 1992) and trychohyalin (Steinert et al., 2003). 
TGase 1 can be found in the cytosolic fraction or bound to the membrane of 
keratinocytes (Kim et al., 1995a; Steinert et al., 1996a). The cytosolic TGase 1 exists 
as a co-translational N-myristoylated low activity form of ~106 kDa or as two 
cleaved forms with higher activity, one of 67 kDa and another one consisting of a 67 
and 33 kDa fragments that form a complex through non covalent bonds (Steinert et 
al., 1996b).  These three forms are responsible for 5 % and 35 % of the total activity 
of TGase 1 in proliferating cells and terminally differentiated keratinocytes 
respectively (Kim et al., 1995b).  
In stationary or proliferating epidermal cells, most of the enzyme exists as an 
inactive zymogen (~106 kDa) attached to the plasma membrane of the keratinocytes 
through fatty acyl linkages, such as myristate and palmitate (Rice et al., 1990; 
Phillips et al., 1993; Steinert et al, 1996b). The binding site for the palmitate and 
myristate is a cluster of five cysteines (Cys47, Cys48, Cys50, Cys51 and Cys53) within 
the sequence C47CGCCSC53 present at the amino terminus of the enzyme (Phillips et 
al., 1993).  To confer membrane anchorage, the presence of two contiguous cysteines 
in the sequence is sufficient, while the presence of a single cysteine is partially 
effective (Phillips et al., 1993). Experiments using protein synthesis inhibitors 
suggest that myristylation occurs co-translationally and that palmitate labelling 
occurs post-translationally (Steinert et al., 1996b). Myristoylation is a specific 
process for the proteins containing a glycine residue in the amino terminus (Boutin, 
1997). This co-translational modification is catalysed by the enzyme N-
myristoyltransferase. The consensus sequence of the myristoylated proteins, 
requieres a glycine residue at the N-terminal and also a small and uncharged residue 
such as serine (Boutin, 1997). Palmitoylation seems to be an enzymatic reaction 
mediated by palmitoyltransferase or an acyltransferase which is able to recognize 
specific sequences on proteins and attach lipids to the target cysteines residue; but it 
has also been shown that under appropriate conditions, it can occur spontaneously 
without enzyme mediation (Dietrich and Ungermann, 2004). Proteins that are 
palmitoylated do not show a consensus sequence, but they have a sequence 
surrounding the target cysteine that contains positive charges and transmembrane 
domains or lipid anchors (Bijlmakers & Marsh, 2003). In stationary or proliferating 
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cells, TGase 1 is thio-esterified by myristate, generating an S-myristoylated enzyme 
that gives a robust anchorage to the membranes but in terminally differentiating cells, 
TGase 1 is S-palmitoylated generating a weaker anchorage; the switch from one state 
to another seems to occur just after the initiation of the differentiation signal (Steinert 
et al., 1996b). Up to half of the TGase 1 anchored in the membrane can be cleaved 
during keratinocyte differentiation, generating fragments of 10, 33 and 67 kDa, that 
remain together as a complex and bound to the membrane via the 10 kDa segment. 
Some of the complex can also be detached from the 10 kDa segment and appear as a 
33/67 kDa or 67 kDa soluble active fractions (Steinert et al., 1996a).  
In vitro studies by Kim, suggested that TGase 1 activity increases when the enzyme 
is proteolysed (Kim et al., 1994b, 1995a).  The complex formed and the soluble 
fractions (33/67 kDa or 67 kDa) generate almost all the TGase 1 activity (Steinert et 
al., 1996a and 1996b). The N-terminal 10 kDa segment has a key role in TGase 1 
activity; therefore any mutation that affects this membrane anchorage domain can 
have consequences in the activity and substrate specificity (Candi et al., 1998). 
TGase 1 can also be phosphorylated in certain serine residues present in the amino 
terminal, especially Ser82 (Chakravarty et al, 1990; Rice et al, 1996). These serines 
are close to the acylation anchoring residues present in TGase 1, therefore suggesting 
a possible influence of phosphorylation in membrane anchoring (Eckert et al., 2005).  
TGase 1 has also been found in human brain, where it is mainly present in the 
cytosolic fraction of the cortex and cerebellum (Kim et al., 1999), although its 
expression in brain and other tissues is only a small percentage compared to the level 
of expression in the epidermis (Lesort et al, 2000a). 
Disruption of TGase 1 activity occurs in a skin disorder called lamellar ichthyosis 
(LI) (Bale et al., 1996). This disease is characterized by the presence of scaling, 
hyperkeratosis and acanthosis (Traupe et al., 1984). The loss of TGase 1 activity 
generates LI (Candi et al., 1998). Mutations of the TGM1 are likely to generate 
protein misfolding or to affect the processing of TGase 1 into its highly active form, 
which will destabilize the activation of the enzyme (Candi et al., 1998). Experiments 
with mice lacking TGase 1 corroborated the idea that the loss in TGase 1 activity can 
cause the disease (Matsuki et al., 1998; Kuramoto et al., 2002). Recent studies have 
suggested that the misfolding of TGase 1 leads to the accumulation of the enzyme in 
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the endoplasmic reticulum where it is ubiquitinylated; processes that may be an 
underlying cause for LI (Jiang et al., 2010). In LI, other TGases can replace TGase 1 
activity, but they can not replace the ceramide attachment function (Nemes et al., 
1999a, 2000; Steinert et al., 1996b). 
1.5.4. Tissue transglutaminase 
Tissue TGase, also known as TG2,  tTGase, TG C or TGase 2, is a 75 kDa enzyme 
formed by 687 amino-acid residues, and encoded in the gene TGM2 located on 
chromosome  20q11-12 (Gentile et al., 1994; Griffin et al., 2002). TGase 2 is a 
ubiquitous and multifunctional enzyme (Fesus and Piacentini, 2002; Griffin et al, 
2002), which is discussed in more detail in section 1.6. 
1.5.5. Epidermal transglutaminase 
Epidermal TGase, also known as TGase 3 and TG E, is a ~77 kDa protein formed by 
692 amino-acid residues (Kim et al., 1993) and encoded by the gene TGM3, which is 
localized on chromosome 20q11-12 (Wang et al., 1994). It is widely expressed in 
tissues like brain (Kim et al., 1999) or muscle (Choi et al., 2000), although it is 
mainly present in the epithelia where it is involved in the formation of the CE 
(Kalinin et al., 2001). The enzyme is expressed in the upper epithelial layers and 
located in the cytosolic fraction of the cells (Hitomi et al., 2003). 
TGase 3 is a zymogen that has to be proteolysed during keratinocyte differentiation 
to become active, in a similar way to that described for Factor XIII and TGase 1. The 
proteolytic target is the Ser469 located in a loop that connects domain 2 with domain 
3. The cleavage of the zymogen generates 27 kDa and 50 kDa fragments that stay 
together, forming a complex that can be activated by Ca
2+
 (Ahvazi et al., 2002; Kim 
et al., 1990). The complex formed, needs the binding of three Ca
2+
 ions to induce a 
conformational change that exposes the catalytic triad. TGase 3 can also bind GTP, 
leading to a change in the conformation that closes the active site. When GTP is 
hydrolyzed to GDP, the enzyme recovers its cross-linking activity (Ahvazi et al., 
2002; Candi et al., 2004). 
Studies have demonstrated that TGase 3 acts as an auto-antigen in celiac disease and 
dermatitis herpetiformis (Sardy et al., 2002). 
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1.5.6. Prostate transglutaminase 
Prostate TGase, also known as TGase 4 and TG P, is a 80 kDa enzyme encoded by 
the gene TGM4, which is located on chromosome 3p21.33-p22 (Gentile et al., 1995). 
In 1896 Camus and Gley described an enzyme in the seminal vesicle secretion of 
rodents that was able to catalyze the formation of the seminal clot (Camus and Gley, 
1896), but it was in 1972 when the enzyme was biochemically characterised 
(Williams-Ashman et al., 1972). TGase 4 is mainly found in the prostate gland, 
where it is present in the lumen of the epithelial cells, although it can be detected in 
other tissues at a very low level (Gentile et al., 1995; Dubbink et al., 1996; An et al., 
1999; Jiang et al., 2009). In rodents, TGase 4 is a highly glycosylated protein with a 
lipid anchor (Mariniello et al., 2003) and catalyses the coagulation of the semen in 
the vagina by cross-linking the seminal vesicle proteins I-V (Williams-Ashman, 
1984; Seitz et al., 1991).  
The N-terminal end of the enzyme is responsible for its activity and the binding of 
GTP. In vitro assays showed that TGase 4 activity can be negatively modulated by 
GTP and positively by SDS and phosphatidic acid (Mariniello et al., 2003; Esposito 
et al., 1996). The role of TGase 4 in humans is still not clear, although it has been 
hypothesized that it may have the same functions as its homologue in rodents, due to 
the presence of activity in human semen and on the spermatozoon surface (Porta et 
al., 1986). It has also been shown that two of the major coagulating proteins in 
human semen, semenogelin I and II are substrates for TGase 4 (Peter et al., 1997). 
The expression of this TGase has been detected in different human cancer cell lines; 
lung cancer, colon cancer and in prostate cancer, where it has different levels of 
expression (Davies et al., 2007). In the prostate cancer line CAHPV-10, TGase 4 is 
expressed at high levels, and a loss of this enzyme provokes a decrease in the 
adhesion to endothelial cells. Therefore, high levels of TGase 4 promote the adhesion 
of cancer cells in to the endothelium (Jiang et al., 2009).  
1.5.7. Transglutaminase 5 
TGase 5, also named TG X, is a 81 kDa enzyme formed by 725 amino acid residues 
(Aeschliman et al., 1998) and encoded in the TGM5 gene, located on chromosome 
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15q15.2 (Grenard et al., 2001). Its expression is not limited to the epithelia, although 
it is mainly involved in the keratinocyte differentiation and CE formation 
(Aeschlimann et al., 1998; Candi et al., 2001). The N-terminus of TGase 5 is 
acetylated (Rufini et al., 2004). Studies with human RNA from keratinocytes 
revealed the existence of three splice variants, delta 3 (lacking exon 3), delta 3/11 
(lacking exons 3 and 11) and delta 11 (lacking exon 11) as well as the full length 
form, although only the last two are active. TGase 5 shows high affinity for 
involucrin, SPR proteins and loricrin (Candi et al., 2001), while the truncated 
isoforms interact with insoluble proteins (Mehta, 2005).  
TGase 5 co-localizes and interacts with vimentin, probably decreasing the solubility 
of the enzyme (Candi et al., 2001). Recent studies have reported that TGase 5 
expressed in mammalian epithelial cells in vitro and in the recombinant baculovirus 
system, is activated by proteolysis, generating a 28 kDa C-terminal fragment and a 
53 kDa active N-terminal fragment (Pietroni et al., 2008). It is also important to 
know that overexpression of intracellular TGase 5 can induce cell death (Cadot et al., 
2004). 
Deregulation in the expression of TGase 5 is associated with some skin disorders, 
although it is not directly involved. In ichthyosis vulgaris, characterized by a mild 
hyperkeratosis and absence of keratohyaline granules in the epidermis (Anton-
Lamprecht and Hofbauer, 1972), Darier‟s disease, characterized by a deficient 
keratinization and a decrease in the adhesion between epidermal cells (Burge and 
Wilkinson, 1992) and LI, TGase 5 expression is altered (Candi et al., 2002).  
Mutations in the gene sequence that eliminate the activity of the enzyme are related 
with the acral peeling skin syndrome (APSS) (Cassidy et al., 2005). 
1.5.8. Transglutaminase 6 
TGase 6, also known as TG Y, is a ~80 kDa enzyme encoded by the gene TGM6 
located on chromosome 20q11 (Grenard et al., 2001). Recent studies have shown that 
TGase 6 could be implicated in the formation of the CE (Thiebach et al., 2007), 
although it seems to be predominantly expressed in neurons from the central nervous 
system, including the Purkinje cells, where it can be important in neurological 
autoimmune disorders (Aeschliman and Hadjivassilliou, 2008). 
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1.5.9. Transglutaminase 7 
TGase 7, also named TG Z, is a ~80 kDa enzyme encoded by the gene TGM7 
located on chromosome 15q15.2, in a cluster that includes EPB42 and TGM5 genes. 
This isoform has not been fully characterized yet, but it is known that the catalytic 
core and Ca
2+
 binding sites are conserved (Grenard et al., 2001). 
1.6. Transglutaminase 2 
TGase 2 is the most studied and most important enzyme in the TGase family as it is 
multifunctional (Figure 1. 5), widely expressed in various tissues and it is implicated 
in several diseases (Griffin et al., 2002). 
1.6.1. Regulators of TGM2 transcription 
In some type of cells like smooth muscle cells, TGase 2 is expressed constitutively 
and at high levels (Thomazy and Fesus, 1989), while in other cells its expression is 
controlled by different signals that interact with the regulatory region of the gene 
(Fesus and Piacentini, 2002). The TGM2 gene consists of 13 exons and 12 introns 
(Grenard et al., 2001); the regulatory region is in the 5‟ terminus and contains several 
binding sites for transcription factors such as transforming growth factor β (TGF-β) 
and epidermal growth factor (EGF) which can modulate the transcription of TGM2 
(Elli et al., 2009). 
TGM2 transcription can be induced by several compounds such as dexamethasone, 
cyclic AMP, sodium butyrate (NaB), vitamin D and hydrogen peroxide, although the 
most studied is retinoic acid (RA)(Elli et al., 2009). It has been demonstrated that the 
activation of TGM2 transcription by RA is important for cell survival and 
differentiation in a neuroblastoma cell line (Melino et al., 1997).  
Studies have shown that other molecules such as the cytokines interleukin-6 (IL-6), 
tumour necrosis factor α (TNF-α) and interferons γ and β (IFNγ and IFNβ) are also 
able to activate the transcription of TGM2 (Elli et al., 2009).  
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1.6.2. Transglutaminase 2 structure 
The only studied TGase 2 structure is bound to a GTP molecule (Figure 1. 4). Like 
other TGases, TGase 2 contains four different domains. The N-terminal β-sandwich, 
formed by residues Met1 to Phe139, contains the FN and integrin binding sites. The 
catalytic core, from Ala147 to Asn460, comprises the catalytic triad (Cys277, His335 and 
Asp358) and the putative Ca
2+
 binding site. The C-terminal β-barrel1 domain from 
Gly472 to Tyr583 contains the binding residues for the guanine nucleotide, and the C-
terminal β-barrel2 domain from Ile591 to Ala687 contains the phospholipase C 
interaction site. The GDP/GTP binding site is very well conserved in TGase 2 but not 
in other TGases (Liu et al., 2002; Piacenti and Fesus, 2002) and some of the 
GDP/GTP interacting residues (Lys173 and Tyr174) are also located in the catalytic 
core (Iismaa et al., 2000). 
 
 
 
Figure 1. 4: Structure and functional elements of human tissue transglutaminase 
protein 
The horizontal arrows indicate the first and last amino-acid for each domain. 
Functional elements are indicated by vertical arrows and coloured. The FN binding 
site is in green, the catalytic triad in red, the calcium binding sites are represented in 
blue, the GTP binding residues are in grey, the PLC interaction site in purple and the 
NLS sites in lilac. Adapted from Fesus and Piacentini, (2002). 
 
TGase 2 also contains two putative nuclear localization signals (NLS1 and NLS2) 
predicted by its homology with non-structural proteins from influenza virus (Peng et 
al., 1999). 
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1.6.3. Functions and localization of TGase 2 
Its ubiquity suggests that TGase 2 is important in diverse cellular functions (Mirza et 
al., 1997). TGase 2 is mainly present in the cytosol, although it has been found in the 
nucleus, in the plasma membrane and in the extracellular matrix (ECM) (Lesort et 
al., 1998; Sing et al., 1995; Slife et al., 1985; Balklava et al., 2002).  
 
 
Figure 1. 5: Cellular functions of TGase 2 
In the presence of Ca
2+
, TGase 2 gets activated and can perform several post 
translational protein modifications in the cytosol or promote cell matrix interactions 
in the ECM.  When TGase 2 is bound to GTP, it gets involved in transmembrane 
signalling. Letter C indicates the functions performed in the cytosol, letter N in the 
nucleus, letter E in the ECM and letter M in the plasma membrane. Obtained from 
Fesus and Piacentini (2002). 
 
Deregulation of the different activities of TGase 2 can lead to alterations at tissue and 
cellular levels, resulting in a contribution to the development of different diseases 
(Malorni et al., 2008). 
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1.6.3.1. Cytosol 
TGase 2 located in the cytosol is involved in several post translational modifications 
of proteins such as amine incorporation, protein crosslinking, deamidation and 
cleavage of isopeptide bonds (Fesus and Piacentini, 2002). The activation of the 
enzyme by Ca
2+
 is crucial to its ability to perform these functions. Several 
intracellular proteins have been identified as TGase 2 substrates, like the cytoskeletal 
proteins. In this case, TGase 2 is involved in the organization of the cytoskeleton by 
crosslinking proteins such as myosin, spectrin, troponin T, actin, thymosin β and β 
tubulin (Fesus and Piacentini, 2002). This is a relevant process in the last stages of 
apoptosis in order to prevent the release of the cell content that can provoke 
inflammatory and autoimmune responses (Fesus and Piacentini, 2002). In the 
cytosol, TGase 2 is more likely to be involved in amine incorporation reactions, as in 
intact cells, several proteins are polyaminated resulting in a regulation of their 
function and metabolism (Esposito and Caputo, 2005). RA treatment induces the 
transamidation of the GTP binding protein RhoA by TGase 2. This reaction promotes 
the binding of GTP-bound RhoA to ROCK-2, resulting in the activation of the latter. 
The autophosphorylation of ROCK-2 and the resultant phosphorylation of the 
cytoskeletal protein vimentin, triggers the formation of stress fibres and increases 
cell adhesion (Fesus and Piacentini, 2002). RA is able to increase TGase 2 activity 
and expression (Chiocca et al., 1989; Suedhoff et al., 1990) as well as induce the 
transcription of TGM2. In the cytosol, TGase 2 can also act as a protein disulphide 
isomerase (PDI), thus modulating the formation of disulphide bonds within proteins. 
It seems that the active site for PDI activity is independent of the one involved in the 
transamidation reaction. PDI activity does not require Ca
2+
 and it is not inhibited by 
nucleotides (Hasegawa et al., 2003). Studies have also reported the ability of TGase 
2 to act as a protein kinase in breast cancer cells and to phosphorylate insulin-like 
growth factor binding protein 3 (IGFBP-3) and 5 (IGFBP-5). In contrast to cross-
linking activity, this kinase activity is inhibited by increasing Ca
2+
 concentrations. 
The phosphorylation of IGFBP-3 could decrease its pro-apoptotic effects (Mishra 
and Murphy, 2004). TGase 2 can also be phosphorylated in vivo and in vitro by 
protein kinase A (PKA), creating the binding sites for protein 14-3-3. The 
importance of the interaction between TGase 2 and protein 14-3-3 is not fully 
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understood, but it has been hypothesized that it could be involved in the regulation of 
TGase 2 activities (Mishra and Murphy, 2006). 
1.6.3.2. Nucleus 
It has been suggested that TGase 2 can be translocated into the nucleus by the 
interaction with the nuclear transport protein importin-α3 (Peng et al., 1999). In the 
nucleus, TGase 2 can act either as a G protein (although no targets have yet been 
described for this function) or as an active enzyme, which can interact with histones, 
retinoblastoma proteins (Rb) and Sp1 proteins (Fesus and Piacentini, 2002). TGase 2 
is also able to phosphorylate Rb (Mishra et al, 2007). The modification of these 
proteins can generate changes in chromatin structure and gene expression, affecting 
mitosis, DNA repair, replication and transcription, suggesting an involvement of 
these effects in the regulation of apoptosis and cell proliferation (Peng et al., 1999; 
Mishra et al, 2007). 
1.6.3.3. Plasma membrane  
It has been suggested that subcellular localization of TGase 2 is important to 
determine its functions, in this case when TGase 2 is associated to the membrane 
shows mainly a GTPase function while in the cytosolic fraction it has mainly 
crosslinking and transamidating activity (Park et al., 2001). TGase 2 localized in the 
plasma membrane is bound to GTP and can act as a G protein (Nakaoka et al., 1994). 
The Gαh/TGase 2 protein intervenes in signal transduction by acting as a transmitter 
of extracellular α1-adrenergic signals between the seven-transmembrane helix 
receptors and phospholipase Cδ1 (PLCδ1) (Iismaa et al., 2000). It has been proposed 
that PLCδ1 activity is inhibited by its interaction with TGase 2, but when GTP binds 
to TGase 2, the PLCδ1 is released from the association and becomes active (Murthy 
et al., 1999), while Feng and his collaborators demonstrated that the interaction 
between PLCδ1 and Gh resulted in the activation of the phospholipase molecule (Feng 
et al., 1996). On the other hand, it has also been suggested that PLCδ1 stabilizes the 
complex TGase 2:GTP and acts as a guanine nucleotide exchanging factor, involving 
a reciprocal regulation (Baek et al., 2001). Studies using NIH3T3 cells have shown 
that the Gh activity of TGase 2 is related with cell survival (Antonyak et al., 2002).  
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1.6.3.4. Extracellular 
Once TGase 2 is externalised, it remains mainly attached to either the plasma 
membrane or to the ECM (Balklava et al., 2002; Scarpellini et al., 2009). On the cell 
surface, TGase 2 without requiring cross-linking activity is associated with the 
extracellular domain of integrin, facilitating the adhesion of FN, thus acting as a 
mediator in the interaction. These interactions support cell adhesion, motility and 
spreading of cells (Akimov et al., 2000; Balklava et al., 2002). TGase 2 present in the 
cell surface has been described as an important tissue stabilizing enzyme during 
wound healing (Haroon et al., 1999). In the ECM the Ca
2+
 concentration is high 
while the levels of nucleotides are low; therefore TGase 2 finds the ideal conditions 
for its activation, getting involved in several processes (Lorand and Graham, 2003; 
Smethurst and Griffin, 1996). In the extracellular space, TGase 2 is associated with 
the stabilization of the ECM and with the interaction between cells and the ECM 
through covalent crosslinking of matrix proteins (Aeschlimann and Thomazy, 2000). 
Secreted TGase 2 binds FN with high affinity, in addition to other proteins such as 
laminin, nidogen, von Willebrand factor, collagen, vitronectin and lipoprotein, which 
are all involved in the assembly and stabilization of the ECM (Esposito and Caputo, 
2005). The externalized TGase 2 can activate and modify covalently some growth 
factors such as TGF-β (Nunes et al., 1997) which regulates the transcription of ECM 
genes and TGase 2 itself or IGFBP-1 which is polymerised by TGase 2 forming high 
molecular weight multimers that regulate the cell responses to insulin-like growth 
factor I (IGF-I) (Sakai et al., 2001). 
The extracellular TGase 2 may also be important in the mineralization of tissues by 
facilitating the formation of clusters of osteonectin and osteopontin (Kaartinen et al., 
2002). 
TGase 2 can be externalised from the cells although the enzyme does not contain any 
leader sequence or post-translational modifications such as the acylation of the N-
terminus, suggesting a possible non-ER/Golgi route (Lorand and Graham, 2003). It 
has been shown that removal of the N-terminal of TGase 2 prevents its interaction 
with FN, which results in the disappearance of TGase 2 on the cell surface. Therefore 
it has been hypothesyzed that the release of TGase 2 from the cells could be related 
to the interaction with FN (Gaudry et al., 1999). The externalization of TGase 2 
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could also happen through the N-acetylation of the enzyme (Chen and Mehta, 1999) 
or in a passive way through stress ruptures in the membrane (Gaudry et al., 1999) 
although more studies are needed to elucidate the exact pathway to export TGase 2 
out of the cells.    
Another possibility is that TGase 2 exits the cell via some other non-classical 
pathway such as exosome-mediated secretion. 
1.6.4. TGase 2 related processes 
It has been demonstrated that TGase 2 is involved in several physiological processes 
such as angiogenesis, cell growth, cell attachment, cell migration, wound healing, 
apoptosis and ECM assembly (Mehta and Fok, 2009). 
In cell adhesion and spreading, TGase 2 is distributed together with integrin β1 in 
areas of cell adhesion, acting as an integrin co-receptor (Gaudry et al., 1999; Akimov 
et al., 2000) for which its catalytic activity is not required (Isobe et al., 1999) while 
recent studies in the migration of cancer cells have shown that TGase 2 accumulates 
at the edges of the cells and becomes catalytically active (Antonyak et al., 2009). A 
decrease in the expression of TGase 2 in human epithelial cells results in a reduction 
in the cell adhesion and cell spreading (Jones et al., 1997) indicating the importance 
of TGase 2 in these processes. A decrease in cell adhesion can trigger an apoptotic 
process known as anoikis; thus TGase 2 has been proposed to play a role in the 
reduction of cell death (Griffin et al., 2002). 
In the apoptotic process, it has been suggested that TGase 2 cross-links intracellular 
components stabilizing the cell structure before it is phagocytosed (Knight et al., 
1991). It has been demonstrated that the effects of TGase 2 on apoptosis are affected 
by both the localization and the activity of the enzyme (Milakovic et al., 2004). 
Experiments have indicated that TGase 2 overexpression can „sensitize‟ cells to 
apoptosis by hyperpolarizing the mitochondria which leads to an increase of reactive 
oxygen species (ROS), loss of mitochondrial membrane potential and a decrease in 
glutathione levels (Piacentini et al., 2002); however, other studies have shown that 
expression and activation of TGase 2 can also enhance cell survival by preventing 
apoptosis through its GTP binding activity (Antonyak et al., 2001). 
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Using in vivo and in vitro models of wound healing it has been shown that there is an 
upregulation of both protein levels and transamidating activity of TGase 2 (Haroon et 
al., 1999; Verderio et al., 2004). It seems that TGase 2 stabilizes the wound area and 
then promotes angiogenesis and deposition of ECM by crosslinking proteins present 
in the matrix. In vivo studies have shown that the addition of recombinant TGase 2 
into wound healing areas causes an increase in the vessel length density, thus 
indicating that angiogenesis is promoted by TGase 2 activity (Haroon et al., 1999). 
1.6.5. TGase 2 inhibitors 
TGase 2 plays a role in different human diseases; therefore it is interesting to study if 
its inhibition have some effects on these diseases contributing to ameliorate them 
(Siegel and Khosla, 2007). 
Three types of TGase 2 inhibitors have been described. These three types are 
competitive amine inhibitors, reversible inhibitors and irreversible inhibitors (Siegel 
and Khosla, 2007). The competitive amine inhibitors are the most widely used as 
they are commercially available, chemically stable and not toxic to living systems 
(Verderio et al., 1998). These inhibitors are constituted by a primary amine bound to 
an aliphatic chain and they inhibit TGase 2 activity by competing with other natural 
amines in the transamidation reaction. Therefore, the enzyme is still active but the 
cross-linking peptide is formed between the glutamine substrate and the amine 
inhibitor (Siegel and Khosla, 2007). Some of the most used amine inhibitors are 
putrescine, spermidine, histamine, biotin cadaverine and cystamine, however none of 
these inhibitors can be considered TGase 2 specific in a biological environment 
(Siegel and Khosla, 2007). The case of cystamine is very interesting as it has been 
suggested to inhibit irreversibly TGase 2 activity in a time dependent manner 
(Lorand and Conrad, 1984). This inhibition was hypothesized to occur by the 
formation of mixed disulfides between the reactive cysteine residue of TGase 2 and 
the cystamine compound (Lorand and Conrad, 1984). 
The reversible inhibitors block the substrate access to the active site of the enzyme 
without modifying it covalently. Some cofactors of TGase 2 such as GTP and GDP 
(Lai et al., 1998) and divalent metal ions such as Zn
2+
 (Aeschlimann and Paulsson, 
1994) are able to inhibit reversibly TGase 2 activity. 
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The irreversible TGase 2 inhibitors act by covalently modifying the enzyme, 
avoiding its interaction with the substrate. These inhibitors are mainly designed to 
attack the cysteine residue using chemical functional groups that form stable 
chemical bonds after reacting (Siegel and Khosla, 2007). The compound 
iodoacetamide is one of the simplest irreversible inhibitors of TGase 2 and it reacts 
with other nucleophilic residues of the enzyme apart from cysteines (Folk and Cole, 
1966). Other irreversible inhibitors are dihydroisoxazoles which are based on the 
natural product acivicin (Castelhano et al., 1988) and are able to inhibit enzymes 
with cysteine residues in their active sites (Tso et al., 1980). The TGase 2 substrate 
carbobenzyloxy-L-glutaminylglycine (Cbz-gln-gly) has been used as the inhibitor 
backbone to design irreversible inhibitors in which the reactive moieties in the gln 
position were substituted by different functional groups (Siegel and Khosla, 2007) 
such as epoxides,  α,β-unsaturated amides, maleimides and chloroacetamides (de 
Macedo et al., 2002; Halim et al., 2007; Pardin et al., 2006). 
Another TGase 2 inhibitor is 2-[(2-oxopropyl)thio]imidazolium also known as R283, 
which has been used in several studies (Freund et al., 1994; Balklava et al., 2002; 
Verderio et al., 2003; Maiuri et al., 2008; Telci et al., 2008) and it is also able to 
inhibit factor XIIIa which makes the potential biological use of this inhibitor 
inappropriate in TGase 2 mediated diseases (Siegel and Khosla, 2007). 
Some of the TGase 2 inhibitors designed are water soluble as is the case of the 
derivatives of 6-diazo-5-oxo-L-norleucine (DON). These compounds contain an 
extra carboxyl group compared to sulfonium peptidylmethylketones inhibitors, in 
order to enhance both their structure–activity profile and their water solubility. These 
inhibitors will remain outside the cells instead of crossing the cell membrane, thus 
they will target extracellular TGase 2 (Griffin et al., 2008). 
It has also been found that β-aminoethyl ketones are potent inhibitors of TGase and 
the best compound synthesized by Ozaki and his collaborators contain a thiophene 
ring and a bromine atom, which are reported as important and critical in the 
inhibitory activity (Ozaki et al., 2010). 
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1.6.6. Purification of TGase 2 
The need to perform kinetic and biochemical studies and to understand better the 
functions of TGase 2, has lead to the development of purification methods for this 
enzyme. TGase 2 has been purified from human erythrocytes (Brenner and Wold, 
1978; Lee et al., 1986; Ando et al., 1987a), human A431 tumor cells (Dadabay and 
Pike, 1989) and bovine testis (Bergamini and Signorini, 1992). But the most widely 
used source to purify TGase 2 is guinea pig liver, due to its high abundance 
compared to other tissues (Leblanc et al., 1999), and its high homology (80 %) with 
human TGase 2 (Dieterich et al., 1997).  
The first step in the different purification methods for guinea pig liver TGase 2 is the 
centrifugation of the homogenate. The resultant supernatant is usually applied to an 
anion-exchange column, although in a one step method described by Ikura et al., 
(1985), the supernatants were loaded into an affinity column using a monoclonal 
antibody against guinea pig liver TGase 2. However, although the affinity 
purification method gives a high recovery and seems rapid, fractions obtained have 
to be neutralised immediately to avoid the loss of activity and a final concentration 
step is required. In this study the purity of the affinity purified TGase was not totally 
assessed, as the image from SDS-PAGE did not have a very high resolution (Ikura et 
al., 1985). 
The first purification method for guinea pig liver TGase 2 was performed by Folk 
and Cole in 1966; it included three IEX steps and two protein precipitation steps and 
it allowed the recovery of 50 % of the total activity, but the SA obtained was not 
very high and there were no images to study the purity of the sample. In 1971, 
Connellan and his colleagues described a similar method with five steps where the 
last one, was size exclusion chromatography (SEC), allowing the proteins to separate 
on the bases of size. This process generated a 20 % yield (Connellan et al., 1971).  
Later in 1983, a three step method was designed, where after an initial IEX and 
hydroxylapatite adsorption steps, a phenylalanine sepharose column chromatography 
was performed. The yield obtained was 30 % and the image included showed a very 
pure sample, although additional bands were visible in the gel which was only 
stained with Coomassie (Brookhart et al., 1983).  
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In 1985, Folk and Chung developed another three step method that involved an anion 
exchange chromatography followed by a protein precipitation and size exclusion 
chromatography. The yield obtained was 20 %, although no gel images showing the 
purity of the preparation were published (Folk and Chung, 1985). 
The most recent purification method described for TGase 2 from guinea pig liver was 
developed in 1999, when Leblanc and his collaborators performed a modified 
method based in the one designed by Folk and Chung (1985). In this method they 
performed an uninterrupted process with fresh livers, using a different DEAE resin 
with more rigid support, and using a different method to concentrate TGase 2 after 
the precipitation and extraction steps as they centrifuge the sample for few hours 
using tubes with a specific molecular weight cut-off (Leblanc et al., 1999). The yield 
obtained was greater (31 %) as well as the purity of the enzyme, although it still 
contained several contaminants on stained SDS-PAGE gels. 
Authors Folk and 
Cole, 1966 
Connellan et 
al., 1971 
Brookhart et al., 
1983 
Folk and 
Chung, 1985 
Ikura et 
al.,1985 
Leblanc et 
al., 1999 Steps 
1
st
 step 
(IEX) DEAE 
cellulose  
(IEX) DEAE 
cellulose  
(IEX) QAE 
Sephadex 
chromatography 
(IEX) DEAE 
cellulose 
Immuno 
affinity 
chromato-
graphy 
(IEX) Macro-
Prep DEAE 
support 
2
nd
 step 
Protamine 
sulphate 
precipitation 
Protamine 
sulphate 
precipitation 
(Adsorption 
chromatography) 
Biogel-HTP 
hydroxyapatite 
Protamine 
sulphate 
precipitation 
 
Protamine 
sulphate 
precipitation 
3
rd
 step 
(IEX) DEAE 
cellulose  
(IEX) 
Carboxymethyl 
cellulose  
(HIC) 
phenylalanine 
sepharose 
(SEC) 
Agarose gel 
 
(SEC) 
Agarose gel 
4
th
 step 
Protamine 
sulphate 
precipitation 
Ammonium 
sulphate 
precipitation 
    
5
th
 step 
(IEX) DEAE 
cellulose  
(SEC) Agarose 
gel  
    
 
Table 1. 2: Purification methods for guinea pig liver TGase 2 
Methods and techniques used in the different purification processes 
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1.6.7. TGase 2 in diseases 
TGase 2 dysregultaion is involved in various human diseases, thus becoming a 
potential therapeutic target (Siegel and Khosla, 2007). Increased TGase 2 enzymatic 
activity is involved in the pathology or etiology of several diseases such as renal 
fibrosis, liver cirrhosis and fibrosis, diabetes, celiac disease, some types of cancer 
and neurodegenerative diseases (Mirza et al., 1997; Molberg et al., 2000; Bernassola 
et al., 2002; Johnson et al., 2003; Issa et al., 2004; Mangala and Mehta, 2005; 
Hoffner and Djian, 2005). 
1.6.7.1. Renal and liver fibrosis 
An important feature in fibrosis is the deposition of ECM. As explained above 
(1.6.4.), TGase 2 plays a role in the deposition and stabilization of the ECM in 
healthy and pathological conditions, either through crosslinking of some components 
of the ECM or by activating a pro-fibrotic growth factor like TGF-β1 which is 
involved in the regulation of fibrogenesis and apoptosis (Johnson et al., 2003; 
Kojima et al., 1993). In fact, some of the proteins present in the ECM are substrates 
for TGase 2 (Nardacci et al., 2003). 
TGase 2 and its cross-linked products are present at high levels in the tubular cells of 
the fibrotic kidneys (Johnson et al., 1997), suggesting the enzyme plays an important 
role in the disease. Also, recent studies performed in experimental models have 
indicated that inhibition of TGase 2 reduces fibrosis and preserves kidney function 
(Johnson et al., 2007).  
In liver fibrosis, it has been demonstrated that there is an increase in TGM2 
expression and in the secretion of several molecules such as IL-1 , TGF-α , TNF-α 
and IL-6 (Mirza et al., 1997) that can activate TGase 2 (Nardacci et al., 2003). But 
the role of TGase 2 in this disease is quite complex, as some studies have 
demonstrated that the increase in levels of TGase 2 in the early stages of liver 
fibrosis protects the liver from damage (Nardacci et al., 2003; Elli et al., 2009). Thus 
the effects of TGase 2 on fibrogenesis are still not well understood and require more 
study.  
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TGase 2 is also involved in other types of cirrhosis such as pulmonary fibrosis in 
which the enzyme is involved in similar processes as in liver fibrosis, which can lead 
to lung failure due to the deposition of scar tissue (Griffin et al., 2002; Richards et 
al., 1991). It has also been demonstrated that specific over-expression of TGase 2 in 
mouse heart cells promotes cardiac hypertrophy, fibrosis and depressed ventricular 
function due to an increase in cross-linking activity (Small et al., 1999).  
1.6.7.2. Diabetes  
TGase 2 is thought to be involved in the regulation of insulin release from the 
pancreas due to Ca
2+
 dependent glucose-stimulation (Gomis et al., 1983; Sener et al., 
1985) and with the internalization, aggregation and intracellular processing of insulin 
receptors (Baldwin et al., 1980; Davies et al., 1980). Studies performed by 
Bernassola et al., (2002) showed that TGase 2 could be associated with the 
modulation of β-cell functions, as TGase 2 knockout mice showed a phenotype with 
mild impairment in glucose stimulated insulin secretion (Bernassola et al., 2002).  
1.6.7.3. Celiac disease  
Celiac disease is an intestinal disorder characterized by damage in the small intestine, 
caused by the intolerance to gluten proteins present in wheat and cereal derivatives 
(Sollid, 2002). Patients usually show problems with intestinal absorption (Kim et al., 
2002). In this disease, TGase 2 is able to deamidate glutamine residues in the gluten 
proteins to form glutamate residues, generating high amounts of gluten peptides with 
negative charges that can bind human leukocyte antigens (HLA-DQ2 or -DQ8), 
triggering a T cell response (Vader et al., 2002; Shan et al., 2002). It has also been 
shown that TGase 2 specific auto-antibodies are present in the small intestine and in 
the blood. The detection of these auto-antibodies in the serum could be used as an 
indicator of celiac disease (Dieterich et al., 1997; Korponay-Szabo et al., 2003; Sardy 
et al., 1999). 
1.6.7.4. Cancer  
TGase 2 dysregulation is involved in the development of some cancers.  Studies have 
shown that TGase 2 is upregulated in certain cancers, such as malignant melanoma 
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(Fok et al., 2006), pancreatic ductal adenocarcinoma (Verma et al., 2006), and 
glioblastoma (Yuan et al., 2005). High expression levels of TGase 2 have been 
reported in cancers that show drug resistance (Mehta et al., 2002) or metastatic 
ability (Mehta et al., 2004). TGase 2 activity protects against apoptosis in certain 
types of cells, while its downregulation with siRNA or its inhibition by 
pharmacological agents causes an increase in the sensitivity of cells to apoptosis 
(Mangala et al., 2007; Antonyak et al., 2004). This phenomenon could be due to the 
activation of the focal adhesion kinase (FAK) by TGase 2, triggering the activation 
of anti-apoptotic pathways (Verma et al., 2006). In other cancers, TGase 2 
expression is downregulated; TGase may be therefore acting as a tumour suppressor 
(Birckbichler et al., 2000; Jones et al., 2006). These conflicting results indicate that 
the importance of TGase 2 in cancer depends on the location of the cancer, the type 
of cancer and the cell type (Siegel and Khosla, 2007). 
1.6.7.5. Neurodegenerative disorders 
Some neurodegenerative diseases such as Alzheimer‟s disease (AD), Parkinson‟s 
disease (PD), Huntington‟s disease (HD) and progressive supranuclear palsy are 
characterized by the formation of insoluble protein aggregates (Grune et al., 2004). 
One of the first reports that related TGase activity with neurodegenerative diseases 
was published in 1982, when Selkoe and his collaborators reported the presence of 
active TGase in the brain and its capacity for cross-linking brain proteins into 
polymers in vitro (Selkoe et al., 1982). It has been identified the presence of TGase 
1, TGase 2 and TGase 3 in normal human brain and although TGase 2 is almost 
nonexistent, it is the most abundant isoform and is mainly localised in neurons (Kim 
et al., 1999; Appelt et al., 1996; Lesort et al., 1998), although its activity has been 
described in other neural tissues (Lesort et al., 2000a). Also, the presence of mRNAs 
for TGase 5, TGase 6 and TGase 7 has been described in human brain (Krasnikov et 
al., 2005; Grenard et al., 2001).  
It is currently believed that TGases do not cause neurodegenerative diseases, 
although once the disease has started they contribute to the pathology (Jeitner et al., 
2009b). It has also been reported that TGase activity is markedly increased in a 
variety of neurodegenerative diseases (Jeitner et al., 2009b). 
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Oxidative stress has been suggested as one of the main pathological causes for 
neurodegeneration and for this reason it has been proposed the use of antioxidants as 
therapeutic treatment (Uttara et al., 2009). Oxidative stress arises when the pro-
oxidant and oxidant homeostasis is disrupted, generating ROS and free radicals. ROS 
causes the oxidation of several molecules such as lipids, proteins and DNA, causing 
cellular damage that leads to cell death mainly by apoptosis (Gilgun-Sherki et al., 
2001). Oxidative stress also initiates excitotoxicity effects which together with 
apoptosis are a very important mechanism in cell death in neurodegenerative diseases 
(Friedlander, 2003). A common feature in all neurodegenerative diseases is 
mitochondrial impairment (Beal, 1992) which has been suggested to contribute to the 
increase of TGase 2 activity (Lesort et al., 2000a). Another common characteristic of 
neurodegenerative diseases is increased intracellular levels of Ca
2+
, as raised Ca
2+
 
levels can potentially lead to the activation of TGases, enhancing the formation of 
aggregates (Lue et al., 1996; Jeitner et al., 2009a) and also can lead to the production 
of ROS by activating the arachidonic acid cascade (Emerit et al., 2004). 
The main proteins (huntingtin, amyloid β, tau and α synuclein) involved in the 
formation of aggregates and thought to be pathogenic in the above mentioned 
neurodegenerative diseases, are substrates for TGase 2 in vitro (Siegel and Khosla, 
2007). It has therefore been suggested that in neurodegenerative diseases, TGase 2 
catalyses the formation of toxic and insoluble high molecular weight oligomers.  
The oxidative modifications of proteins produced by oxidative stress could also 
facilitate the formation of aggregates (Ross and Poirier, 2004), but there are also 
evidences that indicate the production of ROS during the formation of the abnormal 
protein aggregates (Tabner et al., 2003). 
There is currently no cure for the majority of neurodegenerative diseases. The use of 
calcium channel blockers has been studied as a possible treatment for the 
neurodegenerative diseases; however, the mechanisms leading to increased 
intracellular Ca
2+ 
concentration are not the same in the different neurodegenerative 
diseases. On the other hand, the increase in TGase activity is a common feature, 
suggesting the possible use of TGase inhibitors as therapeutic agents (Jeitner et al., 
2009a). 
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Treatment with cystamine, which is able to inhibit TGase activity, has been proved to 
show health benefits in HD (Karpuj et al., 2002) and PD animal models (Stack et al., 
2008). However, cystamine has multiple effects in the brain, such as increasing the 
levels of brain derived neurotrophic factor, attenuating macroautophagy and 
inhibition of apoptosis (Borrell-Pages et al., 2006; Jeitner et al., 2009b; Lesort et al., 
2003), which increases neuronal survival. Therefore it is difficult to know if the 
effects are due to the inhibition of TGase or to other effects of cystamine. Also, some 
studies related with peptide based TGase inhibitors have shown that a calmodulin 
derived peptide is able to attenuate the action of TGase on mutant htt and generate 
health benefits in a HD transgenic murine model (Jeitner et al., 2009a). 
1.6.7.5.1. Alzheimer’s disease 
This is the most common form of dementia, characterized by the loss of memory and 
cognitive decline. Alzheimer‟s disease (AD) was first described in 1906 by Alois 
Alzheimer (Jeitner et al., 2009a) and is caused by the formation of extracellular 
amyloid plaques and intracellular neurofibrillary tangles (Tiraboschi et al., 2004). 
The plaques are formed by the cross-linkage of amyloid β (Aβ), especially the toxic 
form Aβ42 and other proteins like the nonamyloid component (NAC) which is a 
fragment of α-synuclein (Wirths, 2000), while the tangles are aggregates of 
cytoskeletal elements and hyper-phosphorylated tau (Jeitner et al., 2009a). Parkin, 
HSP27, ubiquitin, α-synuclein and γ-glutamyl-ε-lysine bonds have been also 
identified in the tangles of AD brains (Nemes et al., 2004; Citron et al., 2001). There 
are two hypotheses to explain the initiation of the disease, the amyloid hypothesis 
which proposes that it is due to the Aβ deposition (Hardy and Allsop, 1991) and the 
tau hypothesis, which proposes the formation of the neurofibrillary tangles as the 
first step (Mudher and Lovestone, 2002). 
In the affected areas of AD brains, TGase activity is increased as well as the protein 
levels of TGase 1 and 2 (Kim et al., 1999). The factors that regulate TGase 1 
expression in the brain are not yet elucidated, but it has been described that the 
promoter in the TGM2 gene contains a binding site for nuclear factor (NF-κβ) 
through which glutamate and inflammatory molecules that are also related with AD 
can act, thus up-regulating the expression of TGM2 (Jeitner et al., 2009a).  
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A splice variant of TGase 2 shows increased gene expression in AD brains (Fraij et 
al., 1992; Festoff et al., 2002; Citron et al., 2002). This truncated isoform of TGase 2 
can not bind GTP and, using in vivo assays, it has been seen that it is able to induce 
apoptosis without using its transamidating activity (Antonyak et al., 2006). The 
alternative splicing mechanism has been suggested as a means by which the cell can 
generate new isoforms of TGase (Fraij et al., 1992; Rybicki et al., 1994). 
To be able to stablize the Aβ plaques through the formation of γ-glutamyl-ε-lysine 
bonds, TGase 2 has to be present in the ECM. Although the export of TGase 2 from 
neurons has not been described yet, the enzyme could arrive to the ECM via cellular 
release or cell lysis (El Nahas et al., 2004). It has been published that extracellular 
TGase 2 is catalytically inactive, but it can be activated by tissue injury (Siegel et al., 
2008), although other groups have suggested that it is activated by Ca
2+
 (El Nahas et 
al., 2004; Zemskov et al., 2006).  
Other processes such as mitochondrial dysfunction (Beal, 1995) and proteosome 
deregulation are also involved in AD (Martin, 1999). Some studies indicate that AD 
brains have an increase in oxidative damage, which could be due to mitochondrial 
impairment (Beal, 1995), to Aβ42 peptide toxicity (Hensley et al., 1994) or to the 
activation of glial cells by inflammation and cellular stress phenomena (Rosenberg, 
2000). This damage leads to an increase in the levels of intracellular Ca
2+
 and 
excitotoxicity in the neurons (Mark et al., 1996; Mattson et al., 1995). 
TGase 1 could play a similar role to TGase 2, as its cytosolic form can interact with 
some of the TGase 2 substrates. TGase 1 could also contribute to the formation and 
stabilization of the tangles by catalyzing the binding of ceramides to Q residues, 
which could promote the addition of fatty molecules (Jeitner et al., 2009a).  
Finally, it has been hypothesized that TGases could contribute to AD by starting the 
oligomerization and aggregation of amyloid β proteins at physiological levels 
(Hartley et al., 2008). 
1.6.7.5.2. Parkinson’s disease 
Originally described by James Parkinson in 1817, PD is the second most common 
neurodegenerative disorder, characterized by the presence of tremors, rigidness, 
bradykinesia and instability. The etiology of this disease is the loss of dopaminergic 
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neurons in the substantia nigra pars compacta (SNc), but its causes are still unclear 
(Jeitner et al., 2009). The damaged areas of the brain present intraneuronal 
aggregates called Lewy bodies (Lees, 2009). The main component of these 
aggregates is the α-synuclein protein (Spillantini et al., 1997), but the NAC is also 
present (Arima et al., 1998).  
PD patients show very high concentrations of TGase 2 in their cerebrospinal fluid 
(Vermes et al., 2004) as well as co-localization of TGase 2 with α-synuclein in the 
halo of Lewy bodies (Junn et al., 2003). In PD brains, there is also an upregulation of 
TGase 2 mRNA and an increase in TGase 2 protein expression (Citron et al., 2002). 
It also seems that mitochondrial dysfunction occurs in PD (Rosenberg, 2002), as 
some patients show a decrease in the activity of complex I of the mitochondrial 
electron transport system. Studies have demonstrated that the inhibition of this 
complex can provoke Parkinsonism (Emerit et al., 2004) and the dysfunction in this 
organelle, provokes a leak of Ca
2+
 in the cytosol that can activate TGase 2 (Surmeier, 
2007). PD brains show oxidative stress damage (Halliwell and Gutteridge, 1999) as 
well as apoptosis and caspase activation (Friedlander, 2003).  
The neurons that constitute the SNc, use Ca
2+
 instead of Na
2+
 ions to carry the 
electrical signals, suggesting that TGase 2 in the SNc may be regulated in a different 
manner, although is still not known (Jeitner et al., 2009a). More studies are needed to 
fully understand the role of TGase 2 in PD. 
1.6.7.5.3. Huntington’s disease 
HD is an autosomal dominant disorder, associated with an increase in CAG repeats 
in the huntingtin gene (htt). When the gene contains 40 or more CAG repeats, HD is 
developed (Gusella et al., 1993) and the more the number of repeats the more severe 
are the symptoms (Andrew et al., 1993). The CAG codon is translated as a glutamine 
aminoacid (Q), meaning that htt mutant protein contains polyglutamine stretches in 
the N-terminus, which are excellent substrates for TGase 2 in vitro (Kahlem et al., 
1996).  
HD brains show an increase in TGase activity in vivo as well as an increase in the 
levels of Nε-(γ-L-glutamyl)-L-Lysine bond, produced by TGase mediated protein 
cross-linking reaction (Jeitner et al., 2001).  
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HD brains also suffer from inflammation, showing increased levels of molecules 
related with this phenomenon, such as tumour necrosis factor alpha (TNF-α) which 
stimulates the translocation of TGase 2 in to the nucleus as well as the up-regulation 
of TGase 2 protein levels in astrocytes and in microglia (Campisi et al., 2004; Lee et 
al., 2004).  
Mutant htt provokes an increase in the cytosolic Ca
2+
 levels via IP3 receptors after 
the glutamate dependent hydrolysis of PIP2 (Tang et al., 2003). Poly Q htt also 
interferes with the capacity of the mitochondria to store Ca
2+
, by affecting the 
permeability of the organelle membrane to Ca
2+ 
(Lim et al., 2008). The resultant 
increase in the cytosolic Ca
2+
 concentration could activate TGases among other 
proteins. 
It has also been described that calmodulin, a Ca
2+
 binding protein, can interact with 
poly Q-expanded htt, regulating TGase 2 activity. When calmodulin is inhibited or 
its association with poly Q-expanded htt is disrupted, the abilitiy of the poly Q-
expanded htt to act as a substrate for TGase 2 is decreased (Zainelli et al., 2004; 
Dudek et al., 2009).  
Studies with transgenic HD mice that were TGase 2 knockout, showed that the 
absence of TGase 2 improved motor function and the mice lived longer, suggesting 
that TGase 2 cross-linking activity is involved in the pathogenesis of this disease. 
However, further studies with the same mice, revealed that, in the absence of TGase 
2 there was an increase in the formation of insoluble aggregates and the disease 
didn‟t ameliorate. Therefore, evidence suggests that TGase 2 may not be involved in 
the formation of the insoluble aggregates (Matroberardino et al., 2002; Bailey and 
Johnson, 2005). Interestingly, studies have found that using in vitro assays, TGase 2 
is able to cross-link mutant poly Q monomers, generating high molecular weight 
soluble aggregates, which can be important in the pathogenesis of HD (Michalik et 
al., 2003). Currently, it is still not clear if the insoluble, the soluble aggregates or 
both, have toxic effects (Lai et al., 2004).  
As for other neurodegenerative diseases, another characteristic of HD is 
mitochondrial dysfunction, which leads to an increase in TGase activity in situ 
(Lesort et al., 2000a). However findings by Cooper and his co-workers have 
suggested that the increase in TGase 2 activity in HD brains could provoke the 
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incorporation of aconitase, which is an enzyme that catalyses the conversion of 
citrate into isocitrate in the tricarboxylic acid cycle (TCA) (Malorni et al., 2008), into 
inactive polymers, thus contributing to the mitochondrial dysfunction (Kim et al., 
2005).  
The role of TGase 2 in HD has not been elucidated, although it seems there is a link 
between TGase 2 activity and mitochondrial impairment that contributes to the 
pathogenesis of HD (Ruan and Johnson, 2007). In vitro studies have shown that 
TGase 2 is important in the maintenance of certain mitochondrial functions (Malorni 
et al., 2008) and when TGase 2 is over-expressed an important amount of the enzyme 
is localised in the mitochondria affecting their morphology and physiology 
(Piacentini et al., 2002; Rodolfo et al., 2004). The presence of BH3 proteins in the 
mitochondria allows TGase 2 to interact with and modify Bax and Bak, which are 
pro-apoptotic members that play a key role in the regulation of the mitochondrial 
pathway of apoptosis (Rodolfo et al., 2004). The over-expression of TGase 2 
generates a hyper-polarization of the mitochondria, possibly due to an increase in the 
proton pumping from the respiratory chain and also an imbalance of the redox status, 
generating the accumulation of ROS (Piacentini et al., 2002). 
1.6.7.5.4. Progressive supranuclear palsy 
This disorder is characterized by supranuclear vertical gaze palsy, instability and 
cognitive problems (Houghton and Litvan, 2007). It was first described by Steele and 
his collaborators in 1964 (Steele et al., 1964). It is caused by gliosis, demyelination, 
loss of neurons and formation of neurofibrillary tangles (Jeitner et al., 2009a). 
The affected regions in progressive supranuclear palsy brain show an increase in 
TGase activity and in protein and mRNA levels for both TGase 1 and 2 (Zemaitaitis 
et al., 2003). In this disorder there is also disruption of Ca
2+
 homeostasis that could 
account for the activation of the TGases (Albers and Augood, 2001). Other features 
such as mitochondrial impairment and formation of free radicals have been described 
in progressive supranuclear palsy, possibly playing important roles in the disease 
(Albers et al., 2001). 
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1.6.8. TGase 2 in neural systems 
TGase 2 plays an important role in several processes that occur in normal neural 
tissues. The enzyme is thought to be involved in the plasticity and stabilization of the 
synapse in the CNS by the formation of protease resistant structures (Festoff et al., 
2001). It is suggested that TGase is involved in the suppression of catecholamine 
release from neurons, generating a negative feedback that will also prevent an 
excessive release of transmitters (Pastuszko et al., 1986). TGase 2 is also important 
in axonal regeneration, showing a significant increase in activity during this process 
(Chakraborty et al., 1987).  
It has been demonstrated that over-expression of TGase 2 in neuronal cells triggers 
spontaneous apoptosis and makes cells more susceptible to death by affecting 
mitochondrial homeostasis (Piacentini et al., 2002). Studies in SH-SY5Y human 
neuroblastoma cells have shown that TGase 2 is involved in neuronal cell death or 
survival. In this case, when the apoptotic stresses affecting the cells are able to 
induce the transamidating activity, TGase 2 enhances apoptosis, although it does not 
initiate it and it is not required for the process. In contrast, when the stressor fails to 
increase the transamidating activity, TGase 2 reduces apoptotic cell death. Thus, 
TGase 2 plays a modulator role in neuronal survival under stress conditions 
(Tucholski and Johnson, 2002). 
Experiments performed by the same group have indicated that upregulation of the 
transamidating activity of TGase 2 is required in neurite outgrowth (Tucholski et al., 
2001). TGase 2 is essential in the differentiation of neuronal cells because it is able 
to activate directly or indirectly the enzyme adenylyl cyclase (AC), which leads to an 
increase in cAMP production with the subsequent phosphorylation and activation of 
CREB (Tucholski and Johnson, 2003). As CREB is a transcription factor that 
modulates synaptic plasticity, cell survival and cell differentiation (Lonze and Ginty, 
2002), the cAMP-CREB pathway activated by TGase 2 is critical in neuronal 
differentiation (Mena et al., 1995). 
The presence of TGase 2 and its cross-linking activity have also been described in 
neurite adhesion sites or growth cones from cerebellar granule neurons, in which 
there are several substrates for TGase 2 (Perry et al., 1995; Mahoney et al., 2000). 
Some studies have proposed that TGase 2 could be also involved in cytoskeletal 
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stabilization by cross-linking covalently microtubules with other cellular components     
(Maccioni and Seeds, 1986). The formation of neurite adhesion sites and the 
cytoskeletal stabilization are critically important processes in neuronal development 
(Lesort et al., 2000a). 
Other studies have shown that TGase 2 is also present in rat neurons (Perry et al., 
1995) and astrocytes (Monsonego et al., 1997). Rat astrocytes treated with IL-β1 and 
TNF-α cytokines have shown an increase in TGM2 expression together with the 
expression of a novel transcript of TGM2 not detectable in any other tissue and in 
non treated astrocytes. The novel isoform has a molecular mass of 73 kDa and differs 
from the full length isoform in the C-terminal. Both isoforms can probably act as 
TGases or GTPases, although the shorter one shows a GTP-independent TGase 
activity and is more Ca
2+
 dependent, maybe to control its GTP-independent 
crosslinking activity. This novel isoform has been only detected in cytokine-induced 
astrocytes and when TGM2 is over-expressed, which suggests that its expression is 
either specific to these cells or the conditions of its induction in other tissues remains 
unknown. The functions of this short TGase 2 isoform have not been reported 
(Monsonego et al., 1997).  
1.7. Glia 
Glia cells are major components of the nervous system. Although neurons are the 
most important cells in the nervous system in terms of neurotransmission, the interest 
in glia has been rising in the last decade due to their proposed multiple roles. The glia 
include all of the neural cells that do not transmit electrical signals and it can be 
found in most species. The number of glial cells is much higher than that of neuronal 
cells, around 90 % of the cells composing the human brain being glial.  
Glia include different types of cells with different morphologies and functions, 
including microglia, astrocytes and oligodendrocytes in the central nervous system 
(CNS) or Scwhann cells in the peripheral nervous system (PNS) (Figure 1. 6). 
Glial cells originate from the neuroectoderm, except the microglia which are thought 
to develop from the immune system and reach the brain through the blood circulation 
during development of the organism (Allen and Barres, 2009). 
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Figure 1. 6: Schematic representation of neural cells 
Different type of cells present in the glia and their interactions with neurons and 
blood vessels. Image obtained from Allen and Barres, (2009). 
 
  
Historically glia were described as „brain glue‟ with the main function being the 
maintenance of the neurons, but studies have shown that glia have different functions 
depending on the type of glial cell. There is also increasing evidence that glia are 
important in information processing by receiving and sending signals to the neurons 
(Haydon and Carmignoto, 2006; Verkhratsy and Toescu, 2006). Glia disruption is 
also associated with some diseases, as the astrocytes can mutate and generate a 
tumour called glioma, and the oligodendrocytes can become the target of an 
autoimmune attack in multiple sclerosis (Allen and Barres, 2009). 
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1.7.1. Microglia 
It is suggested that microglia are derived prenatally from mesodermal (myeloid) 
tissue (Chan et al., 2007).  These cells have a protective role, checking the brain for 
infections or damage and digesting dead cells. They are also involved in the 
elimination of inadequate synapsis (Allen and Barres, 2009). In some 
neurodegenerative disorders such as AD, microglia are activated (de la Torre, 2002; 
Grammas et al., 2002) changing their phenotype to an ameboid form with a 
phagocytic function (Nakamura, 2002), although it is still not known if this is either a 
beneficial or damaging process (Allen and Barres, 2009). 
1.7.2. Oligodendrocytes 
The oligodendrocytes and Schwann cells are in charge of the synthesis of the myelin 
sheath that insulates the axons of 90 % of neurons in the CNS and PNS. The 
myelination of axons increases the speed of the electrical signals (Allen and Barres, 
2009). In the neurodegenerative disorder multiple sclerosis, the myelin sheath of the 
oligodendrocytes suffers an autoimmune attack provoking the demyelination of 
axons (Antel, 2006). The loss of this glial cell type has also been associated with 
clinical depression (Allen and Barres, 2009). 
1.7.3. Astrocytes 
Astrocytes play several important roles that support the functionality of neurons. 
Traditionally it was thought that the main function was to regulate the levels of 
extracellular K
+
 ions (Orkand et al., 1966), but nowadays it is well known that 
astrocytes have more complex roles. They can act as physical barriers, separating 
synaptic connections of neighbouring neurons; they can also finish the action of 
neurotransmitters by recycling them, protecting the neurons from excitotoxicity. This 
regeneration is via the glutamate-glutamine cycle, where the astrocytes are able to 
amidate the glutamate taken up, obtaining glutamine that is transferred back to the 
neurons where is reconverted into glutamate (Hassel et al., 1997; Hertz et al., 1999). 
This cycle can be stopped by inhibitors of the enzyme glutamine synthetase, which is 
damaged by oxidative stress (Levine, 1983). Therefore the formation of glutamine 
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can be inhibited by oxidative stress, leading to the accumulation of glutamate 
provoking excitotoxicity.  
This phenomenon enhances the production of proteolytic enzymes and ROS 
formation (Lipton et al., 1993) that will activate cell apoptosis. Astrocytes also 
intervene in the formation of synapses and supply the neurons with energy (Allen 
and Barres, 2009). Astrocytes are in contact with both neurons and blood vessels; 
after neuronal activity, there is a Ca
2+
 response in the astrocytes that activates them, 
in order to signal the blood vessels to regulate the blood flow (Zonta et al., 2003) to 
obtain more glucose and oxygen that will be transported to the neurons by the 
astrocytes (Allen and Barres, 2009). In vitro studies have shown that glutamate 
intake by astrocytes induces glycolysis, generating lactate that is released and can be 
then taken up by neurons, which can use it as an energy substrate apart from the 
glucose obtained from the astrocytes or directly from the capillaries (Tsacopoulos 
and Magistretti, 1996). Astrocytes are also able to protect neurons against oxidative 
stress by releasing antioxidants such as glutathione and providing the neurones with 
its precursor cysteine (Sagara et al., 1993). 
It is well known that astrocytes can not transmit electrical signals, but they can be 
excited by chemical signals from neurons or in a spontaneous way. This excitation of 
the astrocytes triggers Ca
2+
 cascades that activate them and are able to propagate to 
other astrocytes, indicating that the cells can communicate with each other (Volterra 
and Meldolesi, 2005). Astrocytes can also communicate with neurons, by releasing 
gliotransmitters such as glutamate, ATP, cytokines, D-serine and other molecules 
that are able to enhance or inhibit neuronal activity, showing the existence of a 
bidirectional signalling (Pasti et al., 1997).  
Astrocytes are not identical, as they can be separated in to at least two groups, the 
protoplasmatic astrocytes which are present in the grey matter and associated with 
the neuronal cell body and synapses, and the fibrous astrocytes present in the white 
matter and associated with the axons (Allen and Barres, 2009).  
1.7.3.1. Transglutaminase activity in astrocytes 
Studies on differentiated astrocytes have shown that prolonged exposure to glutamate 
generates cell damage, and increases the levels of ROS and Ca
2+
, thus activating 
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calcium dependent enzymes that can cause mitochondrial impairment leading to cell 
death (Mawatari et al., 1996; Chen et al., 2000). 
In vitro studies have shown that following a prolonged exposure of astrocytes to 500 
µM glutamate, there is an increase in the expression of TGM2 and in the TGase 2 
protein levels (Campisi et al., 2004). The excessive activation of glutamate receptors 
has been related with several neurodegenerative diseases (Doble, 1999; Meldrum, 
2000). Taken together these studies suggest that a possible alteration in glutamate 
transport, especially in astrocytes could be involved in the development of 
neurodegenerative diseases (Trotti et al., 1998). Whether or not the alteration of 
glutamate transport generates an increase in TGase 2 protein levels remains unclear. 
As described above (1.6.7.5.) there is an upregulation of TGase 2 in 
neurodegenerative diseases, which has been hypothesized to be caused by ROS 
formation triggered by the activation of glutamate receptors (Campisi et al., 2004). 
The formation of ROS can also be induced by exposure to other agents such as 
organophosphates (Garcia et al., 2001) and some of them can disrupt Ca
2+
 
homeostasis (El-Fawal and Ehrich, 1993). 
1.8. Neuronal effects of organophosphates 
1.8.1. Historical view of organophosphates 
Organophosphates (OPs) are chemical compounds formed by a reaction between 
alcohol and phosphoric acid. The first organic phosphorus compounds were 
synthesized in the early 1800s by Lassaigne, although it was in 1854, when Clermont 
described the synthesis of the OPs using tetraethyl pyrophosphate (TEPP) (Singh and 
Khurana, 2009). Their development into insecticides occurred in early 1940s when 
Schradder‟s group synthesized around 2000 compounds, including the pesticide 
parathion and chemical warfare agents such as sarin and tabun (Antonijevic and 
Stojiljkovic, 2007). 
Nowadays, OPs are commercialized in a wide variety of formulations but keeping the 
general structure shown in Figure 1. 7. They are mainly used as pesticides and 
insecticides in agriculture, gardening and industry (Costa, 2006). 
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Some studies indicate that environmental levels of toxins such as OPs, can contribute 
to the formation of neurodegenerative diseases such as PD (Caughlan et al., 2004). 
 
 
     P 
 
 
 
Figure 1. 7: General organophosphate structure 
Oxygen or a sulphur atom can be attached to the phosphorus through a double bond. 
R1 and R2 are usually alkoxy groups and X is the „leaving group‟, as it displaced 
during the phosphorylation of the AChE active site. 
 
1.8.2. Primary targets in the nervous system 
The main target for the insecticide OPs is the enzyme acetylcholinesterase (AChE), 
which is involved in the degradation of the neurotransmitter acetylcholine present in 
the peripheral and central nervous system, generating choline and acetic acid. When 
AChE activity is inhibited, acetylcholine accumulates in the synapses generating an 
over stimulation of the muscarinic and nicotinic receptors (Pope, 1999), causing 
tremors, diarrhoea and muscular convulsions that lead to death due to the paralysis of 
the respiratory muscular centres (Pope et al., 2005). OPs with a P=O moiety (Figure 
1. 7) block the action of the AChE by phosphorylating the hydroxyl group on serine 
present in the active site of the enzyme. This reaction generates a transient 
intermediate complex that is partially hydrolyzed with the loss of the X substituent 
group, forming a phosphorylated, stable and un-reactive inhibited enzyme (Figure 1. 
8) (Sato, 2006). Inhibited AChE can be reactivated by oximes, as their positively 
charged atom can attack the anionic site of the enzyme, dephosphorylating it. 
Reactivation of the enzyme has to occur before the enzyme-inhibitor complex 
becomes „aged‟, otherwise the AChE is irreversibly inhibited and the only way to 
recover the activity is by synthesizing new enzyme.  
R1 O (S) 
R2 X 
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Figure 1. 8: Mechanism of organophosphate mediated esterase inhibition. 
OPs bind to the hydroxyl group of the serine present in the active site of the enzyme 
with the loss of the group labelled “X” in the Figure 1. 7. Obtained from Ahmad, 
2011. 
 
The aging process is due to the loss by nonenzymatic hydrolysis of one of the two 
alkoxy groups (R) present in the OPs, therefore the OP-serine conjugate is 
dealkylated inhibiting the enzyme irreversibly (Costa, 2006; Li et al., 2007). The rate 
of aging is related with the nature of the alkoxy group (Costa, 2006). AChE has been 
used as a model for the study of the aging process. The main mechanism is explained 
by the catalytic involvement of the residues present in the enzyme, in this case, the 
protonated histidine present in the catalytic triad, a glutamic acid residue adjacent to 
the catalytic serine and a nearby tryptophan residue facilitate the dealkylation of the 
OP-enzyme adduct (Viragh et al., 1997; Li et al., 2007). In this process, these 
residues also promote the cleavage of the O-C bond of one of the two alkoxy groups, 
generating a carbocation in the leaving alkoxy group and a negatively charged 
phospho-oxygen. This reaction makes the carbocation vulnerable to a nucleophilic 
attack by water (Viragh et al., 1997; Li et al., 2007). This mechanism has been also 
found in the inhibition of butyrylcholinesterase by diisopropylfluorophosphate 
(Masson et al., 1997). 
Another important target for some OPs is neuropathy target esterase (NTE), which is 
a member of the serine hydrolase family of enzymes. Inhibition of this enzyme 
followed by its aging (in the same process as described for AChE), is related with a 
+ Organophosphate 
“Active” 
target protein 
“Inactive” 
target protein 
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disorder known as organophosphate induced delayed neuropathy (OPIDN) (Johnson, 
1970). 
1.8.3. OPIDN 
This disorder is characterized by the shaking of hands and feet, muscle weakness, 
sensory loss and ataxia (Lotti, 1991; Ehrich and Jortner, 2001). The symptoms can 
appear up to a few weeks following exposure to OPs, as described for tri-ortho-
cresyl phosphate (TOCP), which is a poor AChE inhibitor (Abou-Donia and 
Lapadula, 1990) and it is metabolised into the active congener saligenin cyclic-o-
tolyl phosphate (SCOTP) (Figure 1. 9) (Nomeir and Abou-Donia, 1986).  
 
 
Figure 1. 9: Activation of TOCP to generate the metabolite SCOTP. 
The activation occurs by by hydroxylation and cyclization of the hydroxymethyl 
derivatives in the presence of cytochrome P450 (Chapin et al.,1990; Eto et al.,1962). 
Image obtained from Jokanovic, 2001. 
 
 
One active analogue of is this metabolite is phenyl saligenin phosphate (PSP) which 
is also able to induce OPIDN in animal models (Nomeir and Abou-Donia, 1986), to 
inhibit neurite outgrowth and increase the phosphorylation of the neurofilament 
heavy chain which is a substrate for TGase 2 (Hargreaves et al., 2006). In vitro 
studies have shown that PSP is able to induce the phosphorylation of tubulin from 
porcine brain (Flaskos et al., 2006), thus suggesting that the phosphorylation of 
cytoskeletal proteins is important in the development of OPIDN (Abou-Donia, 
1993). This compound is also able to increase phosphorylation in presence of Ca
2+
, 
TOCP           SCOTP   hydroxymethyl TOCP 
 
                                                                       CHAPTER I. INTRODUCTION 
 
 49 
suggesting that as well as disrupting Ca
2+ 
homeostasis, it is capable of modulating the 
activity of enzymes activated by Ca
2+
 influx (Flaskos et al., 2006). 
Other OPs such as mipafox, diisopropylfluorophosphate, o-tolyl saligenin phosphate 
dioctyl dichlorovinyl phosphate and dibutyryl dichlorovinyl phosphate (Ehrich et al., 
1997) are also able to age the phosphorylated NTE provoking OPIDN. The OPs that 
cannot age the phosphorylated NTE do not generate neuropathic effects, thus 
indicating that the inhibition of NTE activity is not related with the neural 
degeneration (Costa, 2006). In animals, age seems to be important in the 
susceptibility of the enzyme towards the OPs, in that young animals are more 
resistant than adults (Peraica et al., 1993).  
NTE is an integral membrane protein that is expressed in the endoplasmic reticulum 
of all neurons and in some non-neural cells of vertebrates (Glynn, 1999), but it has 
not been localized in glia (Glynn et al., 1998). NTE is an enzyme with esterase 
activity and mainly involved in neural development, although it is also able to 
hydrolyse lipids such as lysolecithin which is a membrane phospholipid with 
demyelination properties as well as being involved in cell signalling between neurons 
and glial cells in the developing nervous system (Glynn, 1999; Costa, 2006). In 
genetic studies, it has been shown that the absence of NTE in the brain leads to loss 
of ER and neural degeneration (Akossoglou et al., 2004). 
The molecular process of OPIDN has not been elucidated yet, but it is known that as 
well as inhibition and aging of NTE, the disorder involves cytoskeletal 
reorganization and the disruption of Ca
2+
 homeostasis (El-Fawal and Ehrich, 1993).  
1.8.4. Intermediate syndrome 
This manifestation of OP toxicity is characterized by weakness in neck, limb and 
respiratory muscles (Senanayake and Keralliedle, 1987). It is not associated with the 
inhibition of AChE and it appears before the signs of OPIDN but after the symptoms 
of cholinergic over-stimulation (Costa, 2006). The mechanisms remain unclear, 
although it is thought that the prolonged activation of the cholinergic receptors leads 
to desensitization, resulting in the muscles weakness (Lotti, 2001). 
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1.8.5. Developmental neurotoxicity 
This effect is related with adverse effects on foetal or child development due to an 
exposure to certain OPs. In this type of toxicity, adults show more resistance to OP 
acute toxicity than the young, while in the case of OPIDN there is an inverse 
response (Peraica et al., 1993). 
Lots of studies have described that developmental exposure to OPs at levels that do 
not inhibit AChE, generate biochemical and behavioural changes (Costa, 2006). In 
vitro experiments have indicated that some OPs such as chlorpyrifos, diazinon and 
parathion are able to inhibit the cell proliferation of rat astrocytes (Qiao et al., 2001; 
Guizzetti et al., 2005) and provoke apoptosis in neuronal cells (Caughlan et al., 
2004). All these data and the recognized exposure of children to some OPs, have lead 
to restrictions in the use of those OPs due to their potential neurotoxicity in children 
(Eskenazi et al., 1999). 
1.8.5.1. Chlorpyrifos and Chlorpyrifos oxon 
In developmental neurotoxicity, one of the most studied OPs is chlorpyrifos (O, O-
diethyl O-(3,5,6-trichloro-2-pyridinyl) phosphorothioate; CPF), also known as 
Dursban. CPF is a widely used pesticide in agriculture, but it is not very widely 
applied in non agricultural uses, as it has been restricted for residential use in USA 
and it is being eliminated in the EU (Eaton et al., 2008). The main target of CPF is 
the enzyme AChE in the CNS and PNS, although it is not a very powerful inhibitor 
in vivo and has to undergo an oxidative desulfuration catalysed mainly by 
cytochrome P-450 oxidase, to become chlorpyrifos oxon (CPFO) (Figure 1. 10) 
which is a more powerful inhibitor of AChE (Betancourt and Carr, 2004; Eaton et al., 
2008). 
CPF also shows neurotoxic effects in developing rodent brains, at concentrations not 
causing inhibition of AChE (Garcia et al., 2001). Studies realised by various groups, 
have shown the existence of a relationship between an increase in the risk of PD and 
exposure to the CPF family of OPs (Di Monte et al., 2002; Checkoway and Nelson, 
1999; Le Couteur et al., 1999). Impairment in the learning and memory of children 
exposed to OPs has also been reported (Guillette et al., 1998). 
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Figure 1. 10: Metabolism of CPF to generate CPFO 
The oxygen molecule substitutes the sulphur present in CPF. Adapted from Eaton et 
al., 2008. 
 
 
Both, CPF and CPFO induce apoptosis and mitochondrial disruption in neuronal 
cells. At low concentrations (<15µM), CPF and CPFO may affect the functionality of 
mitochondria without causing apoptosis (Caughlan et al., 2004). 
In developing rodent brain it has been described that CPF inhibits protein and DNA 
synthesis affecting the normal development of the brain (Whitney et al., 1995). 
In vitro studies have shown that CPF inhibits neurite outgrowth (Das and Barone, 
1999; Sachana et al., 2001), neuronal cell replication (Song et al., 1998) and DNA 
synthesis in neural cell lines (Song et al., 1998; Qiao et al., 2001). CPF interferes 
with the AC transduction cascade (Song et al., 1997; Huff and Abou-Donia, 1995), 
with transcriptional events, affecting AP-1 and SP1 nuclear transcription factors that 
are involved in neuronal cell differentiation (Crumpton et al., 2000a; Kamata et al., 
1996) and with neurotransmission (Dam et al., 1999; Chanda and Pope, 1996). It has 
also been described that in cultured cells, CPF enhances the synthesis of Hsp-90 
(Bagchi et al., 1996) which is a chaperone involved in different functions such as 
protein stabilization and protein trafficking (Goetz et al., 2003) and it has been 
identified as a substrate for TGase 2 (Orru et al., 2003).     
Exposure to this OP also results in the increase of ROS production, although the 
effect disappears when the exposure to CPF is terminated (Bagchi et al., 1996; 
Bagchi et al., 1995; Crumpton et al., 2000a).  
NAPDH, O2 
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In vitro studies performed on glial cells have indicated that CPF affects cell 
replication and differentiation in this type of brain cell (Qiao et al., 2001). Further 
studies have demonstrated that in glial cells, CPF also inhibits DNA synthesis and 
also affects the AC signalling pathway (Garcia et al., 2001) that controls the 
formation of cAMP which plays an important switch signal to activate cell 
differentiation (Bhat et al., 1983). More studies performed by our group, indicated 
that CPF and its metabolite CPFO inhibit glial cell differentiation in NaB treated C6 
cells (Sachana et al., 2008). Glial cells exposed to CPF show an increase in ROS 
formation. The creation of ROS is not associated with direct chemical actions; rather, 
it involves the effects of CPF on cell metabolism (Crumpton et al., 2000b). Studies 
on cultured cells have indicated that ROS are able to disrupt Ca
2+
 homeostasis 
(Bielefeldt et al., 1997); therefore these two phenomena could have an effect on 
TGase 2 activity. 
Also in vivo studies have shown that exposure to sublethal levels of CPF generate a 
preferential decrease in the levels of glial fibrillary acidic protein (GFAP), which is 
an astrocyte marker (Garcia et al., 2002) and in the number of glial cells (Roy et al., 
2004). Taking all the data together, it seems that glial cells are a primary target for 
CPF (Guizzetti et al., 2005).  
1.8.6. Effects of OPs on neural TGase 
As TGase 2 is a Ca
2+
 dependent enzyme, its activity can be disrupted by altered   
Ca
2+
 homeostasis, as well as by the presence of ROS, phenomena known to be 
induced by OPs (El-Fawal and Ehrich, 1993; Bagchi et al., 1996). In studies by our 
group (Harris et al., 2009) it has been described that PSP, an OP that is able to inhibit 
NTE activity and neurite outgrowth in differentiating mouse N2a neuroblastoma 
cells (Hargreaves et al., 2006), decreases TGase activity in vitro in N2a cells and 
increases activity in human HepG2 liver carcinoma cells after 24 h exposure. It is 
also interesting to note that TGase 2 protein levels suffered a decrease in PSP treated 
N2a cells but increased in HepG2 cells, suggesting that the changes in the protein 
levels could be related with changes in activity (Harris et al., 2009). 
Both developmental neurotoxins CPF and CPFO, generate biochemical changes in 
neuronal cells, induce mitochondrial dysfunction, ROS formation and could 
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deregulate Ca
2+
 homeostasis, common features with various neurodegenerative 
diseases. There is also evidence that neurotoxins can affect TGase activity in both 
neuronal and hepatic cells, making TGase 2 a possible target for organophosphate 
toxicity. Studies have addressed the importance of glial cells in ND, and the effects 
of CPF and CPFO on them. Studies performed by our group have indicated that both 
toxins inhibit the differentiation of C6 cells, used as a model of glial cell 
differentiation, although the glial cell type into which C6 cells differentiate in 
presence of NaB has not yet been determined. It is not known whether TGase 2 plays 
an essential role in the C6 cells differentiation, as is the case for neuronal 
differentiation (Tucholski and Johnson, 2003). Therefore it was important to 
investigate the phenotype of the glial model used in this thesis, the role played by 
TGase 2 in this process and how CPF and CPFO could affect TGase 2 present in 
glial cells. 
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1.9. Aims of the project 
 To characterize the differentiating rat C6 glioma cell phenotype 
 To study the effects of CPF and CPFO on TGase 2 activity, protein and gene 
levels in differentiating C6 glioma cells 
 To develop a novel strategy to purify TGase 2 from guinea pig liver and 
porcine brain 
 To study the possibility of direct interactions of highly purified TGase 2 with 
the OPs and other selected esterase inhibitors 
 To study a possible route for the externalization of TGase 2 
  
 
 
 
 
 
CHAPTER II 
 
MATERIALS AND METHODS 
                                                    CHAPTER II. MATERIALS AND METHODS 
 
56 
2. MATERIALS AND METHODS 
2.1. Protein purification  
2.1.1. Purification materials 
2.1.1.1. General reagents 
Laboratory reagents of high purity grade were purchased from Sigma-Aldrich 
Chemical Company (Poole, UK), except where specified in the text. 
2.1.1.2. Purification reagents 
The ion exchange resin Q Sepharose® Fast Flow and the Mono Q™ 5/50 GL column 
were supplied by GE Healthcare Ltd. (Buckinghamshire, UK). Phenyl-Sepharose
® 
CL-4B resin, protamine sulphate salt from salmon (Grade X), TGase 2 from guinea 
pig liver, guanosine triphosphate (GTP) and protease inhibitor cocktail (104 mM 
trypsin inhibitor, 1.5 mM pepstatin A, 4 mM bestatin, 1.4 mM E-64, 2 mM leupeptin, 
0.08 mM aprotinin and 104 mM AEBSF) were obtained
 
from Sigma-Aldrich. The 
sorbents Hexylamine (HEA) Hypercel™, Phenylpropylamine (PPA) Hypercel™ and 
2-mercapto-5-benzimidazole sulphonic acid (MBI) Hypercel™ were purchased from 
Pall (Portsmouth, UK).  
2.1.2. Purification methods 
The purification of a protein is a complex method, with a wide range of possibilities 
and different processes. All the resins and steps studied in this project are described 
in Table 2. 1.  
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Method 
Number 
of steps 
Purification processes involved Starting material 
1 1 HEA, PPA and MBI Guinea pig liver 
2 3 IEX 
Protamine sulphate 
precipitation 
HIC 
Guinea pig liver & 
porcine brain 
3 4 IEX HEA HIC Mono Q Guinea pig liver 
Table 2. 1: Purification processes of TGase 2 from guinea pig liver 
2.1.2.1. Liver homogenisation 
Unless otherwise specified all operations were performed at 2-4˚C. Guinea pig livers 
were obtained from the Nottingham Trent University animal house and stored at        
-80C until required. A volume of 200 ml of homogenisation buffer (25 mM Tris, 
0.25M Sucrose, 5 mM EDTA and 5 mM DTT, pH 7) at 4C containing protease 
inhibitor cocktail (1:200 dilution) was added to fifty grams of guinea pig liver. The 
liver was homogenised for four intervals of 10 seconds, with 15 seconds cooling 
intervals, using a blender (Philips type HR2845\AM). The homogenate was then 
filtered through two layers of muslin, collected and centrifuged at 30,000 g for 30 
min at 4 C in the Avanti™ J-30 I centrifuge from Beckman Coulter Ltd., (High 
Wycombe, UK). The resultant supernatant was then centrifuged at 80,000 g for 45 
min at 4C in the Optima™ L-100 XP centrifuge (Beckman Coulter Ltd). The final 
supernatant was collected, pooled and stored at -20 
o
C in different volume aliquots, 
while the pellet was discarded. 
2.1.2.2. Porcine brain homogenisation 
Porcine brains were obtained from the abattoir and transported to the laboratory on 
ice within 1 h of slaughter. Superficial blood vessels, white matter and the 
hypothalamus, were removed.  Brain tissue was rinsed twice in distilled water then 
placed in 0.5 ml of ice-cold homogenisation buffer per g, containing 100 mM 2-(N-
morpholino)ethane sulphonic acid (MES), 0.5 mM MgCl2, 1 mM EGTA (pH6.8), 
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containing Sigma protease inhibitor cocktail (1:200 dilution). The brain was 
homogenised for 10 seconds in a blender (Philips type HR2845/AM) followed by 4 
passes in a glass-teflon (Potter-Elvehjem) homogeniser at 800 rpm.  Brain 
homogenate was then centrifuged in the same way as for guinea pig liver. The 
resultant cytosolic supernatant was pooled and stored at -20
o
C in working aliquots.  
Brain cytosol was prepared in this way to obtain a higher protein concentration than 
with the liver, as previous preliminary work had suggested that TGase was present at 
much lower levels in brain tissue. 
2.1.2.3. Mixed mode chromatography (PPA resin) 
The aromatic PPA resin (5 ml) was packed into a Biosepra glass column (1.6 x 20 
cm) (Pall) and calibrated with binding buffer (50 mM Tris containing 10 mM CaCl2, 
1 mM DTT) used at pH 5, 5.5, 6 or 7 for each different assay. Crude sample from 
guinea pig liver, was diluted (1/3) in binding buffer to a final volume of 15 ml. 
Before applying it into the column, the sample was centrifuged at 10,000 g for 10 
min at 4˚C in a Sigma 1-15K centrifuge from Scientific Laboratory Supplies Ltd. 
(SLS; Nottingham, UK), to remove any possible precipitated proteins. The sample 
was then loaded into the column at 4 ml/min using the peristaltic pump P-1 from GE 
Healthcare (Chalfont St Giles, UK). When the loading was finished, the resin was 
washed for two column volumes (CV) with binding buffer. TGase 2 was eluted by 
passing 20 ml of elution buffer (50 mM Tris containing 5 mM EDTA, pH 9) at 4 
ml/min
 
through the column. Fractions of 2 ml were collected using a 2110 fraction 
collector model from Bio-Rad (Hemel Hempstead, UK) and analysed for protein 
concentration and TGase activity (sections 2.5. and 2.4.2.1., respectively).  
2.1.2.4. Mixed mode chromatography (MBI resin) 
A volume of 5 ml of MBI resin was packed into a Biosepra glass column (1.6 x 20 
cm). Chromatography was performed as described above (section 2.1.2.3.). 
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2.1.2.5. Mixed mode chromatography (HEA resin) 
The aliphatic HEA resin (5 ml) was packed into a Biosepra glass column (1.6 x 20 
cm). Chromatography was performed as described above (section 2.1.2.3.). 
When the HEA resin was used as a second step in the purification process, the 
method was performed in a different way. A volume of 20 ml of HEA resin was 
packed into a Biosepra glass column (1.6 x 20 cm) and calibrated with 25 mM Tris 
buffer containing 500 µM GTP at pH 7.5. An aliquot (90 ml) of the dialysed pool 
from the IEX (section 2.1.2.6.) was incubated with 500 µM GTP for 5 minutes at 
room temperature. The sample was then loaded into the HEA column at 10 ml/min 
flow using the P-1 peristaltic pump. TGase 2 was collected in the unbound fractions 
which were pooled and transferred into the next step (section 2.1.2.8.). The column 
was then washed as described previously. 
2.1.2.6. Ion exchange chromatography (IEX) 
The XK 50/30 column from Pharmacia Biotech was packed with 250 ml of Q 
Sepharose® Fast Flow resin. Either 100 ml or 50 ml of supernatant prepared as 
described in section 2.1.2.1. or 2.1.2.2., respectively, were diluted (1:10) in buffer A 
(25 mM Tris, pH 7.5) at 4ºC and loaded overnight into the column, previously 
calibrated with the same buffer using the Gilson MINIPULSE volution® peristaltic 
pump from Anachem Ltd. (Luton, UK). The resin was washed at 8 ml/min
 
with 2 CV 
of buffer A to eliminate the unbound proteins. A 900 ml of salt gradient were then 
applied at the same flow rate using buffer A and buffer B (25 mM Tris, 0.6 M NaCl, 
pH 7.5). After three CV, TGase 2 was eluted at 0.3 M NaCl, and 16 ml fractions 
were collected using a 2110 Bio-Rad fraction collector model. TGase activity 
(section 2.4.2.1.) and protein concentrations (section 2.5.) were assayed in the 
fractions obtained, and those showing a specific activity greater than 4 units/ml were 
pooled and dialysed overnight at 4°C against buffer A.  
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2.1.2.7. Protamine sulphate precipitation 
After IEX chromatography (section 2.1.2.6.) and without dialysing the sample, 
protamine sulphate precipitation was performed by the method of Folk and Cole 
(1966) with some modifications. A 1 % (w/v) protamine sulphate solution was 
prepared fresh; 12 ml of this solution was added drop-wise for 20 minutes into 90 ml 
of IEX sample with stirring. The sample was centrifuged at 14,600 g for 15 minutes 
at 4˚C, the supernatant was discarded and the resultant pellet was collected. A 
volume of 10 ml of fresh 0.05 M ammonium sulphate, 5 mM Tris-HCl, 2 mM EDTA 
at pH 7.5 was added to the precipitate prior to homogenisation for 10 passes using a 
Dounce tissue grinder on ice. The homogenate was centrifuged at 2,500 g for 2 
minutes at 4˚C in a Sigma 1-15K centrifuge. The supernatant was collected and the 
pellet was extracted three more times with 10 ml of the ammonium sulphate solution. 
The four extractions were pooled and transferred to the hydrophobic interaction 
chromatography (HIC) column, as described in section 2.1.2.8. 
2.1.2.8. Hydrophobic interaction chromatography (HIC) 
The protamine sulphate precipitation (section 2.1.2.7.) pool was incubated with 20 
mM CaCl2 for 5 minutes at room temperature. Phenyl-Sepharose
® 
CL-4B resin (20 
ml) was packed into a Biosepra glass column (2.3 x 20 cm) (Pall), and calibrated 
with binding buffer (25 mM Tris, pH 7.5 containing 20 mM CaCl2). The sample was 
then applied at 4 ml/min using a P-1 peristaltic pump. The column was washed with 
two CV of binding buffer, then inverted and washed with 70 ml of eluting buffer (25 
mM Tris, pH 7.5 containing 20 mM EDTA). The inversion was performed to try to 
improve the elution and increase the yield of TGase 2 in the first eluting fractions. 
Fractions (6 ml) were collected and analysed for protein concentration and TGase 
activity. Active fractions were pooled, aliquoted in 5 ml volumes and stored at -80˚C 
until required. 
When HEA chromatography (section 2.1.2.5) was the previous stage, HIC was used 
as the third step in the purification process. The sample from HEA chromatography 
was treated as described above and chromatography was performed in the same way. 
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Active fractions obtained were pooled and loaded into the next column (section 0.). 
Mono Q chromatography 
A Mono Q™ 5/50 GL column was assembled in the fast performance liquid 
chromatography (FPLC) ÄKTA™ purifier from GE Healthcare. The column was 
calibrated with IEX buffer A and the pool of active fractions from HIC (section 
2.1.2.8.) was loaded directly on to it at 1 ml/min. The column was washed with two 
column volumes of buffer A and a salt gradient was applied using IEX buffers A and 
B. The NaCl concentration in the elution buffer mix was increased until 0.25 M and 
then maintained for two column volumes. After this step, the salt concentration was 
rapidly increased to elute TGase 2. Active fractions were dialysed for two hours at 
4˚C against 25 mM Tris buffer at pH 7.5 with changes every 20 minutes. The 
resultant sample was stored in working aliquots at -80˚C. 
2.2. Cell culture 
2.2.1. Cell culture materials 
2.2.1.1. Reagents 
Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose, foetal bovine 
serum (FBS), penicillin/streptomycin (100 x concentrated) and L-Glutamine (200 
mM) were supplied by Lonza (Slough, UK). Sodium butyrate (NaB), 
dimethylsulphoxide (DMSO),3-(4-5-Dimethylthiazol-2-y1)-2,5-diphenyl tetrazolium 
bromide (MTT), sodium dodecylsulphate (SDS), phenylmethylsulphonyl fluoride 
(PMSF) and  chlorpyrifos (CPF) PESTANAL
®
 were purchased from Sigma-Aldrich.  
Chlorpyrifos oxon (CPFO) was obtained from Greyhound Chromatography and 
Allied Chemicals (Birkenhead, UK). Phenyl saligenin phosphate (PSP) was 
synthesized at Nottingham Trent University by Dr. Pat Huddleston, School of 
Science and Technology, Nottingham Trent University, obtaining a ~98 % pure 
compound as determined by mass spectrometry analysis.  
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2.2.1.2. Plastic ware 
Sterile flasks (T175, T75 and T25), sterile tubes (50 ml and 25ml), cell scrapers, 
sterile pipettes (10 and 25ml), sterile 24- and 96- well plates and sterile Pasteur 
pipettes were obtained from Sarstedt (Leicester, UK). Sterile pipette tips were 
supplied by SLS. C-chip haemocytomers were obtained from Digital Bio. BD™ 
Safety-Lok™ BD™ disposable 5ml syringe and Microlance Needles (23G x 1 inch) 
were purchased from BD Biosciences (Oxford, UK). 
2.2.2. Cell lines 
2.2.2.1. Mouse neuroblastoma cell line; Neuro-2a (N2a) 
The N2a cell line was established by Klebe and Ruddle (1969) from a tumour of a 
strain A albino mouse. Cells show a neuronal and amoeboid morphology. Cryovials 
of N2a cells were obtained from the European Collection of Cell Cultures (ECACC).  
2.2.2.2. Rat C6 glioma cell line 
The C6 glioma cell strain was established by Benda et al., (1968) after culturing a 
clone of a rat glial tumour induced by N-nitrosomethylurea. The morphology is 
fibroblast-like. Cryovials of C6 cells were obtained from ECACC. 
2.2.3. Cell culture methods 
2.2.3.1. Thawing mouse N2a neuroblastoma and rat C6 glioma cells from 
cryopreservation 
Vials were removed from liquid nitrogen storage and thawed in a water bath at 37C.  
The cell suspension was then rapidly transferred to a sterile 25 ml tube containing 9 
ml pre-warmed growth medium (DMEM supplemented with 10 % (v/v) foetal 
bovine serum, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin) to minimize the damage of the DMSO present in the freezing medium.  
Cells were then harvested by centrifugation at 300 g for 5 min at 24C. The resultant 
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pellet was resuspended in 1 ml of growth medium by passing through a Gilson 
pipette 20 times.  The suspension was then transferred to a T25 culture flask 
containing 10 ml of growth medium. The flask was incubated in a humidified 
atmosphere of 95 % air / 5 % CO2 at 37 C in an MCO-18AIC CO2 Incubator (Sanyo 
Electric Co. Ltd., USA). After 24 h recovery, the growth medium was discarded and 
10 ml of fresh growth medium were added to the cells.  When the cell monolayer 
population reached  70 - 80 % confluence, cells were sub-cultured in either a T25 or 
a T75 culture flask (section 2.2.3.3.). 
2.2.3.2. Maintenance of cell lines 
Mouse N2a neuroblastoma and rat C6 glioma cells were maintained in monolayers 
within sterile flasks containing growth medium as described by Flaskos et al., (1998).  
Flasks were incubated in a humidified atmosphere of 95 % air / 5 % CO2 at 37 C.  
Both cell lines were used before passage 30 in all experiments, to avoid possible 
genetic drift. 
2.2.3.3. Passage of mouse N2a neuroblastoma cells and rat C6 glioma cells 
Mouse N2a neuroblastoma and rat C6 glioma cells were maintained as monolayers in 
T75 flasks.  Cells were maintained in the growth phase (74 h for C6 cells and 96 h 
for N2a cells) and sub-cultured into a new flask when confluence reached 70 - 80 %. 
The growth medium in the flasks was discarded and N2a cell monolayers were 
detached mechanically from the flask by discharging 5 ml of growth medium from a 
Pasteur pipette onto the cells. C6 cells were mechanically detached from the flask by 
scraping the cells in 5 ml of growth medium, as this method was shown to be 
effective and fast. The resultant cell suspension was transferred to a sterile tube and 
harvested by centrifugation at 300 g for 5 min at 24C.  The resultant pellet was then 
resuspended (by 20 passes through a Gilson pipette) in 1 ml of fresh growth medium.  
Two drops (50 µl) of the cell suspension were transferred using a Gilson pipette to 
a new T75 flask containing 40 ml of fresh growth medium and incubated in a 
humidified atmosphere of 95 % air / 5 % CO2 at 37C. 
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2.2.3.4. Cryopreservation of cell lines 
Cell monolayers were grown to 70 – 80 % confluence in a T25 flask and then 
mechanically detached by different methods depending on the cell type and 
resuspended in 5 ml of growth medium. The resultant cell suspension was transferred 
to a 25 ml sterile tube and harvested by centrifugation at 300 g for 5 min at 24C.  
The resultant pellet was then resuspended in 1ml of freezing medium (DMEM 
supplemented with 25 % (v/v) foetal bovine serum, 5 % (v/v) DMSO (which 
permeates the cytoplasm of the cells, acting as a cryoprotectant), 2mM L-glutamine, 
100 units/ml penicillin, 100 µg/ml streptomycin). The cell suspension was then 
transferred to a cryovial wrapped in tissue paper and stored overnight at -80C. Vials 
were then transferred to liquid nitrogen (-180C) and stored in the gaseous phase 
until needed.  
2.2.3.5. Plating out Rat C6 glioma cells for experimentation 
Cell monolayers at 70 – 80 % confluence in T75 flasks were detached using a sterile 
cell scraper, resuspended in 5 ml of fresh growth medium and transferred into a 
sterile 25 ml tube. The suspension was centrifuged at 300 g for 5 min at 24C and the 
pellet resuspended by 20 passes through a Gilson pipette in 1 ml of fresh growth 
medium followed by 4 passes through a 23 gauge syringe needle. A volume of 10 µl 
of this cell suspension was transferred to 190 µl of growth medium (1:20 dilution) 
and cell number determined using a haemocytometer. Chamber cell counts were 
performed in five fields of a Neubauer haemocytometer (each field has a volume of 
10
-4
 cm
3
) using an inverted light microscope (Inverso 3650 Fisher Scientific 
Ltd., UK). Cell density was calculated as follows: 
Cells / ml = cell number (average from five fields) x 10
4
 (volume factor) x dilution 
factor 
The formula was used to calculate the volume necessary to achieve a specific cell 
density. Cells were then seeded at a density of 50,000 cells/ml in the T75 flasks 
containing 40 ml of growth medium or in 96 well-plates containing 4 ml of growth 
medium per well and allowed to recover for 24 h in a humidified atmosphere of 95 % 
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air / 5 % CO2 at 37C. 
2.2.3.6. Induction of differentiation of rat C6 glioma cells 
After 24 h recovery the growth medium was carefully removed without disturbing 
the monolayer and replaced with an equal volume of serum free medium (DMEM 
supplemented with 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2 mM NaB). Cells were then incubated for further 24 h in a 
humidified atmosphere of 95 % air / 5 % CO2 at 37C. 
2.2.3.7. Exposure of rat C6 glioma cells to CPF and CPFO 
CPF and CPFO were dissolved in DMSO (which acts as a carrier) at a stock 
concentration of 2 mM. C6 glioma cells were plated out in T75 flasks at a density of 
50,000 cells/ml (section 2.2.3.5.). Treated cells were induced to differentiate by the 
addition of serum free medium containing either CPF or CPFO at a final 
concentration of 10 µM. Control cells were treated with the appropriate volume of 
DMSO (0.05 % v/v). Flasks were then incubated for 24 h in a humidified atmosphere 
of 95 % air / 5 % CO2 at 37C. 
2.2.3.8. C6 glioma cell disruption 
After 24 h differentiation in presence or absence of the toxins, the serum free 
medium was carefully discarded and cell monolayers were washed twice with ice-
cold PBS. Monolayers were mechanically detached from the flasks by scraping in 5 
ml of ice-cold PBS. The resultant suspension was then centrifuged at 300 g for 5 min 
at 4C. The obtained pellet was resuspended in 5 ml of ice-cold PBS for another 
wash and re-centrifuged for another 5 min. The final pellet was then resuspended in 
300 µl of ice-cold PBS containing 0.5 mM PMSF. Cells were disrupted by 10 passes 
in a Dounce tissue grinder. The resultant suspension was then centrifuged at 100,000 
g for 45 min at 4C in the Optima™ TLX Ultracentrifuge (Beckman Coulter Ltd). 
The pellet obtained was discarded and the cytosolic fraction collected and stored at   
-20C for future assays. 
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2.2.3.9. C6 glioma cell lysis 
After 24 h differentiation in the presence or absence of the toxin, serum free medium 
was carefully discarded and cell monolayers were washed twice with ice-cold PBS. 
Either 2 or 0.5 ml of boiling PBS containing 0.1 % (w/v) SDS was added to the T75 
or T25 flasks, respectively, to lyse the cell monolayers. The resultant suspension was 
boiled at 100C for 5 min and then centrifuged at 100,000 g for 30 min at room 
temperature to remove insoluble material such as nucleic acids that could affect the 
performance of the gel electrophoresis assay. Supernatants were collected and stored 
at -20C for future electrophoretic and western blotting analysis (section 2.6. and 2.8. 
respectively).  
2.2.3.10.   C6 glioma cells subcellular fractionation 
After 24 h incubation and differentiation, serum free medium was carefully discarded 
and cell monolayers were washed twice with ice-cold PBS. Monolayers were 
mechanically detached from the flasks by scraping in 5 ml of ice-cold PBS. The 
resultant suspension was then centrifuged at 300 g for 5 min at 4C. The resultant 
pellet was resuspended in 5 ml of ice-cold PBS for another wash and re-centrifuged 
for another 5 min. The final pellet was then resuspended in 300 µl of ice-cold PBS 
containing 0.5 mM PMSF. Cells were disrupted by 10 passes in a Dounce tissue 
grinder. Extracts were then centrifuged at 1,000 g for 5 min at 4C to obtain the 
nuclear fraction. This pellet was resuspended in 1 ml of PBS and re-centrifuged at 
1,000 g for 5 min at 4C. The pellet obtained was resuspended in 300 µl of PBS and 
stored at -20C for future assays. 
 The first 1,000 g supernatant was then centrifuged at 100,000 g for 45 min to obtain 
a membrane pellet (containing mitochondria and microsomes) which was 
resuspended and washed by centrifugation as before.  The pellet obtained was 
resuspended in 300 µl of PBS and stored in working aliquots at -20C until required. 
The first 100,000 g supernatant fraction was also collected and stored at -20C for 
future assays. 
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2.2.4. Viability assay (MTT reduction assay) 
The MTT reduction assay was described by Mosmann (1983). It is based on the 
ability of cellular succinate dehydrogenase in viable cells to break the tetrazolium 
rings of the pale yellow MTT and form dark blue formazan crystals which are 
impermeable to cell membranes, thus resulting in their accumulation within healthy 
cells. Breakage of the cells by the addition of DMSO, results in the release of the 
crystals which are solubilised. The number of live cells is directly proportional to the 
amount of the formazan product created. The colour can then be quantified using an 
absorbance plate reader. 
Rat C6 glioma cells were plated out at a density of 50,000 cells / ml in sterile         
24-well culture plates and induced to differentiate in the presence and absence of 
CPF or CPFO for 24 h (sections 2.2.3.6. and 2.2.3.7.).  Thirty minutes prior to the 
end of incubation, 50 µl of MTT solution (5 mg MTT / ml PBS) were added to each 
well. After the 24 h exposure time was complete, the medium was carefully removed 
from the wells before 1 ml of DMSO was added.  Plates were agitated to dissolve the 
formazan product and 200 µl from each well were transferred to a 96-well plate to 
read the absorbance at 570 nm using an ASYS Export 96 microplate reader (SLS). 
Blank average values (DMSO only) were subtracted from each final value. 
2.3. Analysis of exosomes produced by mouse N2a neuroblastoma 
cells  
2.3.1. Materials 
Laboratory reagents with a high purity grade were purchased from Sigma-Aldrich. 
Trypsin Gold (mass spectrometry grade) was obtained from Promega Ltd. 
(Southampton, UK). Transmission electron microscopy grids (2.3 mm diameter) 
were obtained from Agar Scientific Ltd. (Essex, UK).  
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2.3.2. Methods 
2.3.2.1. Purification of exosomes from mouse N2a neuroblastoma cells 
Purification of the exosomes produced by N2a cells was performed following the 
method by Raposo et al., (1996) with some modifications. Prior to its use in cell 
culture, FBS was centrifuged at 141,000 gmax for one hour as described by Wubbolts 
et al., (2003) to remove any possible traces of vesicles. N2a growth medium from 40-
50 T175 flasks was collected when the cells were 70 – 80 % confluent (section 
2.2.3.3.). The medium was then centrifuged sequentially at 300 g, 1000 g, 10,000 g 
and 30,000 g for 10 minutes in the Avanti
™
 J-30 I centrifuge at 4C. The final 
supernatant was collected and centrifuged at 100,000 g for one hour at 4C in the 
Optima
™
 L-100 XP centrifuge. The resultant pellet was resuspended in 1 ml of 2.5 M 
sucrose in 20 mM Tris buffer at pH 7.5 and homogenised by 10 passes in a Dounce 
tissue grinder. A discontinuous sucrose density gradient comprising 2.5, 1.25, 0.1 M 
sucrose, each layer in 4 ml of 20 mM Tris buffer at pH 7.5, was layered on to the 
resuspended pellet and the gradients were centrifuged at 200,000 g for 10 hours at 
4C using the SW40 rotor (Beckman). Aliquots from each gradient were collected, 
diluted in 10 ml of phosphate buffered saline (PBS: 137 mM NaCl, 2.68 mM KCl, 
8.1 mM Na2HPO4 and 2 mM KH2PO4 at pH 7.4) and centrifuged at 100,000 g for 
one hour at 4C. The resultant pellet from each gradient layer was resuspended in 
300 µl of PBS, for analysis by electrophoresis, immunoblotting, electron microscopy, 
and thin layer chromatography (sections 2.6., 2.8., 2.3.2.3. and 2.9. respectively). 
2.3.2.2. Trypsinization of exosomes 
A volume of 25 µl from the fraction containing exosomes (1.25 M sucrose) was 
incubated with 50 µg/ml of trypsin for 0, 3 and 10 min at room temperature. When 
the incubation was finished, trypsin activity was stopped by adding 0.5 mM PMSF 
and cooling the sample on ice. Samples were then centrifuged at 100,000 g for one 
hour at 4C, supernatants were collected and pellets were resuspended in 25 µl of 
PBS. Resultant fractions were analysed by electrophoresis and Western blotting (2.6. 
and 2.8. respectively). Results were compared to exosomal fractions incubated with 
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PBS only. 
2.3.2.3. Transmission electron microscopy (TEM) 
The exosomal fraction was diluted 10 times with 25mM Tris buffer containing 5 mM 
EDTA at pH 7. A drop of the diluted fraction was added in to a Petri dish and the 
grid was placed in the top of it for 30 seconds. The excess of the sample on the grid 
was removed by decantation and the grid placed on top of a drop of 1 % (w/v) uranyl 
acetate in dH2O for 10 seconds. The grid was then placed on a piece of filter paper to 
remove the excess stain. Finally, the grid was inserted into a JEOL JEM-2010 
electron microscope and viewed.  
2.4. Transglutaminase activity assay 
2.4.1. Activity assay materials 
N-N’-dimethylcasein, casein, bovine serum albumin (BSA), dithiothreitol (DTT), 
biotinamide trifluoroacetate salt (biotin-cadaverine), 3,3′,5,5′ tetramethylbenzidine 
(TMB), Extravidin® Peroxidase and high purity laboratory reagents were obtained 
from Sigma-Aldrich. Biotin-TVQQEL peptide was supplied by Pepceuticals 
(Nottingham, UK). Nunc immunoplates (F96 Maxisorp) were supplied by Fisher 
Scientific Ltd. (UK). 
2.4.2. Activity assays methods 
2.4.2.1. Biotin cadaverine incorporation assay 
TGase activity was assayed using the amine incorporation method described by 
Slaughter et al., (1992) with some modifications performed by Lilley et al., (1998). 
Nunc Maxisorp 96-well microplates were coated at 4ºC overnight with 250 μl per 
well of 100 mM Tris-HCl pH 8.5 containing N-N’-dimethylcasein (10 mg/ml). 
Unbound protein was discarded, and the microplate was washed twice with 150 mM 
PBS containing 0.05 % Tween 80 and twice with distilled water. The microplate was 
then agitated for 45 minutes at room temperature in the Heidolph Unimax 1010 
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(SLS) with 250 μl blocking buffer per well (3 % (w/v) BSA in 100 mM Tris-HCl at 
pH 8.5). The plate was washed as previously described with a final wash of 100 mM 
Tris-HCl at pH 8.5. A volume of 150 μl of assay buffer  (100 mM Tris-HCl at pH 8, 
13 mM DTT and 225 μM biotin cadaverine) containing either 6.67 mM calcium 
chloride to detect TGase 2 activity or 1.33 mM EDTA used as a blank control was 
added to each well with 50μl of sample. The microplate was then incubated for one 
hour at 37ºC in an SI 20 H Incubator (Stuart Scientific, UK) and then washed as 
previously described. Then 200 μl of 100 mM Tris-HCl at pH 8.5 containing 1 % 
(w/v) BSA and Extravidin® Peroxidase at a 1:5000 dilution were added to each well. 
The plate was incubated for one hour at 37ºC and then washed as previously 
described with a final wash using 100 mM sodium acetate pH 6. Colour development 
was achieved by adding 200 μl of 100 mM sodium acetate pH 6 containing 150 μl of 
TMB (10 mg/ml) and 25 μl of 3 % (v/v) hydrogen peroxide. The reaction was 
stopped after 1 minute by adding 50 μl per well of 5 M sulphuric acid. One unit of 
TGase activity was defined as a change in absorbance at 450 nm of 1.0 per hour. 
2.4.2.2. Biotin-TVQQEL assay 
In this assay, TGase activity was determined in relation to its protein cross linking 
activity using the method described by Trigwell et al., (2004) with small 
modifications. Nunc Maxisorp 96-well microplates were coated at 4ºC overnight 
with 250 μl per well of 100 mM Tris-HCl at pH 8.5 containing casein (10 mg/ml). 
Microplates were washed twice with distilled water and then blocked with 250 μl per 
well of 0.1 M Tris-HCl at pH 8.5 containing 3 % (w/v) BSA and shaken for 45 
minutes at room temperature. The microplate was washed as described above and 50 
μl of sample were added to each well with 150 μl of assay buffer (100 mM Tris-HCl 
at pH 8 containing 13 mM DTT, 5 μM biotin-TVQQEL peptide and either 6.67 mM 
calcium chloride or 1.33 mM EDTA) prior to the incubation at 37ºC for one hour. 
The microplate was then washed twice with distilled water and 200 μl of 100 mM 
Tris-HCl at pH 8.5 containing 1 % (w/v) BSA and a 1:5000 dilution of Extravidin® 
Peroxidase were added to each well. The microplate was incubated at 37ºC for 
another hour and washed as before. Then, 200 μl of 100 mM sodium acetate at pH 6 
containing 150 μl of TMB (10 mg/ml in DMSO) and 25 μl of 3 % (v/v) hydrogen 
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peroxide were added to each well to develop the colour. The reaction was stopped 
after 10 minutes by adding 50 μl per well of 5 M sulphuric acid and absorbance 
values read at 450 nm. 
2.5. Protein concentration assay 
2.5.1. Protein concentration materials 
Microtitre plates (96-well) were obtained from Sarstedt. Bicinchoninic Acid (BCA) 
Kits (1 % (w/v) bicinchoninic acid solution and 4 % (w/v) CuSO4 · 5H2O solution) 
were obtained from Sigma-Aldrich. 
2.5.2. Protein concentration method 
Protein concentration in the samples was assayed by the method of Smith et al., 
(1985). A linear range of BSA standard concentrations from 0 to 1 mg/ml was 
prepared in an appropriate buffer.  In a 96-well microplate, 25 µl of sample were 
mixed with 200 µl of BCA reagent.  BCA working reagent was obtained by mixing 
reagent A (1 % (w/v) bicinchoninic acid, 2 % (w/v) sodium carbonate, 0.16 % (w/v) 
sodium tartrate and 0.95 % (w/v) sodium bicarbonate in 0.1 N sodium hydroxide at 
pH 11.5) with reagent B (4 % (w/v) copper (II) sulphate pentahydrate) in a ratio of 
50:1.  The microplate was incubated for 30 minutes at 37
o
C, and absorbance was 
then read at a wavelength of 570 nm. Protein concentration of the samples was then 
determined by comparison with the calibration graph of BSA standards. 
2.6. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.6.1. SDS-PAGE materials 
AccuGel™ 29:1 acrylamide, 4x Protogel® Resolving buffer, Protogel® Stacking 
buffer, N,N,N’,N’- tetremethylethylenediamine (TEMED) and electrophoresis 
running buffer (25 mM Tris base; 192 mM glycine; 0.1 % (w/v) SDS, pH 8.3) were 
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obtained from Geneflow Ltd. (UK) . Ammonium persulphate (APS) was purchased 
from Sigma-Aldrich. Precision Plus Protein™ Blue Colour Standards were acquired 
from Bio-Rad. 
2.6.2. SDS-PAGE methods 
2.6.2.1. Sample preparation for SDS-PAGE 
Once the protein concentration was determined (section 2.5), the sample was mixed 
with sample buffer (0.25 M Tris, 12 % (w/v) SDS, 40 % (v/v) glycerol, 5 % (v/v) -
mercaptoethanol (ME) and 0.004 % (w/v) bromophenol blue) in a 1:4 ratio and 
boiled at 100ºC for 10 minutes. The same microgram amounts of protein were loaded 
into each well, to obtain comparable results.  
2.6.2.2. Preparation of polyacrylamide gels 
SDS-PAGE was carried out by the method described by Laemmli (1970) with some 
modifications, using the Bio-Rad Mini-PROTEAN III™ electrophoresis cell which 
was assembled according to the manufacturer’s instructions. The resolving gel (10 % 
monomer) was made by mixing AccuGel™ 29:1 acrylamide, 4x Protogel® Resolving 
buffer and distilled water as indicated in Table 2. 2. The indicated volume of 10 % 
APS was added to the gel casting solution and mixed gently, then the TEMED was 
added to the solution, mixed and transferred to the gel casting cassette (volumes 
shown in Table 2. 2.). Distilled water (2 ml) was carefully applied to overlay the 
resolving solution avoiding contact with air and facilitating polymerization. 
Resolving gel was fully polymerized in 1 hour. In the meantime, the stacking gel 
mixture was prepared by mixing, AccuGel™ 29:1 acrylamide, Protogel® Stacking 
buffer and distilled water in the indicated volumes (Table 2. 2.). Once the resolving 
gel monomer was polymerized, the distilled water above it was poured away and 
APS and TEMED were added to the stacking gel solution and mixed gently. The 
stacking gel solution was then applied on top of the resolving gel and the comb to 
generate the wells was placed in it. The polymerization took place in 45 minutes. 
After that, the comb was removed and gels were assembled in the electrophoresis kit 
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apparatus. The inner and outer chambers were filled with electrophoresis running 
buffer (25 mM Tris base; 192 mM glycine; 0.1 % (w/v) SDS, pH 8.3) and samples 
were loaded into the wells in specified amounts as indicated in figure legends 
(Results). Precision Plus Protein™ Blue Colour Standards were loaded in one well to 
identify the molecular weight of the proteins and to monitor the progress of 
electrophoresis. Electrophoresis was run at 150 V until the dye front reached the 
bottom of the resolving gel. 
 
 
 
Table 2. 2: Reagent volumes required for the preparation of four mini gels 
 
Solution 
Resolving 
Gel (10 %) 
Stacking 
Gel (4 %) 
Composition 
AccuGel™ 29:1 
acrylamide 
10 ml 1 ml 
40 % (w/v)  
acrylamide: 
bisacrylamide 
(29:1) 
4x Protogel
®
 
Resolving buffer 
10 ml - 
1.5 M Tris-HCl 
0.4 % (w/v) SDS 
pH 8.8 
Protogel
®
 Stacking 
buffer 
- 2.5 ml 
0.5 M Tris-HCl 
0.4 % (w/v) SDS 
pH 6.8 
Distilled water 19.6 ml 6.9 ml - 
10 % (w/v) APS 400 µl 50 µl - 
TEMED 40 µl 20 µl - 
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2.7. Gel staining 
2.7.1. Gel staining materials 
Instant Blue protein staining reagent was purchased from TripleRed Ltd. (Long 
Crendon, UK). Silver staining kit containing; 2.5 % (w/v) silver nitrate, 37 % (w/v) 
formaldehyde, 25 % (w/v) glutaraldehyde, sodium acetate, sodium carbonate and   5 
% (w/v) sodium thiosulphate was purchased from GE Healthcare. Other reagents 
with a high purity grade were purchased from Sigma-Aldrich. 
2.7.2. Gel staining methods 
2.7.2.1. Instant blue staining 
Once the electrophoresis was finished, gels were removed from the cassettes and 
placed in to a staining tray. Gels were covered with Instant blue staining reagent and 
incubated on a shaker for 10-15 minutes. Instant blue was then removed and gels 
were washed several times with distilled water to reduce the background.  
2.7.2.2. Silver staining 
After the completion of SDS-PAGE, gels were removed from the cassettes and 
placed in to glass bowls previously washed with 2.5% (v/v) nitric acid and rinsed 
with ultrapure water. Proteins were then fixed by incubating the gel with the fixing 
solution (40 % (v/v) ethanol, 10 % (v/v) glacial acetic acid) for 30 min. Fixing 
solution was discarded and the gel covered with sensitizing buffer (30 % (v/v) 
ethanol, 0.2 % (w/v) sodium thiosulphate, 0.125 % (w/v) glutaraldehyde, 0.83 M 
sodium acetate) for another 30 min. To perform mass spectrometry analysis in any 
band of the gels, the glutaraldehyde reagent was avoided. Gels were then washed 3 x 
5 min with ultrapure water and incubated for 20 min with the silver reaction buffer 
(0.25 % (w/v) silver nitrate solution, 0.015 % (w/v) formaldehyde). Gels were 
washed again 2 x 1 min with ultrapure water and the signal was developed by adding 
enough pre-chilled developer (0.24 M sodium carbonate, 0.015 % (w/v) 
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formaldehyde) to cover the gel. After 2-5 min, the reaction was stopped by 
discarding the developer and adding the stopping solution (10 % (v/v) acetic acid, 10 
% (v/v) ethanol). Stained gels were scanned using a Fujifilm FLA-7000 laser scanner 
(RayTek, Sheffield, UK) to obtain a high quality image. 
2.8. Western blotting 
2.8.1. Western blotting materials 
2.8.1.1. Antibodies 
2.8.1.1.1. Primary antibodies 
Mouse monoclonal anti-transglutaminase 2 (CUB-7402) (ab2386), mouse 
monoclonal anti-CNPase (ab6319), rabbit polyclonal anti-flotillin, goat polyclonal 
anti-transglutaminase 2 (ab10445) and mouse monoclonal anti-GAPDH (ab9484) 
were purchased from Abcam. Goat polyclonal anti-transglutaminase 3 (C-19) and 
anti-transglutaminase 1 (C-20) were obtained from Santa Cruz. Mouse monoclonal 
anti-transglutaminase 2 (ID10) was raised by Professor M. Griffin School of 
Biomedical and Natural Sciences, Nottingham Trent University, following 
immunization of mice with guinea pig liver transglutaminase. Mouse monoclonal 
anti-glial fibrillary acidic protein (GFAP) was supplied by Sigma Aldrich. Mouse 
monoclonal anti-transglutaminase 2 (clone TG100) was obtained from Thermo 
Fisher Scientific (Horsham, UK). 
2.8.1.1.2. Secondary antibodies 
Secondary antibodies conjugated with horseradish peroxidase (HRP) were obtained 
from DAKO Ltd. (Cambridgeshire, UK). 
2.8.1.2. Other consumables 
Hybond Nitrocellulose paper was purchased from Amersham (Buckinghamshire, 
UK). Continuous transfer (CTB) buffer 10X (0.25 M Tris, 1.92 M glycine) was 
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obtained from Geneflow Ltd. Enhanced chemiluminescence (ECL) reagent for 
horseradish peroxidase secondary antibody conjugate was purchased from Insight 
Biotechnology, Wembley, U.K. Whatman
®
 filter paper was obtained from Sigma-
Aldrich. 
2.8.2. Western blotting method 
2.8.2.1. Electrophoretic transfer of proteins 
Western blotting was carried out as described by Towbin et al. (1979) with some 
modifications. Two pieces of filter paper were soaked in CTB (192 mM glycine, 25 
mM Tris and 20 % (v/v) methanol) and placed in one side of the blotting cassettes. 
Nitrocellulose paper was also soaked in CTB and placed on top of the filter papers. 
The stacking gel was discarded and the resolving gel containing the separated 
proteins was then removed from the electrophoresis glass plates and placed over the 
nitrocellulose paper. Two more pieces of pre-soaked filter paper were placed on top 
of the gel. Air bubbles were removed using a glass rod, the cassette closed and sited 
in the Bio-Rad Trans-Blot electrophoretic transfer blotting apparatus. The cassette 
was orientated with the nitrocellulose paper located between the gel and the positive 
electrode. The transfer was run either at 75 V for 100 minutes in ice, or at 30 V 
overnight.  
2.8.2.2. Immunoprobing 
Nitrocellulose membranes containing the electro-transferred proteins were blocked 
with 3 % (w/v) BSA in Tris buffered saline (BSA/TBS) at room temperature for at 
least one hour. Membranes were then incubated overnight at 4ºC with an appropriate 
dilution of the primary antibody in 3 % (w/v) BSA/TBS, volumes are shown in Table 
2. 3. Probed blots were then washed in TBS/Tween (0.05 % (v/v) Tween 20 in TBS) 
for 6 x 10 minute washes and incubated for at least two hours with an appropriate 
dilution of the horseradish peroxidase (HRP) conjugated secondary antibody in 3 % 
(w/v) BSA/TBS. Blots were then washed as described above with a final wash of 
TBS to remove possible traces of Tween 20. 
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Table 2. 3: Antibodies and working dilutions used in the detection of proteins 
Antibody Antigen 
Western blot 
dilution and 
concentration 
(µg/ml) 
Immucytochemistry 
dilution 
CUB-7402 
(ab2386) 
(mouse monoclonal) 
(100 µg/ml) 
TGase 2 
1:1000 
(0.1  µg/ml) 
- 
TG100 
(goat polyclonal) 
(1 mg/ml) 
TGase 2 
1:1000 
(1  µg/ml) 
- 
Anti-TGase 2 
(ab10445) 
(goat polyclonal) 
(concentration not 
determined, whole 
antiserum) 
TGase 2 1:1000 1:50 
ID10  
(mouse monoclonal) 
(concentration not 
determined, culture 
supernatant) 
TGase 2 1:250  
Anti-TGase 1 (C20) 
(goat polyclonal) 
(200  µg/ml) 
TGase 1 
1:500 
(0.4  µg/ml) 
- 
Anti-TGase 3 (C19) 
(goat polyclonal) 
(200  µg/ml) 
TGase 3 
1:500 
(0.4  µg/ml) 
- 
Anti-GAPDH 
(ab9484) 
(mouse monoclonal) 
(1 mg/ml) 
Glyceraldehyde 3-
phosphate 
dehydrogenase 
(GAPDH) 
1:2000 
(0.5  µg/ml) 
- 
Anti-CNPase (11-5B) 
(ab6319) 
(mouse monoclonal) 
(6.8  mg/ml) 
2',3'-Cyclic 
Nucleotide 3'-
Phosphodiesterase 
(CNPase) 
1:1000 
(6.8  µg/ml) 
1:40 
(170  µg/ml) 
Anti-GFAP 
(Clone G-A-5) 
(mouse monoclonal) 
(6.5 mg/ml) 
Glial fibrillary acidic 
protein (GFAP) 
1:1000 
(6.5  µg/ml) 
1:40 
(162.5  µg/ml) 
Anti-flotillin 
(ab41927) 
(rabbit polyclonal) 
(1000  µg/ml) 
Flotillin 
1:500 
(2  µg/ml) 
- 
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2.8.2.3. Developing blots using enhanced chemiluminescence (ECL) 
ECL reagents A and B were freshly mixed in equal volumes and applied on to the 
blotted membranes. Excess of luminol reagent was wiped out and membranes were 
then placed in the G:BOX iChemi dark system from Syngene (Cambridge, UK). 
Exposure time to detect the chemiluminescence signal was dependent on the protein 
to be detected and the kind of antibody used. 
2.8.2.4. Stripping and re-probing of nitrocellulose membranes 
Stripping and re-probing of nitrocellulose membranes was performed as described by 
Kaufmann et al., (1987) with modifications. In most cases, primary and secondary 
antibodies could be completely removed from membranes and re-probed several 
times. Nitrocellulose membranes were incubated with the stripping buffer (100 mM 
ME, 2 % SDS, 62.5 mM Tris-HCl at pH 6.7) and incubated in a water bath at 50
o
C 
for 30 min with occasional agitation. The membrane was washed 4 x 10 min in 
TBS/Tween followed by a final wash of TBS before blocking and re-probing it as 
described in section 2.8.2.2. 
2.9. Lipid analysis 
2.9.1. Lipid analysis materials 
Other reagents with a high purity grade, silica thin layer chromatography (TLC) 
plates were purchased from Sigma-Aldrich. BLAUBRAND® disposable 
micropipettes (10µl volume) were obtained from BRAND via SLS.  
2.9.2. Lipid analysis method 
2.9.2.1. Lipid extraction 
Lipid extraction from N2a neuroblastoma cells and from the exosomal fractions was 
carried out as described by Folch et al., (1957) with some modifications. Cells and 
exosomes were homogenised in 300 µl of chloroform: methanol solution (2:1) by 10 
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passes in a Dounce tissue grinder. After the dispersion the solution was mixed 
thoroughly and centrifuged at 2,500 g for 5 minutes at room temperature. The 
aqueous (top) phase was carefully removed and the precipitated protein present in the 
interphase was plugged to one side of the Eppendorf tube. The organic (lower) phase 
containing the lipids was transferred to a new Eppendorf tube.  
2.9.2.2. TLC method 
A line was drawn with a light pencil on the TLC plate 1 cm above the bottom and 7 
equidistant sample application points were marked on it. A volume of 5 µl of each 
standard (phosphatidyl choline, phosphatidyl serine, phosphatidyl ethanolamine, 
sphingomyelin), a mixture of them, a cell lipid extraction and 50 µl of exosomes 
lipid extraction were loaded on the different application points. After loading each 
drop of standard or sample, the TLC plate was dried with hot air to avoid the 
expansion of the spot. The silica plate was placed in the TLC tank with the solvent 
(chloroform:methanol:acetic acid:water 65:25:8:4 v/v) and the lid placed to avoid the 
evaporation of solvent. Chromatography was performed until the solvent front 
reached 1cm from the top. The plate was then removed from the tank, dried and 
developed.  
2.9.2.3. Developing the chromatogram with iodine vapour 
The thin layer chromatogram was developed following the method described by 
Nichols (1964) with a few modifications. The plate was placed in a glass tank with 
heated iodine crystals and the lid placed on to avoid the evaporation of the vapour. 
After 2 minutes the chamber was saturated with iodine vapour and the lipid stain 
started to develop, showing a light brown colour. The chromatogram was removed 
from the chamber and a digital image was recorded. 
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2.10. Immunocytochemical staining 
2.10.1. Immunocytochemistry materials 
Primary antibody goat monoclonal anti-transglutaminase 2 (ab10445) and mouse 
monoclonal anti-CNPase were obtained from Abcam. Mouse monoclonal anti-glial 
fibrillary acidic protein (GFAP) was supplied by Sigma Aldrich. Secondary antibody 
conjugated with fluorescein isothiocyanate (FITC), against mouse, goat or rabbit 
primary antibodies was obtained from DAKO Ltd. The 8-well Lab-Tek™ Chamber 
Slide™ System was purchased from Fisher Scientific. 
2.10.2. Immunocytochemistry methods 
Seeding of C6 glioma cells for immunohistochemistry was performed following the 
method described by De Girolamo et al., (2000) with a few modifications. Cells were 
seeded in 300 µl of growth medium in at a density of 50,000 cells/ml on Labtek       
8-well chamber slides. Cells were incubated in a humidified atmosphere of 95 % air / 
5 % CO2 at 37C for 24 h to allow recovery. Growth medium was then carefully 
removed and 300 µl of fresh growth medium or serum free medium containing either 
DMSO or 10 µM CPF or CPFO were added. Slides were incubated for another 24 h 
in a humidified atmosphere of 95 % air / 5 % CO2 at 37C. Growth medium and 
serum free medium were carefully removed and cells were fixed with 250 
l/chamber of pre-cooled 90 % (v/v) methanol in TBS for 20 minutes at -20oC. 
Slides were then incubated with 250 µl/chamber of 1 % (v/v) Triton X-100 in TBS at 
room temperature for 10 min to permeate the cell membranes. Slides were then 
washed 3 x 10 min with 300 µl of TBS and blocked with 200 µl of 3 % (w/v) 
BSA/TBS for 1 hour at room temperature. Slides were then incubated with 150 l of 
an appropriate dilution of primary antibody in 3 % (w/v) BSA/TBS in a humidified 
chamber at 4
o
C overnight. Each chamber was then washed as described above and 
incubated with 150 l of 3 % (w/v) BSA/TBS containing FITC-conjugated 
secondary antibody diluted 1:40 for 2 h at room temperature. Slides were washed as 
described above, and the chamber assembly and rubber seal were removed before 
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mounting with the anti-fade mountant. A cover slip was added carefully on top of the 
mountant, and fixed in position by adding transparent glue to the edges. Cells were 
then observed in a Leica CLSM Confocal Laser Scanning Microscope fitted with 
epifluorescence optics. 
2.11. Molecular biology 
2.11.1. Molecular biology materials 
2.11.1.1. Molecular biology reagents 
Laboratory reagents with a high purity grade, deoxynucleotide mix (dNTPs), 
ethidium bromide and diethylpyrocarbonate (DEPC) were purchased from Sigma-
Aldrich. TRI Reagent® Solution was obtained from Applied Biosystems, 
Warrington, UK. PCR Master Mix (5x Moloney Murine Leukemia Virus (M-MLV) 
buffer, RNAsin, and M-MLV-Retrotranscriptase and Oligo(dt)primers), 5x Green or 
Colorless GoTaq® Flexi Buffer, MgCl2 Solution and GoTaq® DNA Polymerase 
were purchased from Promega Ltd. QuantiTect SYBR Green PCR Master Mix (2x) 
was supplied by Qiagen (West Sussex, UK). The 100bp DNA ladder was purchased 
from New England BioLabs (Hitchin, UK). Primers were bought from Sigma-
Genosys (Sigma-Aldrich) and donated to our group by Dr. Verderio-Edwards 
(NTU). 
2.11.2. Molecular biology methods 
2.11.2.1. RNA extraction 
Cells from 3 - 4 T75 flasks (6 - 8 × 10
6
 cells) were pooled in a sterile 25 ml tube. 
Cell pellets were resuspended in 500 µl of TRI Reagent by 10 passes through a 
Gilson pipette. The resultant homogenate was incubated for 5 min at room 
temperature before 50 µl of chloroform were added. The solution was mixed by 
inversion for 30 seconds and then incubated for 10 minutes at room temperature. The 
solution was centrifuged at 12,000 g for 15 min at 4C. The resultant aqueous phase 
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was transferred to a new sterile Eppendorf tube and 250 µl of isopropanol were 
added before mixed by vortex for 5 seconds. The solution was centrifuged at 12,000 
g for 8 min at 4C and the supernatant removed without disturbing the pellet. Then, 
500 µl of 75 % ethanol were added to the pellet and resuspended by 10 passes 
through a Gilson pipette. The solution was then centrifuged at 8,500 g for 5 min at 
4C and the resultant pellet was resuspended in a suitable amount of 0.1 % (v/v) 
DEPC-treated H20 (20-30µl). 
2.11.2.1.1. Determination of RNA concentration 
The concentration of RNA in the sample was obtained using the NanoDrop 8000 
spectrophotometer from Thermo Fisher Scientific Inc. The wells of the 
spectrophotometer were cleaned with wet lens tissue before setting the blank with 
distilled water. Each sample (1 µl) was loaded into the wells and the absorbance was 
measured at 260 and 280 nm. RNA concentrations were adjusted to 1 µg/µl with 0.1 
% (v/v) DEPC-treated H20.  
2.11.2.2. Rapid cDNA synthesis 
2.11.2.2.1. Denaturation of secondary structures 
A volume of 2 µl of the obtained RNA (section 2.11.2.1.) with a concentration of 1 
µg/µl was added to 1 µl of oligo dT primers and 7 µl of 0.1 % (v/v) DEPC-treated 
H20. The resultant solution was heated for 5 min at 70C in the Accublock™ Digital 
Dry Bath heater (Labnet International, Inc. Rutland, UK), then cooled on ice and 
pulse centrifuged before starting the cDNA synthesis. 
2.11.2.2.2. cDNA synthesis 
The 10 µl obtained in the denaturation of the secondary structures (section 
2.11.2.2.1.) were added to 15 µl of the master mix buffer (5x M-MLV buffer, 
dNTPs, RNAsin, M-MLV-Retrotranscriptase and 0.1 % (v/v) DEPC-treated H20), for 
which volumes and concentrations are shown in the Table 2. 4. The resultant solution 
was heated for 80 min at 39.2C, then cooled on ice and pulse centrifuged before 
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heating it again for 5 min at 95C. After these steps, the sample was cooled on ice 
and stored at -20C until needed. 
 
Component Final volume (µl) Final amounts 
5x M-MLV Buffer 5 1x 
Oligo(dt)primers 1 0.5 µg 
RNAsin 0.5 20 u 
dNTPs 2 10mM 
M-MLV-RT 1 200 u 
RNA sample 10 2 µg 
Nuclease-Free water 5.5 - 
Table 2. 4: Volumes and amounts of the components used in cDNA synthesis 
2.11.2.3. Reverse transcriptase polymerase chain reaction (RT-PCR) 
A volume of 0.5 µl of cDNA (section 2.11.2.2.2.) was added in to a PCR Eppendorf 
tube containing 24.5 µl of amplification buffer (5x Colorless GoTaq® Flexi Buffer, 
MgCl2 solution, PCR Nucleotide Mix, upstream primer, downstream primer, 
GoTaq® DNA Polymerase, Template DNA and Nuclease-Free water); volumes and 
concentrations are shown in Table 2. 5. 
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Component 
Final volume 
(µl) 
Final amount 
5x Colorless GoTaq® 
Flexi Buffer 
5 1 x 
MgCl2 Solution 3 3 mM 
PCR Nucleotide Mix 4 0.2 mM 
Upstream primer 0.75 0.6 µM 
Downstream primer 0.75 0.6 µM 
GoTaq® DNA 
Polymerase 
0.12 1.25 u 
Template DNA 0.5 0.04 µg 
Nuclease-Free water 11.4 - 
Table 2. 5: Volumes and amounts of the components used in RT-PCR 
Primers used for rat C6 cells, were designed by our lab colleague Izhar Bhurkan. 
Each set of primers was designed manually from two different exons, excepting 
TGase 2 primers which were obtained from Qiu et al., 2007. Primer sequences and 
the size of the fragments are shown in Table 2. 6. 
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Table 2. 6: Primers used for the amplification of six TGases and GAPDH genes 
PCR Eppendorf tubes containing the cDNA and the amplification buffer were placed 
in the TC-512 Thermal Cycler (Bibby-Scientific Ltd., Stone, UK) to perform the 
gene amplification. The conditions for the thermal cycling are shown in Table 2. 7. 
Reaction step Temperature Time 
Number of 
Cycles 
Initial 
Denaturation 
95C 5 minutes 1 Cycle 
Denaturation 94C 30 sec  
 
30 Cycles Annealing 60C 30 sec 
Elongation 72C 20 sec 
Final Extension 72C 5 minutes 1 cycle 
Table 2. 7: PCR steps and conditions 
When the amplification process was finished, the products were separated by agarose 
gel electrophoresis (section 2.11.2.4.). 
Gene Primer sequence (5’ to 3’) 
Size (base 
pairs) 
GAPDH 
Forward: CGTCTTCACCACCATGGAGA 
Reverse: CGGCCATCACGCCACAGCTTT 
300 
TGase 1 
Forward: TGAGTCCTCTGATCGCATTG 
Reverse: TCGCCAATCTGTGCTTCTGT 
384 
TGase 2 
Forward: GTATGATGCGTCCTTCGTGT  
Reverse: TCGCCAATCTGTGCTTCTGT 
235 
TGase 3 
Forward: TGGCAGTAGGCAAAGAAGTC 
Reverse: CACATCGATTTTGAGGCTGC 
461 
TGase 5 
Forward: CTTCCCTTCGACCCAGTGAT 
Reverse: GAGTGATGCTGGCTTTGTTA 
561 
TGase 6 
Forward: ATATGTGGACTCTTATGGCCG 
Reverse: TCCACGCTGAGCAGTTTCTTCA 
459 
TGase 7 
Forward: CATCGCTGAGGTTGAAGAGAC 
Reverse: CCTTGTAGCCTTTGATCTCC 
344 
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2.11.2.4. Agarose gel electrophoresis 
Agarose (1.5 g) was added in to 100 ml of Tris-acetate-EDTA buffer (TAE; 40 mM 
Tris-acetate and 1 mM EDTA, pH 8). The solution was boiled two times in order to 
improve the resolution of the gel. While the solution was cooling down, 1µl of 
ethidium bromide was added and mixed in. After few minutes, the 1.5 % (w/v) 
agarose solution was transferred in to the casting tray and the 10 well comb was 
placed in it. The set agarose gel was covered with TAE buffer containing 1 % (v/v) 
ethidium bromide and the samples with 4 µl of dye were loaded into the wells. 
Standards (10 µl) were loaded in the first well and electrophoresis was run for 45 
min at 100 V. 
2.11.2.5. Visualization of bands on agarose gels 
When the electrophoresis was finished, the agarose gel was removed from the casting 
tray and placed in the G:BOX iChemi dark system. The gel was exposed to 
ultraviolet light for a few seconds, after which DNA bands were detected and a 
digital image was recorded. 
2.11.2.6. Quantitative RT-PCR  
Working under sterile conditions in the Walker class II microbiological safety 
cabinet (Walker Safety Cabinets Ltd, Derbyshire, UK), cDNA obtained (section 
2.11.2.2.) and the primers for the gene of interest were added to the quantitative RT-
PCR buffer. Volumes and concentrations are shown in Table 2. 8. 
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Component 
Volume/reaction 
(µl) 
Final concentration 
2x QuantiTect SYBR Green 
PCR Master Mix 
12.5 1x 
Primer A 0.2 0.16 µM 
Primer B 0.2 0.16 µM 
cDNA 0.4 300 ng 
Nuclease-Free water 11.6 - 
Table 2. 8: Volumes and amounts of the components used in the quantitative 
RT-PCR 
The quantitative RT-PCR Eppendorf tubes containing all the components were 
located in the Rotor Gene Q (Qiagen Ltd., West Sussex, UK). Gene amplification 
was performed under the conditions described in Table 2. 9. 
 
Reaction step Temperature Time 
Number of 
Cycles 
Hold 95C 15 minutes 1 Cycle 
Denaturation 95C 30 sec  
 
40 Cycles Annealing 61C 30 sec 
Elongation 72C 20 sec 
Final Extension 72C 5 minutes 1 cycle 
Table 2. 9: Real time RT-PCR steps and conditions 
When amplification was complete, values obtained were analysed following the 
delta-delta Ct method described by Livak and Schmittgen (2001) and samples were 
loaded into an agarose gel (section 2.11.2.4.) to check the products of the real time 
RT-PCR. 
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2.12. Statistical analysis 
Data were presented as mean ± standard error of the mean (SEM) at a 95 % 
confidence limit. Statistical analysis was performed using two-tailed Students t-test 
at a significance level of p < 0.05 or 0.01. The one way analysis of variance 
(ANOVA) test and the multiple comparison Dunnett’s post ANOVA test were 
performed as appropriate using 95 % confidence limits.  
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3.1. Introduction 
3.1.1. Glial cells 
As discussed in chapter one, glial cells are an important cellular component in the 
nervous system, and they are implicated in several neural functions and 
neurodegenerative diseases. They have been shown to be affected by some 
organophosphates (OPs) that can induce developmental toxicity.  
Glial cells play a key role in antioxidant activity (Tanaka et al., 1999; Sagara et al., 
1993) which is important for the protection against some effects of OPs (Bagchi et 
al., 1996; Bagchi et al., 1995). As glial development is longer than that of neurons, 
glial cells are more susceptible to a prolonged exposure to chlorpyrifos (CPF) 
(Garcia et al., 2001). 
3.1.1.1. Rat C6 glioma cells 
Rat C6 glioma cells are commonly used as a glial cell model. This cell line derives 
from a glial tumour induced by N-nitrosomethylurea (Benda et al., 1968). C6 cells 
are composed of both astrocyte and oligodendrocyte populations, show similar 
hormonal responses to normal glia and can be induced to differentiate by the addition 
of different molecules such as dexamethasone (Garcia et al., 1991), cAMP 
(Takanaga et al., 2004), retinoic acid (RA) (Bianchi et al.,2008) or sodium butyrate 
(NaB) (Sachana et al., 2008). 
It has to be borne in mind that C6 cells are a transformed cell line, which usually 
shows a better resistance to toxins than primary glial cells. This phenomenon has 
also been described in transformed neuronal cells (Crumpton et al., 2000a; Crumpton 
et al., 2000b; Das and Barone, 1999).  
3.1.2. Organophosphate effects on C6 cells 
C6 cells are a good model to study the mechanisms affected by CPF (Garcia et al., 
2001), although they exhibit more resistance to toxins than primary cultures. CPF 
also inhibits cell proliferation in C6 cells (Qiao et al., 2001). Both CPF and its 
metabolite chlorpyrifos oxon (CPFO) are able to inhibit the formation of extensions 
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in C6 cells, therefore affecting the differentiation process. Cytoskeletal proteins are 
also affected by CPFO but not by CPF, therefore indicating that they possibly act on 
different targets (Sachana et al., 2008).  
CPF and its metabolites can disrupt the adenylyl cyclase (AC) pathway (Huff and 
Abou-Donia, 1995; Ward and Mundy, 1996) which is related with cell differentiation 
and replication through an increase in the cAMP production. Studies have also 
demonstrated that CPF is also involved in the generation of oxidative stress in rat 
brain, probably contributing in this way to the increase in toxicity of this compound 
(Mehta et al., 2009; Crumpton et al., 2000). 
In addition to their effects on proteins, some studies have indicated that CPF and 
CPFO provoke a decrease in the synthesis of DNA in C6 cells (Qiao et al., 2001). 
Therefore, the studies performed with these two toxins have shown that at sublethal 
concentrations they generate morphological and molecular changes on developing 
glial cells. 
3.2. Aims 
The main aims of the work presented in this chapter were: 
a) To characterise the glial phenotype induced by NaB; 
b) To identify and quantify the isoforms of TGase present in mitotic and 
differentiating C6 cells; 
c) To measure the activity of TGase in cells induced to differentiate in the presence 
and absence of CPF or CPFO. 
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3.3. Results 
3.3.1. Characterization of the differentiating C6 cell phenotype 
Rat C6 glioma cells are an established glial model, and previous studies have shown 
that C6 can be differentiated into astrocytes or oligodendrocytes depending on the 
experimental conditions (Bianchi et al., 2008). Our group has historically induced the 
differentiation of C6 cells by serum withdrawal and the addition of NaB (Hargreaves 
et al., 1989; Sachana et al., 2008; Sidiropoulou et al., 2009) but we have not yet 
determined whether C6 cells differentiate into oligodendrocytes, astrocytes or both 
types, under these conditions. 
3.3.1.1. Effects of sodium butyrate on the differentiating C6 cell phenotype 
In order to determine the phenotype of C6 cells induced to differentiate by NaB, 
immunocytochemical staining was performed. Figure 3. 1 shows images from 
mitotic and differentiating C6 cells probed with antibodies against 2',3'-cyclic 
nucleotide 3'-phosphodiesterase (CNPase) which is an oligodendrocyte marker and 
against glial fibrillary acidic protein (GFAP), which is an astrocyte marker although 
its presence has been also described in oligodendrocytes (Dyer et al., 1996; Casper 
and McCarthy, 2006). 
Results indicate the presence of astrocyte and oligodendrocyte populations in both 
mitotic and differentiating C6 cells. When the cells were differentiating it was 
possible to observe the formation of processes due to the presence of the protein 
markers in them. Although the staining was more intense in the differentiating cells 
probed with anti-GFAP it was difficult to quantify. Thus, another method was 
necessary to elucidate if one of the populations was more abundant when cells were 
induced to differentiate by serum withdrawal and addition of NaB. It has to be 
remarked that the staining pattern for GFAP seems unusual as it should be a 
filamentous staining, although the magnification was not high enough to visualize 
properly the staining pattern 
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       B) anti-GFAP 
                              
  
 
 
Figure 3. 1: Immunocytochemistry analysis of oligodendrocyte and astrocyte 
markers in mitotic and differentiating C6 cells 
C6 cells were seeded in Lab-Tek chambers and kept in a mitotic state or induced to 
differentiate for 24 h before being permeabilized. Shown are mitotic and 
differentiating (addition of NaB and serum withdrawal) cells probed with A) anti-
CNPase antibody and B) anti-GFAP antibody. Scale bar represents 20 m. 
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Once the presence of both oligodendrocytes and astrocytes in our C6 cell line was 
corroborated, a Western blot analysis was performed to study which of the two 
populations was more abundant when the cells were differentiating with NaB. After 
the treatment, cells were lysed and the samples analysed with antibodies against the 
different markers. 
Figure 3. 2 shows the effects of differentiating C6 cells with NaB on the 
oligodendrocyte and astrocyte populations. Interestingly, when cells were 
differentiating, there was a significant decrease (~50 %) in the protein levels of the 
oligodendrocyte marker compared to the mitotic control, while the astrocyte marker 
experienced a significant increase (~200 %) in its protein levels.  
The cytosolic marker GAPDH (Ronnebaum et al., 2006) was used as an internal 
control as it did not suffer any changes during the differentiation process. 
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Figure 3. 2: Western blotting analysis of mitotic and differentiating C6 cells 
Protein extracts (20 µg) for lysate fractions of mitotic and differentiating C6 cells 
were separated by SDS-PAGE and analysed by Western blotting. Shown are blots 
probed with A) anti-CNPase antibody, B) anti-GFAP antibody and C) anti-GAPDH 
antibody for mitotic control (mit) and differentiated (diff) C6 cells. Densitometric 
peak areas of each band present on the blot were analysed using AIDA software. 
GAPDH was used as an internal control. Values are expressed as an average 
percentage ± SEM of the protein levels of the mitotic control (100 %) after being 
corrected against GAPDH values for five independent experiments. For the statistical 
analysis, a paired t-test was performed, and each antibody was compared to its 
corresponding control (n = 5, * p < 0.05). Std represents molecular weight standards. 
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3.3.1.2. Localization of TGase 2 in mitotic and differentiating C6 cells 
Previous studies indicated that rat astrocytes contain TGase 2 (Monsonego et al., 
1997), but it was important to detect the presence of the enzyme and its distribution 
in the rat C6 glioma cells.  For this assay, cells were disrupted and then subjected to 
subcellular fractionation as explained in section 2.2.3.10. Figure 3. 3 indicates that 
TGase 2 was present in C6 cells and that it was mainly localized in the suggested 
cytosolic fraction. In this assay it would have been interesting to use other 
subcellular markers in order to confirm the fractions identity and to check any 
possible cross contamination during the process. For example, antibodies to lamin A, 
cytochrome C and α-tubulin could have been used to identify the nuclear, 
mitochondrial and cytosolic fractions, respectively, and to confirm loading and 
separation of the sub cellular fractions. 
 
 
A)         Std     nuc    mito    cyto 
 
 
 
 
  B)        Std     nuc    mito    cyto 
 
            
 
 
 
Figure 3. 3: Western blotting analysis for TGase 2 and GAPDH in mitotic C6 
cells 
Protein extracts (10 µg) from different fractions of subcellular fractionation of 
mitotic C6 cells were separated by SDS-PAGE and analysed by Western blotting. 
Shown are blots probed with A) CUB-7402 (anti-TGase 2) antibody B) anti-GAPDH 
antibody for nuclei (nuc), crude mitochondria (mito) and cytosol (cyto). Std 
represents molecular weight standards. 
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An immunocytochemistry assay was performed to corroborate the data obtained in 
Figure 3. 3 and also to study a possible change in the distribution of TGase 2 or a 
morphology change when C6 cells were induced to differentiate by NaB. Figure 3. 4 
shows the images of mitotic and differentiating C6 cells probed with abcam 10445 
anti-TGase 2 antibody as it gave a better signal in the immunocytochemistry assay 
than CUB-7402 anti-TGase 2 antibody. In both cases, TGase 2 was localized 
diffusely in the cytoplasm of the cells and when they were differentiating, TGase 2 
was also present in the processes characteristic of differentiation (arrows).  
 
 
 
 
     Mitotic              Differentiating 
 
     
 
 
 
Figure 3. 4: Immunocytochemistry analysis for TGase 2 in mitotic and 
differentiating C6 cells 
C6 cells were seeded in Lab-Tek chambers and kept in a mitotic state or induced to 
differentiate for 24 h before being permeabilized. Shown are mitotic and 
differentiated cells probed with abcam 10445 anti-TGase 2 antibody. Scale bar 
represents 20 m. 
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3.3.1.3. Protein expression of other TGases in mitotic and differentiating C6 cells 
 
As explained in the introduction (section 1.5.), there are several TGase isoforms. 
Both TGase 1 and 3 are a very important and studied isoforms of TGase that can be 
found in human brain (Kim et al., 1999) and rat brain (Kim et al., 2000). Therefore it 
was important to study the presence of the different TGases in mitotic and 
differentiating C6 cells.  
Figure 3. 5 shows two blots containing C6 lysate sample probed with anti-TGase 1 
and anti-TGase 3. Results indicate that C6 cells contained TGase 1 but not TGase 3 
although in the blot probed with anti-TGase 3 there was a band around 30 kDa, 
which could be the segment produced in the cleavage of the full form, but there was 
no trace of the 50 kDa segment described by Kim et al., (1990) and Ahvazi et al., 
(2002). Protein levels of TGase 1 in mitotic and differentiating cells were quantified 
and the values show a slight but not significant decrease (~25 %) in the protein levels 
of TGase 1 in the differentiating cells compared to mitotic cell extracts. 
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Figure 3. 5: Western blotting analysis for TGase 1, 3 and GAPDH in mitotic and 
differentiating C6 cells 
Protein extracts (20 µg) for lysate fractions of mitotic and differentiating C6 cells 
were separated by SDS-PAGE and analysed by Western blotting. Shown are blots 
probed with A) anti-TGase 1 antibody B) anti-TGase 3 antibody and C) anti-GAPDH 
antibody for mitotic (mit) and differentiating (diff) C6 cells. 5 µg of human 
recombinant TGase 1 and 3 were loaded respectively to use as a TGase control. 
Densitometric peak areas of the bands present in the mitotic and differentiating 
fractions of blot A were analysed using AIDA software. GAPDH was used as an 
internal control. Values are expressed as a percentage average ± SEM of the protein 
levels of the mitotic control (100 %), after being corrected against GAPDH values 
for four independent experiments. For the statistical analysis, a paired t-test was 
performed comparing each TGase isoform in differentiating cells with the 
corresponding mitotic control (n = 4, *p < 0.05). Std represents molecular weight 
standards. 
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3.3.1.4. Gene expression of TGases in mitotic and differentiating C6 cells 
The gene expression of the different isoforms of TGase in C6 cells was also studied. 
RNA was extracted from mitotic and differentiating C6 cells, retro-transcribed to 
cDNA and analysed by RT-PCR as explained in section 2.11.2. The primers used in 
this experiment were designed by Dr. Verderio-Edwards’ group in order to recognise 
rat TGases. Figure 3. 6 shows the agarose gels containing the amplified bands for the 
TGase genes present in the C6 cells. Results indicated the expression of TGM1 and 
TGM2 in both mitotic and differentiating cells. By contrast, TGM3, 5, 6 and 7 were 
not detected. TGase 4, Factor XIIIa and band 4.2 were not assayed due to their 
specific localization in other tissues. 
 
 
            A) Mitotic C6 cells 
 
                Std     TGM1  TGM2  TGM3 TGM5  TGM6  TGM7          
 
 
 
 
            B)  Differentiating C6 cells 
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Figure 3. 6: PCR analysis for TGase 1, 2, 3, 5, 6 and 7 in mitotic and 
differentiating C6 cells 
RNA was obtained from mitotic and differentiating C6 cells and reverse transcribed 
into cDNA and analysed by PCR. Shown are the agarose gels for A) mitotic C6 cells 
and B) differentiating C6 cells. Std represents molecular weight standards. 
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The image obtained from the agarose gel suggests a possible increase in the levels of 
TGM2 and a possible decrease in the levels of TGM1 when cells were induced to 
differentiate, although to obtain quantitative data of the genes expression a real time 
RT-PCR analysis has to be performed. 
It is also important to comment the absence of positive controls for all the primers in 
this experiment, which are necessary to validate the assay. Thus, the results in this 
section cannot be used as conclusive information. 
3.3.2. Transglutaminase activity and TGase 2 protein levels in mitotic and 
differentiating C6 cells 
It has been described that TGase 2 is essential for the differentiation of neurons 
(Tucholski and Johnson, 2003). Thus, to determine whether TGase activity suffers 
any change during the differentiation of C6 cells, the cytosolic fraction of the cells, 
which had been previously shown to contain the higher levels of TGase 2, was 
analysed by two different methods that measure TGase activity.  
Figure 3. 7 show the effects of the induction of differentiation on TGase specific 
activity. Results obtained measuring the ability of TGase to incorporate amines into 
protein, indicated a significant increase (~100 %) in the specific activity when C6 
were differentiating. Data obtained using an assay that measures the ability of TGase 
to catalyse protein cross-linking, also show a significant increase (~300 %) in TGase 
specific activity in differentiating C6 cells, compared to the mitotic controls. It is 
important to note that the absorbance raw values obtained in the TVQQEL assay 
were very low, probably due to a low sensitivity of the assay in C6 cell extracts, thus 
a small change in activity can be shown as a high percentage change. 
After the increase in TGase activity was elucidated, it was important to study how 
the differentiation was affecting the TGase 2 protein levels, because at this stage it 
was clear that TGase 2 was the main isoform in C6 cells and that was mainly 
localized in the cytosol. In order to perform this study, the same cytosolic fractions 
that were analysed for the activity were used to check a possible change in the 
protein levels of TGase 2 by performing Western blotting analysis. 
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Figure 3. 8 shows blots probed with three different anti-TGase 2 antibodies and anti-
GAPDH. Densitometric analyses indicated a significant increase in TGase 2 protein 
levels in the differentiating cells for all three antibodies tested.  
Data obtained using ab10445 and TG100 antibodies show a similar increase relative 
to mitotic cell extracts (~200 %) while data obtained from CUB-7402 antibody show 
a smaller increase (~100 %) although it was still statistically significant.  
The blot probed with CUB-7402 antibody also showed the presence of two more 
bands, one of 60 kDa and another one of 45 kDa. For these experiments, only the 
75 kDa band was analysed as it was the full length form and was the only one 
detected by the other two antibodies. 
 
 
 
  
 
 
 
Figure 3. 7: Measurement of transglutaminase specific activity in mitotic and 
differentiating C6 cells. 
TGase activity in the cytosolic fractions of both mitotic and differentiating cells were 
analysed by two different methods. Values are shown as A) mean units /  mg protein 
± SEM in the biotin cadaverine assays and as B) mean Δ in absorbance / mg protein 
± SEM in the biotin-TVQQEL assay, for five independent experiments (n = 5, *p < 
0.05 and  ** p < 0.01). 
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Figure 3. 8: Western blotting analysis of TGase 2 and GAPDH proteins in 
mitotic and differentiating C6 cells 
Protein extracts (15 µg) for cytosolic fractions of mitotic and differentiating C6 cells 
were separated by SDS-PAGE and analysed by Western blotting. Shown are blots 
probed with A) CUB-7402 antibody B) TG100 antibody C) ab10445 antibody and 
D) anti-GAPDH antibody for mitotic (mit) and differentiating (diff) C6 cells. 
Densitometric peak areas of each band present on the blot was analysed using AIDA 
software. GAPDH was used as an internal control. Values are expressed as a 
percentage average ± SEM of the protein levels of the mitotic control (100 %), after 
being corrected against GAPDH values for five independent experiments. For the 
statistical analysis, paired t-tests were performed, and each antibody was compared 
to its corresponding mitotic control (n = 5, *p < 0.05). Std represents molecular 
weight standards. 
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3.3.3. Effects of CPF and CPFO on differentiating C6 cells 
3.3.3.1. Cell viability in the presence of CPF and CPFO 
Before studying the possible effects of both CPF and CPFO on TGase activity and on 
TGase 2 protein levels, it was important to elucidate the cell viability at different 
concentrations of the toxins. To perform this study, a 3-(4-5-Dimethylthiazol-2-y1)-
2,5-diphenyl tetrazolium bromide (MTT) reduction assay was carried out as 
explained in section 2.2.4.  
The data in Figure 3. 9 show the effects of CPF and CPFO on C6 cell viability. 
Results obtained indicate a very significant decrease (50 %) in the viability when 
cells were incubated for 24 hours with 25 µM CPF. CPFO showed a less toxic effect 
on cell viability, as at 25 µM the decrease in viability was only 25 %, although still 
significant. Therefore the effects of CPF and CPFO on the TGase 2 from C6 
differentiating cells were studied at the concentration of 10 µM. Previous studies by 
our group that involved the effects of both CPF and CPFO on C6 differentiating cells 
were also done at the same toxin concentration (Sachana et al., 2008).  
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Figure 3. 9: MTT reduction assay for CPF and CPFO treated differentiating C6 
cells 
C6 cells were seeded in 24 well plates and induced to differentiate in the presence or 
absence of toxins for 24 h. MTT solution was added 30 min before finishing the 24 h 
differentiation and reduced dye was then solubilised by the addition of DMSO. 
Shown are graphs for the effects on cell viability of different concentrations of A) 
CPF and B) CPFO. For the statistical analysis, ANOVA was performed with a 
Dunnett’s multiple comparison post test for four independent experiments (n = 4, * p 
< 0.05 and *** p < 0.001). 
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3.3.3.2. Morphological changes induced by CPF and CPFO in differentiating C6 
cells 
In this section, the effects of 10 µM CPF and 10 µM CPFO were analyzed by 
studying the morphological changes induced by the toxins on the differentiating 
cells. Figure 3. 10 shows Coomassie stained images for the treated and non treated 
differentiating cells after 24 h of exposure. It is noticeable that both toxins decreased 
the formation of processes in the C6 cells compared to the untreated differentiating 
control, CPFO being the molecule that generated the greater reduction.  
 
 
                   Control                          CPF 
 
               
 
 
        CPFO 
 
 
 
 
Figure 3. 10: Effects of CPF and CPFO on the morphology of differentiating C6 
cells  
C6 cells were seeded in 24 well plates and induced to differentiate in the presence or 
absence of toxins for 24 h. Cells were fixed and stained with Coomassie brilliant 
blue. Shown are images of differentiating control and CPF/CPFO treated cells. Red 
arrows indicate typical processes from the glial cells formed in the differentiation 
step. Scale bar represents 40 µm. 
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3.3.3.3. Molecular changes induced by CPF and CPFO in differentiating C6 cells 
After confirming the morphological effects of the toxins on the differentiating C6 
cells, it was important to study these changes at a molecular level. For this, 
antibodies against the astrocyte and oligodendrocyte markers were used to probe 
Western blots containing the lysate fractions of non treated and treated cells. 
Figure 3. 11 shows that both CPF and CPFO had an effect on the protein levels of 
GFAP. Data indicate a significant decrease in the levels of reactivity with astrocyte 
marker when cells were induced to differentiate in the presence of toxins. Cells 
treated with CPF revealed a decrease of around 20 % while CPFO shows a greater 
effect on differentiation by decreasing the protein levels of GFAP by around 50 % 
compared to the untreated control. 
Figure 3. 12 shows the effects of the same toxins on the oligodendrocyte marker. In 
this case, the results indicate that there was no change in the protein levels of 
CNPase when cells were induced to differentiate in the presence of CPF, but there 
was a 25 % decrease compared to the untreated control when the cells were treated 
with CPFO. However, this effect was not statistically significant. 
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Figure 3. 11: Western blotting analysis of GFAP proteins in differentiating and 
CPF/CPFO treated cells. 
Protein extracts (20 µg) for lysate fractions of differentiating control and CPF/CPFO 
treated C6 cells were separated by SDS-PAGE and analysed by Western blotting. 
Shown are blots probed with A) anti-GFAP antibody and B) anti-GAPDH antibody. 
Densitometric peak areas of each band present in the blot were analysed using AIDA 
software. GAPDH was used as an internal control. Values are expressed as an 
average percentage ± SEM of the protein levels of the control (100 %), after being 
corrected against GAPDH values for four independent experiments. For the 
statistical analysis, paired t-tests were performed, and each antibody was compared 
to its corresponding control (n = 4, * p < 0.05). Std represents molecular weight 
standards. 
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Figure 3. 12: Western blotting analysis of CNPase proteins in differentiating 
and CPF/CPFO treated cells. 
Protein extracts (20 µg) for lysate fractions of differentiating control and CPF/CPFO 
treated C6 cells were separated by SDS-PAGE and analysed by Western blotting. 
Shown are blots probed with A) anti-CNPase antibody and B) anti-GAPDH 
antibody. Densitometric peak areas of each band present in the blot were analysed 
using AIDA software. GAPDH was used as an internal control. Values are expressed 
as an average percentage ± SEM of the protein levels of the control (100 %), after 
being corrected against GAPDH values for four independent experiments. For the 
statistical analysis, paired t-tests were performed, and each antibody was compared 
to its control (n = 4, * p < 0.05). Std represents molecular weight standards. 
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3.3.3.4. Effects of CPF on TGase activity and TGase 2 protein levels in 
differentiating C6 cells 
Biotin cadaverine and biotin-TVQQEL assays were performed on the cytosolic 
fractions from differentiating C6 cells and 10 µM CPF treated cells in order to 
elucidate the in vitro effects of this toxin on TGase activity. Interestingly, Figure 3. 
13 shows a significant increase (60 %) in the activity compared to the 
differentiating control when the amine incorporation assay was used. The results 
obtained in the protein cross-linking assay also indicated a very significant increase 
(100 %) in the TGase activity when cells were induced to differentiate in the 
presence of CPF. 
Having established that there was an increase in TGase activity on cell differentiation 
it was of interest to investigate the response of TGase 2 to the presence of CPF at the 
protein level. The results in Figure 3. 14 indicate that the protein levels of GAPDH 
were not affected by CPF; therefore it could be used as an internal control to quantify 
the densitometry of the bands obtained with TGase 2 antibodies. As seen in Figure 3. 
14 there was no difference in the protein levels of TGase 2 between the control and 
the CPF treated cells. Analysis of three blots probed with different antibodies against 
TGase 2 indicates that CPF did not have any effect on TGase 2 protein amounts over 
a 24 h exposure period.  
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Figure 3. 13: Measurement of transglutaminase specific activity in 
differentiating control and CPF treated C6 cells. 
TGase activity in the cytosolic fractions of both non-treated (control) and treated 
(CPF) differentiating cells were analysed by two different methods. Values are 
shown as A) mean units /  mg protein ± SEM in the biotin cadaverine assays and as 
B) mean Δ in absorbance / mg protein ± SEM in the biotin-TVQQEL assay, for five 
independent experiments (n = 5, * p < 0.05 and  ** p < 0.01). 
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Figure 3. 14: Effects of CPF on protein levels of TGase 2 and GAPDH  
Protein extracts (15 µg) for cytosolic fractions of non treated and CPF treated 
differentiating C6 cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown are blots probed with A) CUB-7402 antibody B) TG100 antibody C) 
ab10445 antibody and D) anti-GAPDH antibody for control differentiating (CON) 
and CPF treated (CPF) C6 cells. Densitometric peak areas of each band present in the 
blot were analysed using AIDA software, using GAPDH as an internal control. 
Values are expressed as an average percentage ± SEM of the protein levels of the 
control (100 %), after being corrected against GAPDH values for five independent 
experiments. For the statistical analysis, paired t-tests were performed, and each 
antibody was compared to its corresponding control (n = 5, *p < 0.05). Std represents 
molecular weight standards. 
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3.3.3.5. Effects of CPFO on TGase activity and TGase 2 protein levels in 
differentiating C6 cells 
After the analysis of the effects of CPF on TGase activity and protein levels, it was 
interesting to study the outcome in TGase activity when the C6 cells were co-
differentiated with a 10 µM concentration of the oxon metabolite of CPF. In this 
study, both the biotin cadaverine and the biotin-TVQQEL assays were performed on 
the cytosolic fractions of differentiating C6 cells, to elucidate the in vitro effects of 
CPFO on TGase activity. 
This toxin showed effects similar to those of CPF on TGase activity. As seen in 
Figure 3. 15, assays of TGase activity indicate a significant increase (50 %) when 
the biotin cadaverine assay was used to detect the activity. The results obtained in the 
protein cross-linking assay also indicate a significant increase in the activity, 
although in this assay the increment seen was much higher (300 %). It is noticeable 
that using the biotin cadaverine assay, the increase in TGase activity was similar for 
both toxins, while in the biotin-TVQQEL assay the increase in TGase activity was 
higher when the cells were exposed to CPFO.  
Western blotting analysis of TGase 2 protein levels was also performed with the 
CPFO treated C6 cells. Cytosolic fractions were loaded into the gels, and the 
resultant blots were probed with anti-GAPDH and anti-TGase 2 antibodies. The 
results in Figure 3. 16 indicate that the protein levels of GAPDH were not affected 
by CPFO, therefore it could be used as an internal control to quantify the 
densitometry of the bands obtained with TGase 2 antibodies. The data obtained 
indicate that CPFO did not have any significant effects on TGase 2 protein levels in 
differentiating cells after 24 h of exposure. Densitometric values show a small but 
not significant increase in reactivity with all three antibodies analysed. 
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Figure 3. 15: Measurement of transglutaminase specific activity in 
differentiating control and CPFO treated C6 cells. 
TGase activity in the cytosolic fractions of both non-treated (control) and treated 
(CPFO) differentiating cells were analysed by two different methods. Values are 
shown as A) mean units /  mg protein ± SEM in the biotin cadaverine assays and as 
B) mean Δ in absorbance / mg protein ± SEM in the biotin-TVQQEL assay, for five 
independent experiments (n = 5, * p < 0.05). 
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ii) QUANTIFICATION 
 
 
 
 
Figure 3. 16: Effects of CPFO on protein levels of TGase 2 and GAPDH  
Protein extracts (15 µg) for cytosolic fractions of non treated and CPFO treated 
differentiating C6 cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown are blots probed with A) CUB-7402 antibody B) TG100 antibody C) 
ab10445 antibody and D) anti-GAPDH antibody for control differentiating (CON) 
and CPFO treated (CPFO) C6 cells. Densitometric peak areas of each band present in 
the blot were analysed using AIDA software, using GAPDH as an internal control. 
Values are expressed as an average percentage ± SEM of the protein levels of the 
control (100 %), after being corrected against GAPDH values for five independent 
experiments. For the statistical analysis, paired t-tests were performed, and each 
antibody was compared to its corresponding control (n = 5, *p < 0.05). Std represents 
molecular weight standards. 
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3.3.3.6. Effects of CPF and CPFO on TGase 2 localization in differentiating C6 
cells 
Previous data indicate that both toxins generated an increase in TGase activity but 
did not have any effect on the protein levels of TGase 2. However this section 
involved a study of the distribution of TGase 2 within the cells in the presence of 
CPF and CPFO.  
Immunocytochemistry images obtained with anti-TGase 2 ab10445 antibody (Figure 
3. 17) show a diffuse distribution of the enzyme in the cytoplasm of the untreated 
and OP treated C6 cells, thus indicating no major changes in the distribution of 
TGase 2. The decrease in the formation of processes could be seen in CPF and CPFO 
treated cells stained with antibody, similar that observed previously in Coomassie 
blue stained cells (section 3.3.2.), although a higher magnification would have been 
more useful to visualize the changes and the distribution of TGase 2. 
 
                 Control 
 
 
 
          CPF             CPFO 
              
 
 
Figure 3. 17: Immunocytochemistry analysis of organophosphate effects on 
differentiating C6 cells 
C6 cells were seeded in Lab-Tek chambers and induced to differentiate in the 
presence or absence of toxins for 24 h before being permeabilized. Shown are control 
(untreated) and CPF/CPFO treated cells probed with ab10445 antibody anti-TGase 2. 
Arrow indicates a typical outgrowth. Scale bar represents 40 µm. 
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3.3.3.7. TGase 2 gene expression in mitotic, differentiating and CPF/CPFO treated 
C6 cells  
This section contains data from a preliminary study of TGase 2 gene expression in all 
four different treatments (mitotic, differentiating, CPF and CPFO treated). For this 
assay a quantitative real time RT-PCR method was used and to obtain the final 
values, TGM2 expression was compared against one housekeeping gene (GAPDH) 
and also against a pool of housekeeping genes (GAPDH and cyclophilin) also known 
as a normalizer factor. Expression values were obtained using the 2(-Delta Delta 
C(T)) method of Livak and Schmittgen (2001). 
The expression values for TGM2 are shown in Table 3. 1 and also in the appendix 
(Appendix: Figure 1). The data indicate significantly lower levels of expression of 
the gene in the mitotic cells compared to both controls. Results also show that in 
presence of the toxins, the expression of TGM2 was reduced compared to the 
differentiating control cells, although it was interesting to note that the values 
showed much smaller discrepancies when they were compared against a combination 
of two different housekeeping genes.  When GAPDH was used as a normalizer there 
was a significant decrease in the gene expression when cells were treated with CPFO 
and a very significant decrease in the case of CPF.  
 
 TGM2 expression 
Treatment 
normalized against 
GAPDH 
normalized against 
two reference genes 
Mitotic 0.04***  0.01 0.07**  0.02  
differentiating 
(control) 
1 1 
CPF 0.17***  0.03 0.7  0.14 
CPFO 0.78***  0.06 0.55  0.17 
 
Table 3. 1: TGM2 relative expression values in mitotic, differentiating and 
CPF/CPFO C6 treated cells 
Shown are the average value expression ± SEM normalized against GAPDH values 
or normalizer values for three independent assays. Expression values were calculated 
using the 2(-Delta Delta C(T)) method. For the statistical analysis, ANOVA analysis 
was performed with a Dunnett’s multiple comparison post test (n = 3, ** p < 0.01, 
*** p < 0.001). 
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In the case of the normalizer factor (GAPDH and cyclophilin), although the values 
demonstrated a decrease in the TGM2 expression in presence of both toxins, the 
reduction was not significant. The expression values obtained using GAPDH 
housekeeping gene were less variable than the values obtained using the normalizer 
factor, which generated the difference in significance. The variability in these values 
could be due to the possibility that the two housekeeping genes used as a normalizer 
factor had different responses to the toxins exposure.   
The analysis of the melting curve did not show either the formation of primer-dimer 
artifacts or the presence of contamination (Appendix: Figure 2). 
3.3.3.8. Effects of CPF and CPFO on TGase 1 protein levels in differentiating C6 
cells 
It has been previously described in section 3.3.1.3. that TGase 1 protein levels 
experienced a decrease when C6 cells were induced to differentiate with NaB. 
Therefore it was of interest to study how the presence of toxins during cell 
differentiation was affecting the protein levels of TGase 1. The Western blotting 
analysis shown in Figure 3. 18 indicates that there were no changes in the protein 
levels of TGase 1 when C6 differentiating cells were incubated with CPF. In the case 
of CPFO, the results indicate a small increase in the protein levels, although it was 
not considered to be significant. 
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i) BLOTS 
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ii) QUANTIFICATION 
 
 
 
Figure 3. 18: Western blotting analysis of TGase 1 and GAPDH proteins in CPF 
and CPFO treated differentiating cells 
Protein extracts (20 µg) for lysate fractions of control differentiating and treated C6 
cells were separated by SDS-PAGE and analysed by Western blotting. Shown is the 
blot probed with A) anti-TGase 1 antibody and B) anti-GAPDH antibody for 
differentiating control, CPF and CPFO treated C6 cells. Densitometric peak areas of 
each band present in the blot were analysed using AIDA software. GAPDH was used 
as an internal control. Values are expressed as an average percentage ± SEM of the 
protein levels of the control (100 %), after being corrected against GAPDH values 
for four independent experiments. For the statistical analysis, paired t-tests were 
performed and each antibody was compared to its corresponding control (n = 4, * p < 
0.05). Std represents molecular weight standards. 
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3.3.3.9. Effects of the TGase 2 inhibitor R283 in transglutaminase activity in 
mitotic, differentiating and CPF/CPFO treated C6 cells 
As demonstrated in section 3.3.1.3. and section 3.3.1.4., C6 cells contain TGase 1 
and 2 isoforms. Although it was found that TGase 2 was the main isoform and TGase 
1 experienced a decrease in protein levels on cell differentiation, it was difficult to be 
sure that the predominant activity detected was due to TGase 2, as both activity 
assays are based on general TGase functions. For this reason, TGase activity from all 
four treatments was analysed again using the biotin cadaverine assay in the presence 
and absence of the TGase 2 inhibitor 1,3,dimethyl-2-[(2-oxopropyl) thio] 
imidazolium chloride (R283) although R283 is also able to inhibit Factor XIIIa 
(Siegel and Khosla, 2007). Cytosolic fractions were incubated with or without 100 
µM R283 for 10 min at room temperature before each assay. 
The data in Figure 3. 19 show a dramatic decrease (95 %) in TGase activity when 
samples were incubated with the inhibitor. It is also interesting that the CPF treated 
cells reported a higher increase in the activity than the CPFO treated. 
 
 
 
Figure 3. 19: Measurement of transglutaminase activity in mitotic, 
differentiating and CPF/CPFO treated cells in presence of TGase 2 inhibitor  
TGase activity in the cytosolic fractions of all four different treatments was 
determined in absence or presence of R283 by the biotin cadaverine assay. Values 
are shown as mean units / ml ± SEM for three independent experiments. For the 
statistical analysis, paired t-tests were performed and the values for each inhibitor 
treatment were compared to their corresponding controls (n = 3, * p < 0.05 and ** p 
< 0.01). 
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3.3.4. Effects of R283 on the differentiation of C6 cells  
In this section, it was of interest to study the effects of the inhibition of TGase 2 
activity on the differentiation of C6 cells. This experiment was performed using the 
method described by Beck et al., (2006) with some modifications. C6 cells were 
induced to differentiate with NaB in the presence or absence of 250 µM R283, which 
is a cell permeable and irreversible site-specific inhibitor of TGase activity (Telci et 
al., 2009). After 24 h differentiation, C6 cells were disrupted and centrifuged at 
100,000 g for 45 min at 4C to obtain the cytosolic fraction of the control and R283 
treated cells, which were then analysed by the biotin cadaverine assay. The inhibitor 
was not removed before the activity assay was conducted. The data obtained are 
shown in Figure 3. 20. Results demonstrate a significant decrease (70 %) in the 
TGase activity when C6 cells were induced to differentiate in the presence of R283, 
showing that the specific TGase inhibitor was able to reduce partially the activity of 
the enzyme in situ. 
 
 
 
 
 
Figure 3. 20: Effects of R283 on transglutaminase activity in differentiating C6 
cells 
TGase activity in cytosolic fractions of both untreated (control) and R283 treated 
differentiating cells was determined by biotin cadaverine assay. Values are shown as 
mean units / mg protein ± SEM for three independent experiments. For the statistical 
analysis, paired t-tests was performed (n = 3, * p < 0.05). 
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The next step was then to study the possible effects of the inhibition of TGase 
activity by R283 on C6 cell differentiation and TGase 2 protein levels. The effects 
were only studied at a molecular level as there were no significant visual changes at a 
morphological level, indicating that the formation of processes was not altered by the 
inhibition of TGase activity. Studies on the extent of cell differentiation were 
performed using the oligodendrocyte and astrocyte markers, CNPase and GFAP 
respectively.  
The results shown in Figure 3. 21 suggest that GAPDH protein levels were not 
affected by the inhibition of TGase activity, thus it could be used as an internal 
control. Values also show no change in the protein levels of TGase 2 although its 
activity was partially inhibited. It was interesting to observe in Figure 3. 22 that 
CNPase protein levels suffered a significant decrease (60 %) compared to non-
R283 treated controls, while GFAP levels exhibited a significant increase (150 %), 
indicating that the inhibition of TGase activity could promote the differentiation of 
astrocytes. 
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i) BLOTS 
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ii) QUANTIFICATION 
 
 
 
 
 
Figure 3. 21: Western blotting analysis of TGase 2 and GAPDH proteins 
induced to differentiate in the presence and absence of R283  
Protein extracts (10 µg) for cytosolic fractions were used to calculate the protein 
levels of TGase 2 and GAPDH. All fractions were separated by SDS-PAGE and 
analysed by Western blotting. Shown are the blots probed with A) TG100 antibody 
(anti-TGase 2) and B) anti-GAPDH antibody for differentiating control (CON) and 
cells differentiating in presence of R283 (R283). Densitometric peak areas of each 
band present in the blots were analysed using AIDA software. GAPDH was used as 
an internal control. Values are expressed as an average percentage ± SEM of the 
protein levels of the control (100 %), after being corrected against GAPDH values 
for three independent experiments. For the statistical analysis, paired t-tests were 
performed and each antibody was compared to its corresponding control (n = 3). Std 
represents molecular weight standards. 
 
75 kDa 
37 kDa 
                                        CHAPTER III. GLIAL TRANSGLUTAMINASE 2 
 
 124 
i) BLOTS 
 
     A)            Std       CON     R283          B)    Std      CON     R283           
   
                        
 
  
     C)           Std       CON     R283                   Std       CON     R283                   
 
                       
 
 
ii) QUANTIFICATION 
 
 
 
 
Figure 3. 22: Western blotting analysis of GFAP, CNPase and GAPDH proteins 
in C6 cells induced to differentiate in the presence and absence of R283 
Protein extracts (20 µg) for lysate fractions of differentiating control and R283 
treated C6 cells were used to determine the protein levels of CNPase, GFAP and 
GAPDH. 10 µg of protein for cytosolic fractions were used to calculate the protein 
levels of TGase 2 and GAPDH. All fractions were separated by SDS-PAGE and 
analysed by Western blotting. Shown are the blots probed with A) anti-GFAP 
antibody, B) anti-CNPase antibody, and C) anti-GAPDH antibody for differentiating 
control (CON) and cells differentiating in presence of R283 (R283). Densitometric 
peak areas of each band present in the blots were analysed using AIDA software. 
GAPDH was used as an internal control. Values are expressed as an average 
percentage ± SEM of the protein levels of the control (100 %), after being corrected 
against GAPDH values for three independent experiments. For the statistical 
analysis, paired t-tests were performed and each antibody was compared to its 
corresponding control (n = 3, * p < 0.05). Std represents molecular weight standards. 
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3.4. Discussion 
3.4.1. C6 cell phenotype and TGase profile 
Rat C6 glioma cells contain two types of glial cells, oligodendrocytes and astrocytes 
as discussed by Bottenstein (1986) and shown in this thesis by the presence of the 
astrocyte and oligodendrocyte markers in Figure 3. 1 and 3.2. To clarify the presence 
of both types of glial cells and to determine which population is more abundant in C6 
cells, it would have interesting to perform an immunofluorescence dual stain method 
of the cells using the astrocyte and oligodendrocyte markers. C6 cells can be induced 
to differentiate to any of these two types of cells depending on the conditions 
(Bianchi et al., 2008). The induction of C6 cells differentiation by serum withdrawal 
and addition of NaB has long been studied but the predominant phenotype has not 
been clarified yet. New data obtained in this project from Western blot analysis 
suggest that, in the presence of NaB, C6 cells were induced to differentiate into 
astrocytes in preference to oligodendrocytes, as there was a significant increase in 
GFAP protein levels while the oligodendrocyte marker experienced a significant 
decrease. Although GFAP antibody is used as an astrocyte specific marker 
(Takizawa et al., 2008; McCall et al., 1996) there is evidences for its presence in 
oligodendrocytes (Dyer et al., 1996; Casper and McCarthy, 2006). Therefore, to 
confirm the differentiation of C6 cells into astrocytes it would have been useful to 
monitor another astrocyte marker such as S100 antibody (Ghandour et al, 1981) or 
ABCA 1 antibody. The fact that GAPDH protein levels were not altered during 
differentiation, indicates that altered expression of this protein in the cell was not 
important in the process. 
3.4.1.1. TGase expression and activity in C6 cells 
Although it was already known that TGase 2 is present in primary cultures of rat 
astrocytes (Monsonego et al., 1997), the presence of this isoform and some of the 
others was studied in C6 cells. Results of Western blot analysis in section 3.3.1.2. 
confirm the presence of TGase 2 in mitotic cells and localise it mainly in the 
cytoplasm, although the use of other subcellular markers such as proliferating cell 
nuclear antigen (PCNA) or lamin A (nuclear markers), actin (cytosol marker) and 
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cytochrome c (mitochondrial marker) (Ferecatu et al., 2009) would have given more 
detailed information about the subcellular fractions. Data from the Western blots 
probed with CUB-7402 antibody show the presence of three bands, the smaller of 
which could be due to the presence of truncated isoforms of TGase 2 in C6 cells. 
These bands with a molecular weight lower than 75 kDa were not recognised by any 
other anti-TGase 2 antibodies used in this project. This result could be due to the 
absence in these bands of the epitope region recognised by the antibodies or to a non 
specific cross reaction of the bands with CUB-7402 but not with any of the other 
anti-TGase 2 antibodies. 
From the data obtained in this thesis, it can be appreciated that when cells were 
differentiating, TGase 2 seemed to remain concentrated in the cytoplasm and it also 
appeared in the glial processes formed, suggesting that the functions performed by 
the enzyme in the cytosol may be important for cell differentiation. 
The presence of TGases 1 and 3 was also studied by Western blotting analysis. Data 
shown in section 3.3.1.3. indicate that mitotic C6 cells contain TGase 1 and it seems 
TGase 3 is not present although there is a band present at around 30 kDa which could 
be a cleaved fraction of the enzyme, but the 50 kDa segment is not visible. So, it 
could be that the 50 kDa segment was proteolysed or that the 30 kDa band was a 
cross-reaction product. However, these data do not rule out the possibility that TGase 
3 could be present in other types of neural cells, as studies by Kim et al., (2000) have 
shown the presence of both TGase 1 and 3 in rat brain. It was also interesting to note 
that when cells were differentiating, TGase 1 protein levels decreased. This could be 
due to a reduction in TGase 1 protein synthesis, a reduction in TGase 1 gene 
expression, increased TGase 1 degradation and/or activation of the enzyme. 
Although there was a big increase in TGase activity, the last option was not likely to 
happen because the activation of TGase 1 is due to a cleavage of the enzyme 
generating small fragments. Although smaller cross-reactive fragments were 
detected, data obtained did not show any band at 67 kDa and the one detected around 
33 kDa showed a small decrease in protein levels compared to the mitotic control 
(Appendix: Figure 3). 
Using the primers for rat TGase 1, TGase 2, TGase 3, TGase 5, TGase 6 and TGase 7 
which were designed by Dr. Verderio-Edwards’ group, the presence of the genes for 
these isoforms in the C6 cells was studied. Results presented in section 3.3.1.4. 
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corroborate the presence of TGase 1 and 2, but also suggest the absence of TGase 3 
and any of the other isoforms studied in the mitotic and differentiating states.  
Although the PCR data obtained in Figure 3. 6 cannot be accurately normalised and 
quantified, it is interesting to note that the expression of TGM1 in both mitotic and 
differentiated cells was lower than the expression of TGM2. It was also noticeable 
that the results from the blots probed with anti-TGase 2 and anti-TGase 1 antibodies 
showed a higher reactivity of TGase 2 band; although the reactivity of the bands does 
not only depend on the amount of protein present, the data could be used to 
hypothesize that TGase 2 is the most abundant isoform in C6 cells.  
The data obtained in this project from the PCR assay (Figure 3. 6) also suggested that 
during the differentiation of C6 cells there is an increase in TGM2 expression, 
although it has to be remarked that with this assay, gene expression can not be 
quantified. The hypothesized increase in the expression of TGM2 could be 
associated with the increase in TGase 2 protein levels. A possible reduction in the 
expression of TGM1 was also noted, which could generate the decrease found in the 
protein levels of TGase 1 detected on Western blots. It seems that differentiation of 
the cells did not provoke the synthesis of TGase 3; although it is known to be present 
in rat brain (Kim et al., 2000), it seems to be absent from C6 cells. The data obtained 
from the PCR assay has to be analysed carefully, because the absence of positive 
controls for the primers used does not allow confirming the absence of the other 
TGase isoforms. It would be interesting as a further work to perform a PCR assay 
with positive controls for all the primers employed as well as Western blot analysis 
using a different anti-TGase 3 antibody and PCR with different primers for TGase 3 
to be able to corroborate the absence of TGase 3 in this cell line. 
3.4.1.2. TGase 2 changes induced by cell differentiation 
As discussed before, in the presence of NaB C6 cells differentiate into astrocytes 
showing morphological changes, particularly an increase in the number of processes. 
The differentiation procedure also involves changes in several proteins and the data 
shown in section 3.3.2. indicate that TGase 2 may be one of these. When C6 cells 
were induced to differentiate, in vitro TGase activity and TGase 2 protein levels 
increased significantly.  
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TGase activity was analysed by two different methods, which are based on different 
functions of TGase. The amine incorporation assay shows a significant increase in 
the activity of about 100 % while the assay based on the protein crosslinking proved 
a very significant increase in the activity of about 300 % of mitotic control values. 
This discrepancy in the extent of increase could be due to the nature of the assays, as 
it appears that the one that measures amine incorporation could be more sensitive 
than the protein crosslinking assay. The protein crosslinking assay seems to be more 
limited because the values obtained in the measurement of TGase activity are much 
lower than the values obtained for the amine incorporation assay for the same 
samples. Therefore, when working with low values, a small change will be detected 
as a high percentage alteration when values are compared. For this reason, the amine 
incorporation assay should be considered more robust and more representative of the 
changes in TGase activity, while the protein crosslinking assay data should be 
considered as support information. Alternatively, the data may reflect a genuinely 
greater increase in protein cross-linking activity. 
The densitometric values for the protein levels of TGase 2 were studied with three 
different antibodies in order to obtain a confident assessment of the possible effects 
on the enzyme following exposure to the toxins. The densitometric data obtained 
from all three antibodies show a significant increase in the protein levels of TGase 2 
in differentiating cells. The fact that TG100 and ab10445 antibodies show a higher 
increase than CUB-7402 could be due to a higher reactivity with the rat TGase 2, as 
CUB-7402 seems to be less specific in that it cross-reacted with other bands that 
were not recognized by any of the other two antibodies. There was also the 
possibility that the bands recognized by CUB-7402 were TGase truncated isoforms 
generated by alternative splicing mechanisms as described for other cell types (Lai et 
al., 2007; Antonyak et al., 2006). However as they did not appear with any of the 
other two antibodies used, only the full length form was studied. It is important to 
clarify that although all three antibodies recognize TGase 2, only TG100 antibody is 
specific for rat, therefore the data analysis should be mainly based on the results of 
this antibody. 
In this case it seems that the increase in TGase activity was due to the increase in 
TGase 2 protein levels. This upregulation indicates a possible role of this enzyme in 
astrocyte differentiation, suggesting it could be acting in a similar way to TGase 2 in 
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the differentiation of human neuroblastoma SH-SY5Y cells (Tucholski et al., 2001). 
The upregulation of TGase activity might be required for the differentiation process 
of C6 cells, as the enzyme is able to activate the AC pathway in neuronal cells 
(Tucholski and Johnson, 2003) and could be playing the same role in this glial 
model. TGase 2 is also able to interact with cytoskeletal proteins such as β-tubulin 
(Fesus and Piacentini, 2002) and with microtubule-binding proteins such as tau, 
which can be cross-linked (Murthy et al., 1998) and may facilitate the formation of 
glial processes. Although there is no definitive evidence, it could be hypothesized 
that the increase in protein levels of TGase 2 could generate a negative feedback on 
the gene expression or protein levels of TGase 1, thus inducing this isoform to reduce 
its levels in the differentiated C6 cells. 
3.4.2. Effects of CPF and CPFO on differentiating C6 cells 
Previous studies with CPF and its metabolite CPFO performed by our group showed 
that at 10 µM concentration there was an inhibition of cell differentiation and 
disruption of cytoeskeletal proteins. More studies by Garcia et al. (2001) also showed 
that low levels of CPF inhibit C6 cell differentiation and cell replication by targeting 
different pathways.  
3.4.2.1. Effects of CPF and CPFO on C6 cell viability 
The first step in this study was to corroborate the viability results obtained in earlier 
studies by performing MTT reduction assays at different toxin concentrations.  The 
data obtained for the viability assay in the section 3.3.3.1 show very different EC50 
values for each compound. CPF presented an EC50 value around 25µM while the 
EC50 value for CPFO was above 100 µM, thus indicating that CPF has a more 
powerful cytotoxic effect than CPFO on differentiating C6 cells. The toxins 
employed in this project were from a new batch which would explain the differences 
in the EC50 values obtained in previous studies (Sachana et al., 2008). Despite this 
discrepancy, exposure of cells to concentrations of 3 and 10 µM for both toxins did 
not cause a significant decrease in cell viability, corroborating the data obtained by 
Sachana et al. (2008).  
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With all the data gathered, it was decided to perform subsequent experiments at the 
organophosphate concentration of 10 µM. 
3.4.2.2. Effects of CPF and CPFO on C6 cell differentiation 
To study the effects of 10 µM CPF and 10 µM CPFO on C6 cell differentiation, 
morphological and molecular assays were performed. Digital images obtained from 
the treated and non treated differentiating C6 cells stained with Coomassie show a 
clear effect of the toxins on cell morphology as there was an important decrease in 
the formation of glial processes (Figure 3. 10). The exposure of the cells to CPFO 
generated a greater reduction than CPF in the formation of these processes, 
corroborating the results found previously by our group (Sachana et al., 2008). The 
data indicates that CPFO has a greater effect on cell differentiation, whereas the 
viability assays indicated that this compound was less cytotoxic than CPF.  
The effects of both compounds were also studied at a molecular level by Western 
blotting and densitometric analysis. As described earlier, in presence of NaB, C6 
cells differentiate towards astrocytes; it was therefore interesting to study the effects 
of the toxins on the protein levels of the astrocyte and oligodendrocyte markers. 
Previous studies with animals have shown that the administration of CPF during 
gestation provokes an increase in GFAP levels due to the process of gliosis, but when 
CPF was administrated at a postnatal time, GFAP suffered a decrease followed by an 
increase that followed the pattern of a delayed glial differentiation (Garcia et al., 
2002). Data obtained in this study and shown in Figure 3. 11 indicate a significant 
decrease in the protein levels of GFAP following exposure of differentiating cell to 
both toxins, although CPFO generated a greater reduction (50 %).  The lack of 
effect of OPs on protein levels of the CNPase marker (see section 3.12) indicate no 
major effects on oligodendrocytes, although it cannot be confirmed that this type of 
glial cells is not a target for CPF or CPFO as this population seems to be at a very 
low levels when C6 cells were induced to differentiate with NaB. Thus, the results 
obtained for the astrocyte marker agree with the morphological data, confirming the 
effects of CPF and CPFO on astrocytic differentiation and no major effects on the 
oligondendrocytic population. The in vitro effects of both toxins on cell 
differentiation are also in good agreement with previous in vivo studies that indicate 
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a delayed differentiation effect on glial cells due to the exposure to CPF (Garcia et 
al., 2002). 
3.4.2.3. Effects of CPF and CPFO on TGase activity and TGase 2 protein levels in 
differentiating C6 cells 
The fact that TGase 2 is able to activate the cAMP-CREB pathway, which is very 
important in neuronal cell differentiation (Tucholski and Johnson, 2003), together 
with the observation that some cytoeskeletal proteins are substrates for TGase 2, 
made it of interest to evaluate the possible effects of exposure of the cells to the 
toxins on the protein levels and activity of TGase 2. After the study of cell viability 
and cell differentiation, the effects of CPF and CPFO on TGase 2 were studied by 
activity assays and densitometric analysis of Western blots. 
The data obtained in Figure 3. 13 indicate that the presence of CPF during cell 
differentiation provoked a significant increase in TGase activity in vitro. In this 
experiment, both assays again showed different levels of increase in TGase activity. 
Interestingly, TGase 2 protein levels did not change. Probing with all three different 
antibodies showed that the protein levels were not affected by the toxins, suggesting 
that the increase in the in vitro activity was not related with the TGase 2 levels. It is 
unlikely that any other TGase is involved in this increase of in vitro activity, as C6 
cells seems to contain only TGase 2 and TGase 1 and, as described earlier, TGase 1 
protein levels decrease during cell differentiation and it also seems that TGM1 levels 
are reduced. 
The results obtained from CPFO exposed cells were very similar to those from CPF 
treatment. The data obtained in Figure 3. 15 indicate an increase in TGase activity 
after exposing the cells to CPFO. There was again a difference in the extent of the 
increase in activity between the assays performed, but in both cases the increase was 
statistically significant compared to the non OP treated control. The images and the 
data shown in Figure 3. 16 reveal that CPFO exposure did not produce any change in 
the protein levels of TGase 2. Therefore, both CPF and CPFO have a similar effect 
on glial TGase, in that they generate an increase in TGase activity with no effect on 
the amounts of TGase protein.  
                                        CHAPTER III. GLIAL TRANSGLUTAMINASE 2 
 
 132 
It was interesting to note that in the biotin cadaverine assay, the activity suffered a 
higher increase in the presence of CPF (~60 %), while with the biotin-TVQQEL 
assay the increase in the activity was higher in the presence of CPFO (~300 %). 
Thus, it was difficult to predict which compound has a greater effect on TGase 
activity, as both assays measure different functions of the enzyme, although it seems 
that the biotin cadaverine assay gives more robust data. 
Thus, taken together all of the data, it can be hypothesized that both toxins could 
have a direct or indirect effect on TGase 2 generating the increase in the activity. The 
toxins could distort the metabolic activity of the cells or interact with some targets 
that could regulate the activity or the sensitivity of TGase 2. The increase in the 
activity could also be due to a rise in ROS production generated by the exposure to 
the toxins, as it is has been described that ROS activates indirectly in situ TGase 2 
(Park et al., 2010) and hypothesized that in situ oxidative stress can result in the 
modification of specific proteins, becoming a better substrates for TGase (Lesort et 
al., 2000b). There is no evidence that CPF and CPFO provoke a deregulation in the 
Ca
2+ 
homeostasis, although it is known that ROS disrupts Ca
2+ 
homeostasis 
(Bielefeldt et al., 1997) which could generate the increase in the TGase activity. 
Alternatively, it could be hypothesized that there is a direct interaction of the toxins 
with TGase 2, which could provoke a conformational change in the enzyme 
increasing its activity or making it more sensitive to regulatory molecules such as 
Ca
2+
, though there is no evidence to support this idea. Further studies are necessary 
to elucidate in which manner CPF and CPFO affect TGase activity, but the 
possibility that one or more of the above factors contribute to the upregulation of 
TGase activity cannot be discounted.   
After the detection of the increase in activity, the localization of TGase 2 within the 
cell was studied to check if the change in the activity was related with a possible 
variation in enzyme distribution. As seen in Figure 3. 17, TGase 2 seemed to be 
localized in the cytoplasm and in the processes of the control differentiating cells. In 
the OP treated cells the distribution of the enzyme was the same, although the 
reduction in the formation of the glial processes was evident. Thus, the images 
appear to show no change in the localization pattern of TGase 2 during exposure to 
the toxins, other than that corresponding to the morphological changes observed in 
Coomassie blue stained cells. 
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As previous studies have shown that exposure of C6 cells to CPF and CPFO causes 
inhibition of DNA synthesis (Qiao et al., 2001), it was of interest to know if the 
toxins also reduce the synthesis of TGM2 and how the gene expression was affected 
when cells were induced to differentiate. Data shown in Table 3. 1 represents the 
expression values for TGM2 relative to one housekeeping gene or to a normalizer 
factor. When values for TGM2 were normalized against only GAPDH values, the 
data obtained indicated a major increase in the gene expression when cells were 
induced to differentiate while expression level for TGM2 were significantly lower in 
the presence of CPF or CPFO. In order to obtain another point of view of the effects 
of the toxins, the values for TGM2 were normalized against a normalizer factor, 
obtained by the average of two housekeeping genes (GAPDH and cyclophilin).  
The expression values obtained with the normalizer factor suggest a significant 
increase in the gene expression when cells are induced to differentiate and, although 
it also shows reduced gene expression in the presence of the toxins, the changes were 
not statistically significant. Interestingly, there is also a difference between relative 
changes obtained by both methods; in the case where GAPDH is used as a 
normalizer, CPF shows a greater effect on the TGM2 expression, whereas with the 
normalizer factor CPFO is the toxin that generates a higher decrease. The data 
obtained by Qiao et al. (2001) indicate a higher decrease in the DNA synthesis with 
CPF than with CPFO, which corroborates the results obtained in the expression of 
TGM2 using GAPDH as a housekeeping gene. But the fact that the DNA synthesis 
decreases further in presence of CPF, does not mean that TGM2 expression should 
follow the same pattern, as in this experiment the expression of only TGM2 is 
monitored and also the values acquired with one housekeeping gene may not be as 
robust since GAPDH gene expression was affected by the toxins.   
Thus the results obtained using both methods of normalisation indicate an increase in 
TGM2 levels when cells are induced to differentiate by NaB and reduced levels of 
expression when cells are exposed to the toxins. However, to obtain more robust 
results and a better idea of the effects of the toxins on TGM2 expression, a more 
comprehensive set of genes could be used to create the normalizer factor (Andersen 
et al., 2004; Huggett et al., 2005).  
As previously described in this thesis, TGase 1 isoform is also present in C6 cells. 
Studies on cell differentiation show a decrease in the protein levels of TGase 1 
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compared to mitotic control, but it was still of interest to investigate a possible effect 
of the toxins on these levels. The image and the densitometric data from section 
3.3.3.8. indicate no changes in the protein levels of TGase 1 compared to untreated 
differentiating cells when the toxins are present. This suggests that CPF and CPFO 
exposure does not affect the protein levels of any of the two isoforms after 24 h 
exposure. 
As explained before, the TGase activity assays performed in this experiment are not 
specific for TGase 2; therefore, the TGase 2 inhibitor R283 (Telci et al., 2008) was 
used in order to determine the amount of activity produced by TGase 2. Results in 
Figure 3. 19 show almost complete inhibition of activity in the presence of the 
inhibitor in all treatments, suggesting that most of the activity could correspond to 
TGase 2, but the possibility that R283 may also inhibit TGase 1 activity cannot be 
discounted, as R283 is able to inhibit Factor XIIIa (Siegel and Khosla, 2007).  
Western blotting analysis was also performed on total cell lysates from the 
experiments, thus analysing the total TGase 2 present in the cells. The results 
acquired (Appendix: Figure 4) follow the same pattern as those obtained from 
analysis of the cytosolic fraction, further confirming that the toxins have no effect on 
the levels of TGase 2. 
3.4.3. Effects of TGase activity inhibition on C6 cell differentiation  
Previous data obtained by other groups have shown that TGase 2 upregulation is 
essential for neuronal cell differentiation in human neuroblastoma SH-SY5Y cells 
(Tucholski and Johnson, 2003). As the data obtained with differentiating C6 cells 
show an increase in the TGase 2 activity, protein levels and gene expression, 
suggesting a possible role of the enzyme in astrocyte differentiation, it was of interest 
to study the effects of inhibition of TGase 2 by R283 on this process.  
The effect of R283 on TGase activity was analysed by the biotin cadaverine assay 
and the data obtained indicate a significant decrease in TGase activity of around 70 
%, as shown in Figure 3. 20. Although R283 has been used as a TGase 2 specific 
inhibitor in different studies (Balklava et al., 2002; Verderio et al., 2003; Maiuri et 
al., 2008; Telci et al., 2008), it might also be able to inhibit the activity of the TGase 
1 isoform present in the cells, because R283 is a site-directed inhibitor that binds to 
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the active site cysteine residue (Telci et al., 2009). Thus, the results obtained in this 
section can not be conclusively related to the inhibition of TGase 2 activity. The 
effects of the TGase activity reduction on cell differentiation were studied by 
analysis of the astrocytic and oligodendrocytic markers on Western blots. 
Densitometric analysis show that R283 only inhibits the activity of the enzyme, as it 
does not cause any change in the TGase 2 protein levels. The data presented in 
Figure 3. 22 demonstrate that the inhibition of TGase activity generates a significant 
decrease in the protein levels of CNPase and a significant increase in the protein 
levels of GFAP compared to untreated controls, while GAPDH was not affected. 
These results suggest that TGase activity may either modulate or not be required for 
the differentiation of C6 cells, as when the activity decreases, cells differentiate 
further towards astrocytes while the population of oligodendrocytes decreases. The 
R283 treated differentiating C6 cells, did not show morphological changes as they 
continue presenting processes, suggesting that the partial inhibition of TGase activity 
does not have an effect in the development of the outgrowths. 
These data match with the results obtained from the exposure to the toxins, because 
in the presence of CPF and CPFO, TGase activity increases while the astrocytic 
differentiation decreases. Thus, the toxins could be inhibiting cell differentiation by 
increasing the activity of TGase. However, it would have also been interesting to 
study in this project the in vitro effects of longer exposures or different 
concentrations of CPF and CPFO on TGase activity and TGase 2 protein levels. As 
further studies, it would be interesting to study the localization of TGase 2 in 
different types of glial cell, for example by using immunofluorescence staining 
techniques. A complete block of TGase activity and expression would also be of 
value in determining the role of TGase 2 in glial development and toxicity. This 
could be achieved using the siRNA technique. The data obtained from these 
experiments would lead to a better understanding of TGase 2 functions on glial cells. 
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4.1. Introduction 
4.1.1. Purification of proteins 
Protein purification is a necessary step to understand the properties of proteins. 
Proteins can be purified to study their basic biochemical parameters, the effects of 
activators and inhibitors, to form crystals for structural studies and to raise antibodies 
against them (Bonner, 2007). 
As it is difficult to produce a highly purified protein, sometimes a partially pure 
preparation is enough to perform the studies. In the case of antibody production or 
the measurement of biochemical parameters, a partially purified protein can be used, 
but if the target of the study is to obtain a therapeutic protein or to create crystals, the 
protein product has to show the maximum purity possible. 
If the aim of the purification is to obtain a catalytically active pure protein, other 
factors have to be controlled in order to minimize the loss of activity. One of these 
factors is the proteolytic activity of hydrolytic enzymes, which can attack and 
damage the protein of interest; thus the addition of inhibitors is essential to reduce 
the effects of these proteolytic enzymes. The temperature of the purification process 
and the pH of the buffers are also important factors, as each protein has an optimum 
temperature and pH for its activity. Some proteins have reduced sulfhydryl groups on 
their surface or in their active site which can interact with divalent ions, thus 
inactivating the enzyme or altering its properties. For this reason, the presence of 
divalent ions is another factor to take into account in a purification process. In order 
to reduce the effects of these ions some chelating agents such as EDTA or reducing 
agents such as DTT are added to the buffers (Bonner, 2007). 
4.1.2. Purification of transglutaminases 
The isolation of transglutaminases has been studied using the most popular methods 
such as ion exchange, hydrophobic interaction, size exclusion, adsorption and 
affinity chromatography (Wilhelm et al., 1996). Different types of TGase have been 
isolated from different species and tissues, but the most studied has been TGase 2 
(Wilhelm et al., 1996).  
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Obtaining pure transglutaminase enzymes is necessary to be able to perform the 
above mentioned protein studies. However, purified TGases can be also used in the 
clinical field. For example, Factor XIIIa can be used to improve wound healing and 
restore normal blood coagulation in patients with a deficiency in this enzyme 
(Gootenberg, 1998). In the case of TGase 2, the isolated enzyme can be used to 
induce cell adhesion as well as in other commercial applications such as a catalyst in 
cosmetic, food and textile industries (Griffin et al., 2002). 
4.1.3. Purification of Transglutaminase 2 
Several purification processes have been performed to isolate TGase 2 from 
mammals (see section 1.6.6.) and the most recent method described to purify TGase 
2 from guinea pig liver (Leblanc et al. 1999) is a modified version of the standard 
purification protocol described by Folk and Chung (1985). Some of the existing 
methods are laborious or time consuming and some of them are also expensive. In 
the majority of the described methods, the final results did not show homogenously 
pure TGase 2 enzyme and yields were around 30 %.  Since the publication of the last 
method, new resins, systems and columns with higher resolution have appeared; thus 
it was of interest to try to develop a more efficient purification process for TGase 2. 
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4.2. Aims 
The purification of TGase 2 is a widely studied process which has been performed 
using different purification protocols and one of the most used methods was 
developed by Folk and Chung (1985). The development of new resins made 
interesting the approach for new purification procedures for TGase 2 from guinea pig 
liver, for this reason two of the aims of this chapter were: 
a) To develop an efficient and reproducible purification method for TGase 2 using a 
novel group of resins. This process was investigated by several approaches: 
 The first option was to develop a one step process using a novel group of 
resins,  2-mercapto-5-benzimidazole sulfonic acid (MBI), phenylpropylamine 
(PPA) and hexylamine (HEA), known as mixed mode chromatography resins 
(MMC), 
 The second option was to use HEA resin as an intermediate step in a more 
complex purification process. This process involved two ion exchange 
chromatography steps, the HEA step and a hydrophobic interaction step 
which was used in a similar way than in the process performed by Brookhart 
et al., (1983), 
 The third option was to perform a three step purification method by 
combining high specificity processes for TGase 2, which includes a 
protamine sulfate step and the hydrophobic interaction step, similarly 
performed as described by Leblanc et al., (1999) and Brookhart et al., (1983) 
respectively, 
b) To develop a one step cleaning process using the hydrophobic interaction 
chromatography for the commercially available TGase 2 from Sigma-Aldrich. 
Other aims for this chapter were to apply the new three step purification method 
developed in this thesis to the purification of TGase 2 from porcine brain.  
Also the purified TGase 2 fraction from guinea pig liver was used to study/verify in 
the next chapter the results obtained in the cell model system previously described 
(chapter III). 
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4.3. Results 
4.3.1. Purification of TGase 2 from guinea pig liver 
4.3.1.1. Purification of TGase 2 using MMC 
In this section, the purification process of TGase 2 from guinea pig liver was 
attempted in a single step. The resins used for this study are classified as a mixed 
mode chromatography (MMC), which is a novel type of resin that combines 
properties from ion exchange chromatography (IEX) and hydrophobic interaction 
chromatography (HIC), making them different to any existing resin. Thus it was of 
interest to analyze the possibility of performing a purification process in a single 
step. The resins used for the purification were 2-mercapto-5-benzimidazole sulfonic 
acid (MBI) which is an acidic ligand that can be used at 5 – 9 working pH range, 
phenylpropylamine (PPA) which contains an aromatic synthetic ligand, and 
hexylamine (HEA) which contains an aliphatic synthetic ligand and have a 2 – 12 
working pH range. The purification of the enzyme was studied at four different pH 
values. In Table 4. 1 are shown the maximum values for TGase specific activity 
(activity of TGase per milligram of total protein) obtained with pH 5 – 7.  
In this purification assays, the binding buffer used for all different resins and at 
different pH contained 50 mM Tris, 10 mM CaCl2 and 1 mM DTT. TGase 2 fractions 
were eluted using a buffer containing 50 mM Tris, 5 mM EDTA at pH 9 for all 
different assays and resins. Also, one unit of TGase activity was defined as a change 
in absorbance at 450 nm of 1.0 per hour. 
The purification of TGase 2 from guinea pig liver using the MMC resins performed 
at pH 7 gave the best results for all three resins, as the specific activity obtained were 
higher than the ones obtained at lower pH. The values obtained at pH 7 for MBI, 
PPA and HEA resins throughout the chromatography processes are shown in the 
Figure 4. 1. 
Results indicate than in all three processes the most active fractions appeared with 
the elution buffer. In the case of MBI chromatography (Figure 4. 1A), data suggest 
that not all the TGase 2 was binding to the column and also that there was an elution 
of the enzyme when the column was washed (fraction 14 and 23). 
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Resin pH 
Highest specific activity  
(units/mg protein) 
 
2-mercapto-5-
benzimidazole 
sulfonic acid 
(MBI) 
 
5 9 
5.5 5 
6 7 
7 14 
phenylpropylamine 
(PPA) 
5 0.35 
5.5 3.5 
6 3 
7 5 
hexylamine  
(HEA) 
5 0.5 
5.5 2.5 
6 3 
7 27 
 
Table 4. 1: Maximum specific activity for TGase purification performed in 
different resins at a different pH values 
TGase specific activity in the fractions from different chromatography resins and at 
different pH values were analysed by the biotin cadaverine assay. Values are shown 
as units / mg protein for a typical set of data.  
 
Results obtained for PPA chromatography (Figure 4. 1B) indicate a loss of TGase 2 
probably due to a poor binding to the resin, but there was no removal of the enzyme 
until the elution buffer was applied. It was also noticeable that the specific activities 
obtained with this resin were not as high as these obtained with MBI.  Finally, data 
obtained for HEA chromatography (Figure 4. 1C) show the highest values for the 
specific activity, although there was also a minor loss of TGase during the binding 
and washing steps. 
Western blotting analysis was performed on the highest specific activity fractions 
obtained from the three different resins. Results obtained in Figure 4. 2A show the 
presence of several bands in all of the fractions. As was expected, the fractions with 
the higher specific activities (fractions 35 and 36 from HEA) were the fractions with 
least bands, while fractions 33 and 34 from PPA showed the presence of more bands, 
corresponding to lower specific activities observed previously. The blots probed with 
ID10 antibody shown in Figure 4. 2B indicated the presence of TGase 2 at the 
correct molecular weight (~75 kDa). Although TGase 2 was detectable on the probed 
blots, in the copper stained blots it was barely visible, meaning that after the 
chromatography it was not the most abundant protein. 
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pH 7 wash 
 
pH 7 wash  
 
pH 9 wash elution buffer A)  MBI 
 
 
B)  PPA 
 
 
 
C) HEA 
 
 
 
 
Figure 4. 1: Measurement of Transglutaminase specific activity in MMC 
fractions for different resins 
TGase activity of each fraction from the different MMC performed at pH 7 was 
analysed by the biotin cadaverine assay. Values are shown as units / mg protein for 
A) 2-mercapto-5-benzimidazole sulfonic acid (MBI), B) phenylpropylamine (PPA) 
and C) hexylamine (HEA) resins. In the three graphs, fraction 14 and fraction 23 
corresponds to a column wash with a buffer containing 50 mM Tris, 10 mM CaCl2 
and 1 mM DTT at pH 7 and pH 9 respectively, while fraction 30 corresponds to the 
addition of the eluting buffer (50 mM Tris, 5 mM EDTA at pH 9). 
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                   A)        Std      33      34          33      34             35    36 
 
                                               
 
 
 
 
                   B)         Std      33      34           33      34             35    36 
 
                                                
 
 
 
Figure 4. 2: Copper phthalocyanine staining and Western blotting analysis of 
different fractions from the MMC performed at pH 7 
Protein extracts (15 µg) from the different steps of the MMC purification process 
were separated by SDS-PAGE and analysed by copper phthalocyanine staining and 
Western blotting. Shown are blots A) stained with copper phthalocyanine and B) 
probed with ID10 anti TGase 2 antibody for 2-mercapto-5-benzimidazole sulfonic 
acid (MBI), phenylpropylamine (PPA) and hexylamine (HEA) resins. 
 
 
 
 
 
 
 
 
 
MBI fractions HEA fractions PPA fractions 
75 kDa 
75 kDa 
MBI fractions PPA fractions HEA fractions 
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4.3.1.2. Purification of TGase 2 in a four step process 
In this section, the purification of TGase 2 was performed using four different 
chromatographic steps. At the beginning of the process, Q sepharose resin was used 
due to its high binding capacity and its ability to remove a large number of 
contaminant proteins. This step was performed using a gradient of two buffers, 
buffer A (25 mM Tris, pH 7.5) and buffer B (25 mM Tris, 0.6 M NaCl, pH 7.5). In 
the second step, MMC chromatography was performed using the hexylamine resin as 
it was the one that gave the best results in the previous experiments (section 4.3.1.1.). 
This chromatography step was carried out as a cleaning process instead of a proper 
chromatography; for this reason, the resultant active fractions from IEX were 
incubated with 500 µM GTP. In the presence of GTP, TGase 2 is in its non active 
structure conformation, thus reducing the hydrophobic interaction with the 
hexylamine resin. As a result, TGase 2 eluted in the unbound fraction and was 
incubated with Ca
2+ 
before being applied to the Phenyl-Sepharose
® 
CL-4B resin. 
This intermediate incubation step, provoked a conformational change in TGase 2 
structure that generated the opening of the active site of the enzyme (Figure 1.3), 
thus increasing its hydrophobicity. TGase 2 was eluted from the column using the 
elution buffer (25 mM Tris, pH 7.5 containing 20 mM EDTA). The fractions from 
HIC that contained TGase 2 were then loaded directly onto the Mono Q ion 
exchange column to perform the last step of the process. This step was performed 
using the same two buffers than in the first step of the process (IEX, Q sepharose 
resin), but the purification was performed in a different way, because the NaCl 
concentration in the elution buffer mix was increased until 0.25 M and then 
maintained for two column volumes, after which, the salt concentration was rapidly 
increased to elute TGase 2. 
The results obtained for this purification process are shown in the Table 4. 2. It was 
interesting that after the IEX step there was an increase in the yield compared to the 
homogenate, thus the final yield specific activity values for each step were compared 
against both the homogenate and IEX specific activity values. At the end of the 
purification process, the high value of the fold purity indicated a significant 
enrichment of TGase 2, although the yield obtained was very low. During each step 
of the whole process there was a loss in the total activity, which is a normal condition 
in any purification method.  
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In this case, the major loss was in the last step where the activity was reduced 
approximately 20 fold compared to HIC. 
 Volume 
Total 
Protein 
Activity  
Fold 
purity 
Yield  
Yield 
compared 
to IEX 
Step ml mg 
Total 
activity 
(units) 
Specific 
activity 
(units/mg) 
 % % 
Homogenate 90 6750 450 0.07 1 100  
IEX  
Q Sepharose 
 
180 171 1530 9 128.5 380 100 
HEA 
Hexylamine 
140 70 910 13 186 217 59.4 
HIC 
Phenyl-
Sepharose 
40 6 200 34 485 80 13 
Mono Q 3 0.24 10.5 43 614 2.3 0.68 
 
Table 4. 2: Purification of guinea pig liver TGase using a four step purification 
process  
Table showing the volume, protein amount, activity, specific activity, fold purity and 
yield for every step of the purification process. TGase activity was analysed by the 
biotin cadaverine assay and the protein concentration was evaluated using the BCA 
assay. 
 
 
Once the purification data were obtained, each fraction was analysed by Instant 
Blue™ staining and Western blotting in order to study the purity of the samples and 
the presence of TGase 2. In the image obtained from the Western blot analysis 
(Figure 4. 3B) it can be appreciated that TGase 2 enzyme was present throughout the 
process and that it was more abundant in the latter stages.  
The purity of the sample was checked in the digital image obtained from the Instant 
Blue™ stained gel (Figure 4. 3A). There was an improvement in the enrichment of 
TGase 2 (75 kDa), although in the last fraction there was a major band at 100 kDa 
and another visible band at around 20 kDa. The three bands obtained in the Mono Q 
fraction were analysed by Matrix-assisted laser desorption/ionization time of flight 
(MALDI-TOF) mass spectrometry by Dr. Carlile from Nottingham University. The 
results from peptide mass fingerprinting using the Mascot database are shown in 
Table 4. 3.  
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It is interesting to note that although TGase 2 is not the main band (~20 % of the 
total protein) and there are two extra bands in the last step, the TGase 2 sample 
produced by the newly developed method was cleaner and purer than the 
commercially available TGase 2 from Sigma-Aldrich (Sigma TGase 2). 
 
         Sigma 
                   A)            Std   HOM   IEX   HEA   HIC   MQ                                TGase 2 
 
                                                    
 
 
           Sigma 
                    B)                   HOM   IEX    HEA    HIC    MQ                              TGase 2 
 
                                                                
 
Figure 4. 3: Instant Blue™ stain and Western blotting analysis of different steps 
of the purification process and the commercial TGase 2 from Sigma 
Protein extracts (10 µg) from the different steps of the purification process and 
Sigma TGase 2 were separated by SDS-PAGE and analysed by Instant Blue™ 
staining and Western blotting. Shown are A) gel stained with Instant Blue™ and B) 
blot probed with CUB-7402. Samples include homogenate (HOM), Q Sepharose ion 
exchange fraction (IEX), hexylamine fraction, (HEA), Phenyl-Sepharose 
hydrophobic interaction fraction (HIC), Mono Q™ fraction (MQ) and TGase 2 from 
Sigma-Aldrich. Bands 1, 2 and 3 were taken for MALDI-TOF mass spectrometry 
analysis. 
 
 
75 kDa 
75 kDa 
Band 2 
Band 1 
Band 3 
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Table 4. 3: Identification of bands detected in the Mono Q fraction of the four 
step process of TGase 2 purification 
The identity of the bands analysed by MALDI-TOF mass spectrometry was obtained 
by peptide mass fingerprint using the Mascot database, in which protein scores 
greater than 70 are significant (p<0.05). 
 
Bands Identity 
Molecular 
weight 
(kDa) 
Matching 
sequence 
start-end 
Matched peptides and 
sequence coverage  
Mascot 
score 
1 
10-
formyltetrahydrofolate 
dehydrogenase (FDH) 
 100  
39 - 51 
115 – 129 
167 - 174      
211 - 225     
521 - 531     
621 - 636     
637 - 644      
803 - 814     
827 - 841     
866 - 876     
883 - 894     
K.ADPLGLEAEKDGR.A 
R.GASAINWTLIHGDKK.G 
R.FLFPEGIK.G 
K.INWDQPAEAIHNWIR.G 
K.THVGMSIQTFR.Y 
K.GVVNILPGSGSLVGQR.L 
R.LSDHPDVR.K 
K.EESFGPIMIISR.F 
R.ANATEFGLASGVFTR.D 
K.TDVAAPFGGFK.Q 
K.DLGEAALNEYLR.I 
Sequence coverage : 15 % 
89 
2 TGase 2  75 
36 - 48      
49 - 76      
 
49 - 76      
 
215 - 222      
264 - 271     
274 - 289     
388 - 406     
415 - 424     
444 – 452 
468 - 479     
554 - 565     
568 - 583     
605 - 613     
R.GQPFWLTLHFEGR.G 
R.GYEAGVDTLTFNAVTGPDPSEEA
GTMAR.F 
R.GYEAGVDTLTFNAVTGPDPSEEA
GTMAR.F  Oxidation (M) 
R.SRPVYVGR.V 
R.WKDYGCQR.V 
K.YGQCWVFAAVACTVLR.C 
K.YDAPFVFAEVNADVVNWIR.Q 
K.SINHLVVGLK.I 
K.YPEGSEEER.E 
K.EEAQEETGVAMR.I 
K.YGDYLTESNLIK.V 
R.GLLIEPAANSYVLAER.D 
R.KLIAEVSLK.N 
Sequence coverage: 23 % 
139 
3 ferritin light chain  20 
7 - 19      
41 - 53      
77 - 92      
106 - 121     
122 - 140     
144 - 153     
145 - 153     
154 - 169     
155 - 169     
R.QNYSTEVEAAVNR.L 
R.DDVALAGVGHFFR.E 
R.ALFQDVQKPSEDEWGK.T 
K.SLNQALLDLHALGSAK.T 
K.TDPHVCDFLENHFLDEEVK.L 
K.KIGDHLTNLR.R 
K.IGDHLTNLR.R 
R.RLDGPQAGLGEYLFER.L 
R.LDGPQAGLGEYLFER.L 
Sequence coverage: 58 % 
174 
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4.3.1.3. Purification of TGase 2 in a three step process 
This purification method involves modifications to the method described by Folk and 
Cole (1966). It also started with an IEX using a Q sepharose resin, but in this case it 
was followed only by two more steps. The first step of this process was performed in 
the same way as explained in section 4.3.1.2. In the second step the protamine 
sulphate peptide was used to precipitate specifically TGase 2. A volume of 12 ml of 
1 % (w/v) protamine sulphate solution was added drop-wise for 20 minutes into the 
obtained IEX sample. TGase 2 was recovered from the resultant pellet by 
homogenizing it with a volume of a buffer containing 0.05 M ammonium sulphate, 5 
mM Tris-HCl, 2 mM EDTA, pH 7.5. The resultant fraction was then incubated with 
Ca
2+ 
before being applied to the Phenyl-Sepharose
® 
CL-4B resin. In this selective 
step that was employed at the end of the process, TGase 2 was eluted from the 
column using a buffer containing 25 mM Tris, 20 mM EDTA, pH 7.5.  
 The data obtained in this purification method are presented in Table 4. 4. In this 
process the total activity was again higher in the IEX step, thus the final yields were 
compared to this step and to the homogenate. In the last stage, both the specific 
activity value obtained (94.2 units/mg) and the yield (42.5 %) were very high 
compared to the IEX step, indicating an elevated enrichment of TGase 2 and a very 
clean fraction. In the protamine sulphate step there is a high decrease in the activity 
due to the interaction of this peptide with TGase 2, therefore, in order to obtain a 
significant value, protamine sulphate should have been removed. In other 
purification assays, a carboxymethyl cellulose resin column is used as an 
intermediate filtration step that removes protamine (Connellan et al., 1971).  
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 Volume 
Total 
Protein 
Activity  
Fold 
purity 
Yield 
Yield 
compared 
to IEX 
Step Ml mg 
Total 
activity 
(units) 
Specific 
activity 
(units/mg) 
 % % 
Homogenate 210 15246 2268 0.15 1 100  
Supernatant 
80,000 g 
175 10377 1771 0.17 1 78  
IEX  
Q Sepharose 
490 1327 6247.5 4.7 32 275 100 
Protamine 
sulphate 
245 196 400 2 14 18 6.4 
HIC 
Phenyl-
Sepharose 
235.2 28.2 2658 94.2 633 117 42.5 
 
Table 4. 4: Purification of guinea pig liver TGase using a three step purification 
process  
Table showing the volume, protein amount, activity, specific activity, fold purity and 
yield for every step of the purification. TGase activity was analysed by the biotin 
cadaverine assay and the protein concentration was evaluated using the BCA assay. 
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The encouraging data obtained using the biotin cadaverine assay made it of interest 
to perform further analysis by studying the activity of the enzyme using the protein 
crosslinking assay described by Trigwell et al., (2004). The values obtained for the 
protein crosslinking assay are shown in the Table 4. 5. The raw values obtained for 
the absorbance were very low, probably due to a low sensitivity of the assay. 
Interestingly, the yield obtained was similar than the one obtained from the biotin 
cadaverine assay. The fold purity was also very high and gave a similar value (450) 
to the one obtained with the biotin cadaverine assay indicating a high enrichment. 
 
 
 Volume 
Total 
Protein 
O.D. (450nm) 
Fold 
purity 
Yield 
Yield 
compared 
to IEX 
Step ml mg 
Total 
O.D. 
 
Specific 
O.D. 
(mean 
O.D./mg) 
 % % 
Homogenate 210 15246 116 0.01 1 100  
Supernatant 
80,000 g 
175 10377 101.5 0.01 1 87.6  
IEX 
Q Sepharose 
490 1327 305 0.23 23.5 150.5 100 
Protamine 
sulphate 
245 196 4.8 0.02 2.5 4.14 1.57 
HIC 
Phenyl-
Sepharose 
235.2 28.2 127.32 4.5 450 110 41.7 
 
 
 
Table 4. 5: Purification of guinea pig liver TGase using a three step purification 
process  
Table showing the volume, protein amount, activity, specific activity, fold purity and 
yield for every step of the purification process. TGase activity was analysed by the 
biotin-TVQQEL protein crosslinking assay and the protein concentration was 
evaluated using the BCA assay. 
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After analysing the fractions with two different activity assay methods and the BCA 
protein concentration assay, it was of interest to investigate the purity of the samples 
and to corroborate the presence of TGase 2 in the fractions. The fractions stained 
with Instant Blue™ and silver stain are shown in Figure 4. 4A. The images show that 
there was removal of contaminant proteins at each stage of the process. The HIC step 
was the most specific, as there was an elimination of almost all the proteins present 
in the protamine sulphate step, producing an enrichment of TGase 2. The silver 
staining analysis of the commercially available TGase 2 from Sigma-Aldrich show 
the presence of several bands, some of them quite abundant, indicating a poor purity 
level of TGase 2. 
    Sigma 
    A)      Std   HOM IEX   PS    HIC       B)   Std  HOM IEX   PS     HIC     TGase 2      
 
                      
 
 
C)      Std  HOM  IEX    PS    HIC        
 
          
 
 
Figure 4. 4: SDS-PAGE and Western blotting analysis of different steps of the 
purification process and the commercial TGase 2 from Sigma 
Protein extracts (5 µg) from the different steps of the purification process and Sigma 
TGase 2 were separated by SDS-PAGE and analysed by Instant Blue™ stain, silver 
stain and Western blotting. Shown are A) a gel stained with Instant Blue™  B) a gel 
stain with silver and C) a blot probed with TG100. Samples include a) homogenate 
(HOM), Q Sepharose ion exchange fraction (IEX), protamine sulphate precipitate 
(PS), Phenyl-Sepharose hydrophobic interaction fraction (HIC) and TGase 2 from 
Sigma-Aldrich.  
 
75 kDa 
75 kDa 
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It is also noticeable in the Western blot the very low signal of TGase 2 in the 
homogenate fraction, which could be due to a degradation effect or to a very low 
presence of this enzyme in the total homogenate. A further study with a fourth step 
was also performed. In this case, a Mono Q column was used after HIC. Values 
obtained indicate an increase in the specific activity but a dramatic decrease in the 
sample volume and in the amount of protein recovered and hence in the total activity. 
It therefore seems that the Mono Q step was able to concentrate TGase 2 at the 
expense of recovered activity (Appendix: Figure 5). The significant loss of protein 
and activity in this last step could be due to a very strong binding with the resin, to a 
very poor binding, thus getting a loss of protein throughout the process, or to a 
possible degradation. The decrease of TGase activity could also be provoked by 
possible modifications of the enzyme like the formation of TGase 2 complexes.  
Another variable on the process was to do a two step procedure. In this case the HIC 
was used after IEX. Values obtained show a lower specific activity than the normal 
three step process, thus indicating the importance of the protamine sulphate 
precipitation step. 
4.3.2. One step cleaning process for TGase 2 from Sigma-Aldrich 
As shown previously in Figure 4. 3 and Figure 4. 4, TGase 2 from Sigma-Aldrich 
was not a pure sample. For this reason, a one step selective HIC cleaning process was 
performed to purify the commercial TGase 2.  The values for the most active 
fractions and for the pool of all the fractions obtained are shown in Table 4. 6. Data 
indicate a very high recovery of around 93 % in the total pooled HIC fraction. For 
further analysis, fractions showing a specific activity over 200 (units/mg protein) 
were pooled as they showed the highest purity. 
It was also important to study the purity of the fractions by protein staining. The 
digital image presented in Figure 4. 5 shows that the fractions eluted from the HIC 
were enriched in a polypeptide band corresponding in molecular weight to TGase 2 
and they only had traces of other bands. In the last fractions of the purification 
(HIC20 sample) the amount of TGase 2 decreased, but the fractions still showed 
activity. 
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 Volume 
Total 
Protein 
Activity  
Fold 
purity 
Yield 
Fractions ml mg 
Total 
activity 
(units) 
Specific 
activity 
(units/mg) 
 % 
TGase 2 from 
Sigma 
13 1.04 163 157.3 1 100 
Phenyl-
Sepharose 
fraction  4 
2 0.11 29.3 258 1.6 18 
Phenyl-
Sepharose 
fraction  5 
2 0.05 27.5 547.5 3.5 17 
Phenyl-
Sepharose 
fraction  6 
2 0.04 16.8 442 2.8 10.5 
All Phenyl-
Sepharose 
fractions 
44 0.89 152.6 171.5 1.1 93.3 
 
 
Table 4. 6: Clean up process of Sigma TGase by using HIC 
Table showing the volume, protein amount, activity, specific activity, fold purity and 
yield for the most active fractions and total pooled HIC fractions of the purification. 
TGase activity was analysed by the biotin cadaverine assay and the protein 
concentration was evaluated using the BCA assay.  
 
 
                  Sigma 
                Stdd     HIC5   HIC6   HIC20   TGase 2 
 
 
 
 
Figure 4. 5: Silver stain of different fractions from the HIC clean up of TGase 2 
from Sigma-Aldrich 
Protein extracts (5 µg) from the different fractions of the purification of TGase 2 
from Sigma were separated by SDS-PAGE and analysed by silver staining. Shown is 
75 kDa 
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the stained gel with HIC fraction 5 (HIC5), HIC fraction 6 (HIC6), HIC fraction 20 
(HIC20) and TGase 2 from Sigma-Aldrich. 
 
4.3.3. Purification of TGase from porcine brain 
Once the purification method was developed, it was applied to the purification of 
TGase 2 from porcine brain. Fractions obtained were analysed using the biotin 
cadaverine assay and the data obtained for each fraction of the purification are shown 
in the Table 4. 7. Compared to the measurements made on the fractions from guinea 
pig liver TGase 2 purification, the final specific activity, yield and fold-purity of 
porcine brain TGase were relatively low.  
In this purification it was noticeable that there was a major loss of activity when the 
protamine sulphate step was applied, indicating that this step (which was essential in 
the purification of the guinea pig liver TGase 2) was not effective in the purification 
of porcine brain TGase 2. 
 
 
 Volume 
Total 
Protein 
Activity 
Fold 
purity 
Yield 
 
Yield 
compared 
to IEX 
Step ml mg 
Total 
activity 
(units) 
Specific 
activity 
(units/mg) 
 % % 
Homogenate 200 9440 1172 0.12 1 100  
Supernatant 
80,000 g 
160 2608 1414 0.54 4.5 120  
IEX 460 441.6 2650 3.14 26 226 100 
Protamine 
sulphate 
184 47.9 161 3.35 28 13.7 6 
HIC 55.2 2.76 49.7 14.5 121 4.24 1.9 
 
 
 
Table 4. 7: Purification of porcine brain TGase using the three step purification 
process  
The table shows the volume, protein amount, activity, specific activity, fold purity 
and yield for every step of the purification process. TGase activity was analysed by 
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the biotin cadaverine assay and the protein concentration was evaluated using the 
BCA assay. 
 
 
In order to study the purity and to detect the presence of TGase 2 in the fractions a 
Western blotting assay and silver staining were performed. In Figure 4. 6A it can be 
seen that there was a decrease in the number of bands throughout the process, 
although in the last stage there were several abundant bands, none of which 
corresponded in molecular weight to TGase 2.  
The Western blot probed with anti-TGase 2 ab10445 antibody (Figure 4. 6B) shows 
the presence of a  25 kDa cross-reactive band in the last two steps of the 
purification, which could potentially be a truncated isoform of TGase 2 or a 
degradation product. A band of  75 kDa, corresponding to the full length isoform 
was detected in the IEX step, but it disappeared in the protamine sulphate 
precipitation step. In the blot probed with CUB-7402 antibody (Figure 4. 6C) the 
only bands showing cross-reactivity were around 45 kDa. In this case, reactivity was 
more abundant in the IEX step, became reduced after protamine sulphate 
precipitation and was not detected after HIC.   
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A)  Silver staining  
 
         Std    HOM    IEX      PS     HIC5          
 
 
 
 
B)  ab10445 anti TGase 2 antibody     
 
         Std   HOM    IEX     PS    HIC5         
 
 
 
 
C)  CUB-7402 anti TGase 2 antibody       
 
           Std   HOM     IEX     PS    HIC5         
 
         
 
 
Figure 4. 6: Silver stain and Western blotting analysis of different steps of the 
purification process 
Protein extracts (5 µg) from the different fractions of the purification of TGase 2 
from porcine brain were separated by SDS-PAGE and analysed by silver staining 
and Western blotting. Shown are the A) stained gel and B) blot probed with ab10445 
and C) blot probed with CUB-7402 for homogenate (HOM), IEX fraction (IEX), 
Band 2 
Band 1 
75 kDa 
25 kDa 
25 kDa 
75 kDa 
50 kDa 
75 kDa 
Band 3 
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protamine sulphate fraction (PS) and HIC fraction 5 (HIC5). Bands 1, 2 and 3 were 
taken for MALDI-TOF mass spectrometry analysis. 
 
Due to the cross-reactivity of ab10445 and CUB-7402 with bands at different 
molecular weights seen in Figure 4. 5B and Figure 4. 5C, the three labelled bands 
present in the silver stained gel (Figure 4. 5A) were analysed by MALDI-TOF mass 
spectrometry performed by Dr. Durose from Nottingham Trent University. The 
results obtained from peptide mass fingerprinting using the Mascot database are 
indicated in Table 4. 8. 
The  48 kDa band was recognized as enolase 2 (gamma enolase) and both the  28 
and  26  kDa  were identified as 14-3-3 proteins, thus showing that none of the main 
bands present in the HIC fraction were TGase 2. 
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Bands Identity 
Molecular 
weight 
(kDa) 
Matching 
sequence 
start-end 
Matched peptides and sequence 
coverage  
Mascot 
score 
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Table 4. 8: Identification of the major stained bands in the HIC fraction from 
porcine brain TGase purification 
The identity of the bands analysed by MALDI-TOF mass spectrometry was obtained 
by peptide mass fingerprint using the Mascot database in which proteins score 
greater than 54 are significant (p<0.05). 
 
1 
enolase 2 
(gamma 
enolase) 
 48 kDa 
16 - 28      
33 - 50      
163 - 179     
180 - 193     
184 - 193    
203 - 228     
229 - 239     
240 - 253     
254 - 262     
270 - 285     
307 - 326     
359 - 372     
407 - 412      
413 - 422     
423 - 429      
423 - 434      
R.GNPTVEVDLYTAK.G 
R.AAVPSGASTGIYEALELR.D 
K.LAMQEFMILPVGAESFR.D 
R.DAMRLGAEVYHTLK.G 
R.LGAEVYHTLK.G 
K.DATNVGDEGGFAPNILENSEALELVK.E 
K.EAIDKAGYTEK.I 
K.IVIGMDVAASEFYR.D 
R.DGKYDLDFK.S 
R.YITGDQLGALYQDFVR.D 
K.FTANVGIQIVGDDLTVTNPK.R 
K.LAQENGWGVMVSHR.S 
K.YNQLMR.I 
R.IEEELGDEAR.F 
R.FAGHNFR.N 
R.FAGHNFRNPSVL.-   
Sequence coverage: 48 % 
116 
2 
14-3-3 
protein 
zeta/delta 
 29 kDa 
12 – 18 
28 - 41      
42 – 49 
104 - 115     
121 - 127      
128 - 139     
140 - 157     
140 - 158     
158 - 167     
159 - 167     
K.LAEQAER.Y 
K.SVTEQGAELSNEER.N 
R.NLLSVAYK.N 
K.FLIPNASQAESK.V 
K.MKGDYYR.Y 
R.YLAEVAAGDDKK.G 
K.GIVDQSQQAYQEAFEISK.K 
K.GIVDQSQQAYQEAFEISKK.E 
K.KEMQPTHPIR.L 
K.EMQPTHPIR.L 
Sequence coverage: 35 % 
55 
3 
14-3-3 
protein 
eta 
 27 kDa 
1 – 10 
13 - 19       
13 - 28      
29 - 42      
29 - 50      
43 - 50       
43 - 56   
62 - 69       
126 - 132      
133 - 143  
143 - 155     
156 - 172     
163 - 172  
199 - 217           
         
-.MGDREQLLQR.A 
R.LAEQAER.Y 
R.LAEQAERYDDMASAMK.A 
K.AVTELNEPLSNEDR.N 
K.AVTELNEPLSNEDRNLLSVAYK.N 
R.NLLSVAYK.N 
R.NLLSVAYKNVVGAR.R 
R.VISSIEQK.T 
K.MKGDYYR.Y 
R.YLAEVASGEKK.N 
K.KNSVVEASEAAYK.E 
K.EAFEISKEQMQPTHPIR.L 
K.EQMQPTHPIR.L 
K.QAFDDAIAELDTLNEDSYK.D 
Sequence coverage: 52 % 
72 
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4.4. Discussion 
4.4.1. Guinea pig liver TGase 2 purification with MMC 
As discussed in the introduction, MMC resins have been proposed as a new model 
for protein purification. For this reason it was interesting to study their application in 
the isolation of TGase 2 in order to develop a new and better method. Several 
experiments were performed using three different types of MMC resins calibrated at 
different pH values. It has been reported that the isoelectric point (pI) of guinea pig 
liver transglutaminase is 4.92 (Fraij and Gonzales, 1996; Folk and Chung, 1985); 
therefore the purification studies with MMC resins were performed from pH 5 to pH 
7 (neutral). 
Results obtained from the purifications performed at pH 5, 5.5 and 6 are shown in 
Table 4. 1. The data show low specific activity values for all three resins, MBI being 
the resin that generated the highest specific activity value and, as a consequence, the 
higher purity levels of TGase 2. In the case of the MBI resin, increasing the pH of the 
binding buffer led to a reduction in the purity of the sample. This result could be due 
to the acidic properties of the resin; an increase in the buffer pH would generate an 
increase in the negativity of TGase 2, provoking repulsion from the column. 
However, when the purification was performed at pH 7, the specific activity values 
obtained were higher (see Figure 4. 1A). This enrichment in specific activity could 
be associated with a higher stability of TGase 2 or its interaction with other 
molecules that might affect the interaction between the enzyme and the resin. 
Purifications performed with PPA and HEA resins at pH 5-6 did not show 
particularly high purity levels; in fact, the specific activity values obtained were 
lower than with MBI. However, it was curious to note that for both resins, when the 
pH of the buffer was increased, the chromatography process became more selective, 
resulting in a purer sample. This fact could be mainly related to a higher stability of 
TGase 2, because the closer the proteins are to their isoelectric point (pI), the more 
unstable they are. Chromatography assays were also performed with PPA and HEA 
at a pH 7, as seen in Figure 4. 1. At neutral pH, the values obtained for the specific 
activity were the highest, although there were important differences in the values 
depending on the resin used. In this case, HEA resin gave the higher values (~ 28 
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units/mg protein), while the PPA resin generated a product with the lowest specific 
activity (~ 5 units of TGase/mg protein), probably because its aliphatic nature was 
not compatible with TGase 2. It is important to bear in mind that in all three resins 
there was a major loss of TGase 2 in the different steps of the purification. The resin 
with the highest loss of enzyme activity was MBI, consistent with the idea that it was 
not a good ligand for the purification of TGase 2. The loss of the enzyme may be 
avoidable by changing the conditions of the washing buffers, although that could 
interfere with the final specific activity values, resulting in lower purity. The data 
obtained with the buffer systems at pH’s below 7 have to be considered very 
carefully as the buffer systems contained 50 mM Tris which has a pKa of 8.1, 
indicating that it can be used in the pH range of 7 to 9. Therefore, the fact that some 
of the buffers prepared were out of this pH range could have had an effect in the 
purification process. In this case, it would have been important to use other buffer 
systems with the appropriate pKa.  
To study the purity of the samples and the presence of TGase 2 in the fractions 
obtained from each MMC separation, copper phthalocyanine staining and Western 
blotting analyses were performed. The images obtained (see Figure 4. 2) show the 
presence of TGase 2 in all the fractions, although it was evident in the stained gel 
that it was not the main polypeptide band. Although the results obtained from all 
three mixed mode media at different pH values indicate that the MMC resins were 
not suitable for the purification of TGase 2 in a single step, the fact that HEA resin 
gave the highest performance for the purification of TGase 2, was consistent with its 
potential use in a more complex process involving more steps. 
4.4.2. Guinea pig liver TGase 2 purification by multi-step purification 
procedures 
The purification of any protein is a very difficult process and it can only be 
performed in a single step on very few occasions. For this reason more purification 
steps were added to the method, in order to achieve a better purification of TGase 2.  
The IEX chromatography is usually used as a first step in protein purification as it is 
a versatile technique that has high resolution and a good recovery of activity 
(Bonner, 2007). In this method, the IEX resin used was anionic because the pH of the 
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binding buffer was 7, meaning that TGase 2 was negatively charged. As previously 
reported by other groups (Folk and Cole, 1966; Kwak et al., 1998), in this 
performance, TGase 2 started to elute at ~ 0.3 M NaCl. After this step, HEA resin 
was used as a removal step (section 4.3.1.2.) as TGase 2 did not bind to the column 
but other proteins did. The next step was HIC which involved a selective interaction. 
The specificity of the HIC is due to the Ca
2+
 dependency of TGase 2, as in the 
presence of this ion, the enzyme undergoes a conformational change, opening its 
active site and therefore increasing its hydrophobicity (see section 1.3.). This 
approach has been already used to purify TGase 2 from rat testes (Seitz et al., 1991), 
TGase 2 from guinea pig liver (Brookhart et al., 1983) and by other groups to purify 
the 60 and 52 kDa Ca
2+
 dependent protein kinase (CDPK) from the green alga 
Dunaliella tertiolecta (Yuasa et al., 1995), indicating that it is a useful and practical 
method. However, it has to be considered that the addition of Ca
2+
 can provoke the 
formation of crosslinked complexes of TGase 2, which could generate a loss in the 
yield. This HIC step was followed by another IEX column, but in this case it was a 
pre-packed Mono Q column with a very high resolution to allow a final purification 
and concentration step. 
The final data obtained for the process are shown in Table 4. 2. The results indicate a 
final specific activity of 43 units of TGase/mg protein and a fold purity of 614, 
suggesting a good purification of the enzyme. However, the yield obtained was very 
low, pointing to a major loss of TGase 2. It was interesting to note that in the IEX 
chromatography, the value obtained for the yield was higher than in the homogenate, 
suggesting that there was an underestimation of the total activity in the homogenate. 
This phenomenon could be due to the presence of endogenous inhibitors or some 
other molecules that interfered with the activity assay. When the homogenate sample 
was dialysed prior to activity assays the specific activity values did not show any 
difference from the undialysed control, suggesting that the cause of the effect was 
not removable by simple dialysis, although it was clearly eliminated by the IEX step. 
It would have been also interesting to use a weak cation exchange resin in the first 
step of the purification process, as it has different characteristics than the strong 
anion exchange resin used in this thesis, therefore could have generated different 
results. 
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This possible underestimation of the real activity in the homogenate may have 
caused the final recovery value to be overestimated. The largest loss of activity took 
place in the final step of the four step purification scheme. This suggests that, despite 
the fact that the Mono Q column purified and concentrated the TGase 2, its use 
caused a major decrease in activity. This loss could be due to a very strong binding 
interaction between the enzyme and the column or to possible modifications in the 
enzyme structure that affected its activity. It is unlikely to be associated to a poor 
binding interaction because no traces of TGase 2 were found either in the unbound or 
in the washing fractions. 
Apart from the activity assays, the purity and the presence of TGase 2 in each 
fraction were monitored by Instant Blue™ staining and Western blotting. Digital 
images of Western blots shown in Figure 4. 3 confirm the presence of TGase 2 in all 
of the fractions but it seems that in the IEX, Mono Q and Sigma TGase samples there 
was some degradation or fragmentation of the enzyme, as indicated by cross reaction 
with lower molecular weight bands. The presence of these bands could be due to an 
excessive amount of protein loaded, to the sensitivity of the antibody and also to the 
specific region of the enzyme that is recognized by the antibody, as in other Western 
blot analysis cross reaction of antibodies with these bands is much lower. 
In the image obtained from the Instant Blue™ stained gel (Figure 4. 3A) a decrease 
in the number of bands was evident as the purification process progressed. Indeed, in 
the last three steps of the purification some bands disappeared altogether and others 
became more intensely stained. After the final step of Mono Q chromatography, 
there were three visible bands, two of which were very intense indicating that the 
final fraction was not completely pure. For this reason, it was necessary to identify 
the main polypeptide bands and to determine if the 75 kDa band was TGase 2. As 
commented earlier, the results from MALDI-TOF mass spectrometry indicated that 
the main band was FDH, the low molecular weight band was ferritin light chain and 
that the middle band was confirmed as TGase 2.  
The presence of FDH is consistent with its possible interaction with TGase 2, which 
could be important for both enzymes in order to enhance their activities. It could also 
be that either TGase 2 is having an effect on FDH although it is not a recognized 
substrate, or that they intervene in common pathways. Previous studies have shown 
that FDH is able to suppress the proliferation of cancer cells by activating an 
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apoptotic pathway that promotes the phosphorylation of p53 by c-Jun N-terminal 
kinases (JNKs) (Ghose et al., 2009; Oleinik et al., 2007). Other studies on TGase 2 
kinase activity have indicated that the enzyme is able to phosphorylate p53 (Mishra 
and Murphy, 2006). This common feature could explain the presence of both 
proteins in the last step of this purification procedure. In support of the interaction 
hypothesis is the fact that some dehydrogenases are substrates for TGase 2; examples 
include aldehyde dehydrogenase, glutamate dehydrogenase, glyceraldehyde 3 
phosphatase dehydrogenase and alpha ketoglutarate dehydrogenase (Cooper et al., 
1997; Madi et al., 2004). However, it is important to note that there are no evidences 
for a direct interaction between FDH and TGase 2, and it has not been found in any 
other purification process previously developed, which strongly suggests that the 
presence of FDH in the last step is due to a co-purification. The other protein present 
was ferritin light chain which has not been identified as a TGase 2 substrate, so its 
presence could be explained by similar properties to TGase 2 that allowed the ferritin 
to co-purify. 
Even with the presence of FDH and ferritin light chain, the final sample contained 
fewer components than the commercially available TGase. Unfortunately, however, 
TGase 2 was not the main protein; therefore the results from subsequent assays with 
this fraction could be subject to any effects that FDH and ferritin might cause. Due to 
the presence of these two contaminating proteins, other methods for the purification 
of the guinea pig liver transglutaminase were examined. The method that gave the 
best results was composed of three steps based on a previous method developed by 
Folk and Chung (1985). However, in the new method, the last step was replaced by a 
more specific process, thus obtaining a purer sample. 
In this method, fractions were analysed using two different TGase activity assays 
reflecting different properties of the enzyme. The results of the biotin cadaverine 
incorporation assay presented in Table 4. 4 show a very high specific activity at the 
last step of the process and a very high fold enrichment value which indicates that the 
fraction obtained had a high level of purity. The yield value for the final step showed 
a 117 % recovery when the value was compared against homogenate and 42.5 % 
recovery when compared against IEX value, thus confirming the underestimation of 
the activity value in the homogenate fraction.  
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The values obtained for the biotin-TVQQEL assay (Table 4. 5) showed similarities 
with the final values obtained using the biotin cadaverine incorporation assay, as the 
final fold purity for the former was 450 and the final yield gave very similar values 
with 110 % when compared against homogenate and 41.7 % when compared against 
the IEX fraction. It is interesting that using the biotin-TVQQEL assay, the raw values 
obtained for the absorbance were very low, indicating that it was near the limit of the 
activity detection, thus suggesting that it is less sensitive than the biotin cadaverine 
incorporation assay. The final activity values obtained with this process were higher 
than those previously obtained by Folk and Chung (1985) and by Leblanc et al., 
(1999) although the values from the method developed may involve overestimation 
due to its comparison against IEX values instead of the homogenate. 
Both activity assays gave similar values as it should be expected, although they 
measure different characteristics of TGase activity. The biotin cadaverine assay 
measures the polyamine incorporation by assaying for the acyl acceptor while the 
TVQQEL assay measures the protein crosslinking by assaying for the acyl donor.  
It has to be noticed that after the protamine step, the total activity and specific 
activity values decreased, indicating an inhibition of TGase activity due to the 
possible presence of protamine sulphate in the fraction. To examine the reduction of 
the activity, the protamine sample was dialysed, but the data obtained did not show 
any change, thus indicating that the protein/protein interaction generates an inhibition 
effect that was only removed by the HIC step. In fact, previous purification assays, 
after the protamine precipitation include an intermediate filtration step through a 
carboxymethyl cellulose resin column that is used to remove the protamine 
(Connellan et al., 1971).  
In the new purification process developed in this thesis, this intermediate filtration 
step was not performed; therefore the presence of protamine sulphate could influence 
the next step of the purification, as its interaction with TGase 2 could generate a not 
expected response affecting the yield obtained in the process. 
Fractions from the purification process were also studied by SDS-PAGE and 
Western blotting analysis. The digital images obtained (Figure 4. 4) show a decrease 
in the number of bands along the process and in the HIC fraction there was a visible 
strong band among other faint bands that corresponded to TGase 2, as it was at the 
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correct molecular weight and it was recognized by TG100 anti-TGase 2 antibody in 
the Western blotting analysis. In the image obtained by silver staining (Figure 4. 4B) 
only a single band was detected, indicating a very effective purification method. By 
contrast, in the method described by Leblanc et al., (1999) the final fraction 
contained many bands on a zinc stained SDS-PAGE gel. In the same image, staining 
of the Sigma TGase 2 sample shows the presence of a number of extra bands 
pointing to relatively low level of purity compared to the HIC purified sample. 
4.4.3. Clean up of Sigma TGase 2 by HIC 
After developing an improved purification method for guinea pig liver TGase 2, it 
was of interest to study the possibility of removing the contaminants present in the 
TGase 2 sample from Sigma-Aldrich in a single step. To perform this experiment, 
the highly specific HIC chromatography step was selected. The process was executed 
in the same way as for the three step guinea pig liver TGase purification. The 
fractions obtained from HIC were analysed by the biotin cadaverine assay and SDS-
PAGE. 
Results obtained from the activity assay are shown in Table 4. 6, where it can be seen 
that fractions 5 and 6 were the ones with the highest specific activity and fold purity. 
The fold purity values for these fractions were not as high as the values obtained in 
the purification processes of guinea pig liver and porcine brain, but it was due to the 
fact that the Sigma-Aldrich sample was already partially purified. The pool of all the 
fractions obtained from HIC showed a TGase activity recovery of ~93 %, thus 
indicating a very small loss of the enzyme.  
The main fractions were studied by SDS-PAGE and silver staining in order to 
determine their purity levels. In the digital image obtained (Figure 4. 5) the 
elimination of a number of bands that were present in the original sample was 
evident, thus indicating a purer sample which could be used in subsequent studies 
with inhibitors. Therefore, the one step cleaning method produced a TGase 2 sample 
of high purity in a simple, fast, easy and inexpensive process with high recovery 
levels and a reusable resin. 
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4.4.4. Application of the three step process to the purification of porcine brain 
TGase 
The final method developed for the purification of the guinea pig liver TGase 2 was 
applied to the purification of the porcine brain transglutaminase. This new source of 
transglutaminase was used because previous data obtained by our group showed the 
presence of possible truncated TGase 2 isoforms (Howden, 2006); therefore the new 
developed purification method was applied in order to try to obtain a purified 
hypothetical TGase 2 isoform. The data obtained for this process are shown in the 
Table 4. 7. The specific activity for the HIC purified sample and the final yields 
obtained (either compared to the homogenate or to the IEX fraction) were very low. 
This suggests a lower efficiency of the method for the purification of porcine brain 
transglutaminase. The final fold purity obtained was also very low, which indicated 
that this purification method did not generate a sample of high purity from porcine 
brain cytosol. Interestingly, the protamine sulphate step was the one in which the loss 
of TGase activity was greatest; although losses occurred in this step with the guinea 
pig liver transglutaminase, in the case of porcine TGase there was no increase in 
TGase activity after the HIC, suggesting that the loss of TGase 2 in the protamine 
sulphate precipitation step was real.  
From SDS-PAGE analysis (Figure 4. 6A) a decrease was evident in the number of 
bands after the different steps. The protamine sulphate technique was the step that 
eliminated most of the bands in the purification of TGase 2 from guinea pig liver, but 
in the digital image from the porcine protein blots probed with ab10445 anti TGase 2 
antibody (Figure 4. 6B), it was clear that the normal length isoform of TGase 2 
disappeared, which could explain the decrease in the activity measurements after this 
step. The loss of TGase 2 in the protamine sulphate step indicated a difference 
between the isoforms of guinea pig liver and porcine brain, as the enzymes behaved 
differently in the precipitation step. The difference could be associated with the 
species of origin or the tissue from which TGase 2 was extracted.  
Interestingly, some other bands were recognized by the antibodies indicating either 
the presence of fragments, other TGase isoforms or a cross reaction with other 
proteins that contain a similar antigenic sequences. Of particular note was the 
detection of a ~25 kDa band throughout the process as well as its enhancement in the 
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last stage of the purification, suggesting an increase in its concentration. Previous 
studies have described the presence of truncated isoforms of TGase 2 in human 
cultured erythroleukemia cells (HEL) (Fraij and Gonzales, 1996; Fraij et al., 1992) 
and in human brain (Citron et al., 2002; Antonyak et al., 2006). Two more splice 
variant isoforms that miss the C-terminal end but with a similar molecular weight as 
the full length isoform, have been identified in human leukocytes, endothelial cells 
and vascular smooth muscle (Lai et al., 2007). It was also interesting that blots 
probed with CUB-7402 exhibited a ~45 kDa cross-reactive band in the Western 
blots. This band showed high reactivity in the IEX fraction but disappeared in the 
HIC step.  
Each fraction from the purification process was also analysed by Western blotting for 
the presence of TGases 1 and 3. The results obtained did not show any trace of 
TGase 1, although its presence at a very low concentrations should not be 
discounted. On the other hand, TGase 3 could be present in all the fractions 
(Appendix: Figure 6) as there was a cross-reactive band around 50 kDa which could 
be one of the fragments generated from the cleavage of the isoform. There were no 
traces of a smaller fragment (27 kDa) which did not allow confirmation of the 
presence of active TGase 3 (Ahvazi et al., 2002; Kim et al., 1990). However, this 
absence of the small fragment could be due to a rapid degradation or to the inability 
of the antibody to recognise the small fragment. The presence of TGase 3 in all the 
fractions suggests that this isoform could be the responsible of the activity detected 
in the final stages of purification of TGase from porcine brain.  
The labelled bands in Figure 4. 6A were analysed by MALDI-TOF mass 
spectrometry and, as commented in section 4.3.2. none of them corresponded to any 
isoform of TGase. Therefore it seems possible that the signals obtained from both 
antibodies were due to a non-specific cross reactivity, although the possibility of the 
presence of truncated isoforms of TGase 2 cannot be discounted. Both of the bands at 
around 25 kDa in the silver stained gel were identified as 14-3-3 isoforms, which 
have been found to interact with the phosphorylated form of TGase 2 (Mishra and 
Murphy, 2006), although in the last fraction, none of the bands analysed 
corresponded to this isoform. However as TGase 2 was not detected in the last stages 
of purification it could be hypothesized that TGase 3 could also be capable of 
binding 14-3-3 isoforms. 
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Taking all the results together, it can be concluded that this method was not effective 
in the purification of TGase 2 from porcine brain. This process showed to be very 
complex, as it has to take in account that the levels of TGase 2 in porcine brain are 
much lower than in guinea pig liver. It is also very important to consider the possible 
presence at low levels of different TGase isoforms in the porcine brain as the 
existence of at least TGase 1, TGase 3 (Krasnikov et al., 2005) and TGase 6 
(Aeschliman and Hadjivassilliou, 2008) in the brain have been described. Therefore, 
the possible presence of these isoforms that share similar characteristics to TGase 2 
together with the low amounts of TGase 2 makes this purification a very difficult 
process. It has also to be borne in mind that although all mammalian TGase forms 
have a very similar structural homology, they show differences (Griffin et al., 2002). 
TGase 2 isoform also shows discrepancies among different species as it does not 
have an exact aminoacid sequence homology in all of them (Gentile et al., 1991). 
Also, it has been suggested that although rat brain TGase shares major characteristics 
with TGase 2 enzyme, it is distinct, as it reacts weakly with guinea pig liver and 
human anti-TGase 2 antibodies (Ohashi et al., 1995). Thus, the differences among 
TGase 2 from different species could also explain the different results obtained in the 
purification method of TGase 2 from two different sources, indicating that the new 
developed method is not suitable for the purification of TGase 2 from porcine brain. 
As a future work, it would be of value to study the purification of porcine brain 
TGase 2 using other methods previously described and also using the MMC resins. 
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5.1. Introduction  
5.1.1. Esterase inhibitors as pesticides 
Pesticides are used to control, avoid or mitigate pests. They can be classified in 
different groups, organophosphates (OPs) being one of the most widely used. OPs 
act by inhibiting esterase enzymes by phosphorylating the serine residues present in 
the active sites of the enzymes (O‟Callaghan, 2003). One of the most important 
enzymes affected by OPs is acetylcholinesterase (AChE), although delayed OP 
toxicity is also related with the inhibition and „aging‟ of another esterase molecule, 
neuropathy target esterase (NTE) (Costa, 2006).  
5.1.1.1. Neuropathy target esterase inhibitors 
Some OPs such as tri-ortho-tolyl phosphate (TOTP) or phenyl saligenin phosphate 
(PSP) are able to „age‟ NTE, generating a condition known as organophosphate-
induced-delayed-neuropothy (OPIDN) (Costa, 2006). The neurological characteristics 
of this condition are the degeneration of axons from the spinal cord and peripheral 
neurons, although some other regions of the brain are affected (O‟Callaghan, 2003). 
Cytoskeletal reorganization and the disruption of Ca
2+
 homeostasis (El-Fawal and 
Ehrich, 1993) are also characteristics of this condition. 
Studies performed by our group have indicated that sublethal concentrations of PSP 
inhibit neurite outgrowth in neuronal cells (Hargreaves et al., 2006) and also 
provokes a decrease in TGase activity when applied directly to the cytosol of human 
hepatic cells and neuroblastoma mouse cells (Harris et al., 2009). This effect could 
be due to different reasons, one possibility being a possible direct interaction 
between PSP and TGase 2. 
5.1.1.2. Acetylcholinesterase inhibitors 
The main target of OP pesticides is the enzyme AChE, although not all OPs are 
potent inhibitors. The widely used pesticide chlorpyrifos (CPF) expresses its toxicity 
by inhibiting AChE through its metabolite chlorpyrifos oxon (CPFO) (Garcia et al., 
2001).  Studies performed by our group showed that CPF and CPFO inhibit process 
outgrowth in differentiating rat C6 glial cells and that CPFO also affects 
microtubular proteins (Sachana et al., 2008) but nothing is known about a possible 
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effect on TGase 2 enzyme, which is known to be involved in important processes in 
the neural system (section 1.6.8.).  
5.1.2. Targets of organophosphates  
Numerous studies have shown that, in addition to the above mentioned esterase 
enzymes, OPs are able to affect other molecules like muscarinic and nicotinic 
receptors, signal transduction systems and different types of enzymes that are 
involved in the metabolism of peptides, such as acetylpeptide hydrolase, which can 
be inhibited by different oxons (Costa, 2006). The literature also indicates the 
interaction of different OPs such as CPFO or diisopropylfluorophosphate (DFP) with 
human albumin (Li et al., 2006). The interaction is due to a covalent binding of the 
OPs with tyrosine 411 residue of human albumin. It is also interesting to know that 
these OPs do not age when bound to albumin, probably because the residues that 
promote aging are not present near the Tyr411 attacked (Li et al., 2006). 
As commented previously, CPF and CPFO are able to affect microtubular proteins 
(Sachana et al., 2008) and also studies performed by Prendergast and his colleagues 
have shown that low doses of CPF and DFP inhibit the polymerization of tubulin 
(Prendergast et al., 2007). Data obtained using tandem mass spectrometry and Q-trap 
mass spectrometry allowed to identify the residues affected by the reaction of the 
OPs with tubulin. Results indicated that the covalent binding sites for the OPs were 
four tyrosines and it has been hypothesized that the binding could alter the 
conformation of tubulin or GTP binding which could explain the inhibition of the 
tubulin polymerization (Grigoryan et al., 2008). 
Other studies have also reported the covalent binding of OP to tyrosine residues for 
papain (Chaiken and Smith, 1969) and bromelain (Murachi et al., 1965). 
Therefore, the fact that OPs can affect other targets makes the study of this area an 
interesting issue. Indeed, OPs are compounds that affect TGase activity (Harris et al., 
2009) although the pathway or the cause of that effect remains unclear. 
5.1.3. Compounds that affect TGase activity 
There are molecules with different functions that can affect TGase activity, 
generating diverse responses. Treatment with retinoic acid (RA) increases TGase 
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expression and activation (Antonyak et al., 2004), while antiflammins and other 
designed peptides are able to decrease TGase activity (Miele, 2003). Cystamine is 
also a recognized inhibitor of TGase activity and it has been tested as a treatment in 
some neurodegenerative diseases (Stack et al., 2008). Studies have shown that the 
protease inhibitor chymostatin is able to inhibit the activity of TGase in epidermal 
cultured cells treated with RA or the tumour promoter 12-O-tetradecanoylphorbol-
13-acetate (Kawamura et al., 1983). Also, in vivo experiments have shown that 
exposure of keratinocyte cells to the protease inhibitor pepstatin A, which inhibits 
aspartyl proteases, resulted in a reduction in TGase 1 activity. However, a possible 
direct effect of this inhibitor on TGase activity was not studied (Egberts et al., 2004). 
5.2. Aims 
The aims of the work presented in this chapter were to study direct effects of selected 
esterase inhibitors, including aspartyl protease inhibitors, on TGase activity in vitro. 
In order to study the possible effects of these agents, different preparations of TGase 
from guinea pig liver and porcine brain were used. Studies were also performed on 
commercially available TGase 2 (from Sigma) purified by hydrophobic interaction 
chromatography (HIC).  
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5.3. Results 
5.3.1. Effects of OPs on the activity of purified TGase 2 
5.3.1.1. Effects of CPF and CPFO on the activity of purified TGase 2 
This section presents data obtained on studies of the effects of a possible in vitro 
direct interaction between TGase 2, CPF and CPFO. Purified samples were incubated 
for 4 h at 37 ˚C with the toxins and then the TGase activity was analysed by the 
biotin cadaverine assay. Results expressed in Figure 5. 1 indicate an increase in the 
activity of TGase 2 (50 %) in the presence of CPF and a significant increase in the 
activity (120 %) when TGase 2 was incubated with CPFO.  
 
 
 
 
 
 
Figure 5. 1: In vitro effects of CPF and CPFO on the activity of purified TGase 2  
Purified samples of Sigma TGase 2 were pre-incubated at 37˚C for 4 h with 10 µM 
CPF/CPFO or DMSO (control) before performing the biotin cadaverine assay to 
elucidate TGase 2 activity. Values are shown as mean in % activity compared to 
control ± SEM for four independent experiments. For the statistical analysis, 
ANOVA analysis was performed with a Dunnett‟s multiple comparison post test (n = 
4, *p < 0.05). 
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In order to study the possible interaction in an environment similar to the cell 
cytoplasm, mercaptoethanol (ME) at a final concentration of 24 mM was added to 
the preincubation buffer, thus mimicking the reducing environment of the cytosol. 
The data shown in Figure 5. 2 indicate that there was a significant increase in TGase 
activity compared to the untreated controls for both toxins. The presence of CPF 
generated an increase of around 90 % while CPFO increased the activity by 120 %. 
Levels of TGase activity in the presence of CPFO were similar to those obtained 
without ME, but when ME was added to the preincubation buffer with CPF, the 
activity experienced a greater increase than its absence. Although the increase in 
TGase activity in the presence of CPF/CPFO + ME was significant when compared 
against the untreated control, the difference between the samples with or without ME 
was not statistically significant.  
 
 
 
 
Figure 5. 2: In vitro effects of CPF and CPFO on the activity of purified TGase 2  
Purified samples of Sigma TGase 2 were pre-incubated at 37˚C for 4 h with ME and 
10 µM CPF/CPFO or DMSO (control) before performing the biotin cadaverine assay 
to elucidate TGase 2 activity. Values are shown as mean in % activity compared to 
control ± SEM for four independent experiments. For the statistical analysis, 
ANOVA analysis was performed with a Dunnett‟s multiple comparison post test (n = 
4, *p < 0.05). 
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5.3.1.2. Effects of PSP on the activity of purified TGase 2 
Previous studies by our group have shown that TGase activity is also affected by 
phenyl saligenin phosphate (PSP); this OP produces a decrease in TGase activity in 
hepatic and neuronal cell lines (Harris et al., 2009). Therefore it was of interest to 
determine whether PSP had a direct effect on the purified TGase 2 enzyme. To 
elucidate the possible effect, the compound was incubated with TGase 2 at room 
temperature for 15 minutes and then the sample was analysed by the amine 
incorporation activity assay. 
The results presented in Figure 5. 3 indicate a concentration dependent decrease in 
TGase 2 activity in the presence of this compound. The decrease was visible at low 
concentration levels of PSP, although it was at 0.78 µM when the decrease became 
very significant (30 %). At the highest concentrations, it seems that reduction of 
activity remained more or less constant with a decrease of 50 % of the activity. 
 
 
 
Figure 5. 3: In vitro effects of different concentrations of PSP on the activity of 
purified TGase 2  
Purified samples of guinea pig liver TGase 2 were pre-incubated at room temperature 
for 15 min with different PSP concentrations or DMSO (control) before performing 
the biotin cadaverine assay to elucidate TGase 2 activity. Values are shown as mean 
in % activity compared to control ± SEM for three independent experiments. For the 
statistical analysis, ANOVA analysis was performed with a Dunnett‟s multiple 
comparison post test (n = 3, *** p < 0.001). 
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5.3.1.3. Effects of PSP on the activity of partially purified TGase 2 from porcine 
brain 
The direct effects of PSP on TGase activity were also studied in the partially purified 
fraction from porcine brain obtained from the ion exchange chromatography (IEX) 
step. As shown in section 4.3.3., the IEX fraction from porcine brain seems to 
contain the full length isoform of TGase 2, although it could not be the main one as 
there are different cross reactive bands for the TGase 2 antibody, therefore it is 
interesting to study the activity response to the exposure to PSP.  
The data shown in Figure 5. 4 indicate an increase in TGase activity in the presence 
of PSP. The augmentation of the activity became significant from 0.2 µM PSP. 
Interestingly, the increase in activity was related with the increase in the 
concentration of the toxin, 25 µM PSP exhibiting the highest increase in TGase 
activity (~100 %). 
 
 
Figure 5. 4: In vitro effects of different concentrations of PSP in the activity of 
partially purified TGase 2 from porcine brain 
Samples of IEX purified TGase 2 from porcine brain were pre-incubated at room 
temperature for 15 min with different PSP concentrations or DMSO (control) before 
performing the biotin cadaverine assay to elucidate TGase 2 activity. Values are 
shown as mean in % activity compared to control ± SEM for three independent 
experiments. For the statistical analysis, ANOVA analysis was performed with a 
Dunnett‟s multiple comparison post test (n = 3, * p < 0.05, ** p < 0.01 and *** p < 
0.001). 
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5.3.1.4. Effects of protease inhibitors on the activity of purified TGase 2 
As explained in the section 5.1.3., chymostatin can affect TGase 1 activity in 
epidermal cultured cells. For this reason it is interesting to study the possible direct 
effects of different protease inhibitors on TGase 2 activity. To perform this study 
seven different inhibitors present in the commercially available inhibitor cocktail 
from Sigma-Aldrich were incubated with a purified sample of TGase 2. The final 
concentrations of the protease inhibitors in the sample were, 20 µM bestatin 
(aminopeptidase inhibitor), 7.5 µM pepstatin A (aspartic proteases inhibitor), 7 µM 
[L-trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane] (E-64) (cysteine 
proteases inhibitor), 10 µM leupeptin (cysteines and serine proteases inhibitor), 0.4 
µM aprotinin (serine proteases inhibitor, but it does not affect thrombin or factor X), 
0.52 µM 4-(2-Aminoethyl) benzenesulfonyl fluoride (AEBSF) (serine proteases 
inhibitor) and 0.52 µM trypsin inhibitor, thus using the same concentrations as in the 
purification process (section 2.1.2.1.). 
Figure 5. 5 shows the activity values for TGase 2 after being incubated in the 
presence and absence of protease inhibitors and cocktail inhibitor. Data indicated a 
significant decrease (60 %) in TGase 2 activity in the presence of pepstatin A, while 
the other protease inhibitors did not have any significant effects on TGase 2 activity. 
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Figure 5. 5: In vitro effects of different protease inhibitors on TGase 2 activity 
Samples of the commercially available Sigma TGase 2 purified by HIC were pre-
incubated at 37˚C for 20 min with 20 µM bestatin (aminopeptidase inhibitor), 7.5 
µM pepstatin A (aspartic proteases inhibitor), 7 µM E-64 (cysteine proteases 
inhibitor), 10 µM leupeptin (cysteines and serine proteases inhibitor), 0.4 µM 
aprotinin (serine proteases inhibitor), 0.52 µM AEBSF (serine proteases inhibitor), 
0.52 µM trypsin inhibitor and protease inhibitor cocktail (containing all the inhibitors 
used in the assay at the same concentrations) or DMSO (control) before performing 
the biotin cadaverine assay to elucidate TGase 2 activity. Values are shown as mean 
in % activity compared to control ± SEM for three independent experiments. For the 
statistical analysis, ANOVA analysis was performed with a Dunnett‟s multiple 
comparison post test (n = 3, ** p < 0.01). 
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In order to determine whether the observed inhibition of TGase 2 by pepstatin A was 
dose dependent, a further TGase assay was performed using a pepstatin A 
concentration gradient. The data shown in Figure 5. 6 indicated a progressive 
decrease in TGase activity as the pepstatin A concentration increased. Data indicated 
a significant reduction (~40 %) of TGase 2 activity at 4.5 µM and a very significant 
decrease (~50 %) at a 72.5 µM, which would be a very high concentration for this 
protease inhibitor.  
 
 
 
 
Figure 5. 6: In vitro effects of different concentrations of pepstatin on the 
activity of purified TGase 2  
Samples of the commercially available Sigma TGase 2 purified by HIC were pre-
incubated at 37˚C for 20 min with different concentrations of Pepstatin A or DMSO 
(control) before performing the biotin cadaverine assay to elucidate TGase 2 activity. 
Values are shown as mean in % activity compared to control ± SEM for three 
independent experiments. For the statistical analysis, ANOVA analysis was 
performed with a Dunnett‟s multiple comparison post test (n = 3, *p < 0.05 and ** p 
< 0.01). 
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5.4. Discussion 
Having demonstrated an effect of CPF and CPFO on rat C6 cell differentiation and 
on TGase activity present in those cells, it was interesting to determine whether a 
direct interaction between the OPs and TGase 2 might occur. To perform this study, 
purified samples of guinea pig liver TGase 2 or from commercially available TGase 
2 purified by HIC were used.  
5.4.1. Direct effects of CPF and CPFO on TGase 2 
To study the possibility of a direct interaction between CPF/CPFO with TGase 2, the 
purified enzyme from guinea pig liver was used. The experiment was performed as 
explained in section 5.3.1.1. The results shown in Figure 5. 1 suggest that an in vitro 
assay and under the conditions of the experiment, both toxins promoted an increase 
in the amine incorporation function of the enzyme, the oxon metabolite of CPF being 
the one that generated the more significant increase. In presence of CPF, the increase 
in TGase 2 activity was not significant, this could be due to the possibility that CPF 
interacts with different regions of the TGase 2 sequence than CPFO does, therefore 
generating different activity level responses. 
The assay pre-incubation was also performed in the presence of ME in order to 
mimic the reducing conditions present in the cytosol of the cell where the toxins 
would interact with TGase 2. The data obtained for this experiment (Figure 5. 2) 
indicate a statistically significant increase in TGase activity in the presence of both 
toxins. These data suggest that under cellular reducing conditions, the interaction 
between the toxins and TGase 2 could be favoured, supporting the hypothesis that 
TGase 2 is a direct target for both CPF and CPFO. Other non cholinergic targets 
have been suggested for these compounds; for example, it has been suggested that 
they can bind G-proteins coupled with membrane receptors, AC and G-proteins 
alone, although this phenomenon is not fully understood (Auman et al., 2000; Huff 
and Abou-Donia, 1995). The fact that both CPF and CPFO are selective neurotoxins 
that induce unique effects on brain tissue (Auman et al., 2000), suggests that these 
compounds may exhibit neurotoxicity by acting on either neural specific targets or 
on more widespread proteins that have unique functions in nerve tissue. 
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The data presented in this chapter suggest a possible direct interaction of CPF and 
CPFO with TGase 2 that could generate a change in the enzyme making it more 
active. This increase in activity could be due to a conformational change in the 
enzyme making it more active and/or altering its response to intracellular regulators 
such as Ca
2+
 or GTP. It is interesting to note that, when the activity was analysed 
from the cell extract after 24 hours exposure, CPF treatment generated a higher 
increase in TGase activity, whereas in the assay with purified TGase 2, CPFO 
treatment generated a larger increase in activity. This difference could be explained 
by the fact that CPFO is more selective for AChE in crude extracts than CPF, but it 
could also be due to differences in the mechanism of the possible interaction between 
the OPs and the TGase 2, as the experiments were performed using TGase 2 from 
two different species and organs, such as guinea pig liver and rat glial cells. Studies 
have shown that although rat brain TGase share major characteristics with TGase 2, 
it shows differences (Ohashi et al., 1995), and it has also been described that TGase 2 
isoforms do not have an exact aminoacid sequence homology among different 
species (Gentile et al., 1991). Thus, the data obtained using the purified guinea pig 
liver TGase 2 has to be carefully compared with the data obtained from the rat glial 
cell extract. In order to obtain a more comparable and robust data, a purified TGase 2 
sample from rat brain should have been used. 
The “leaving group” of the OPs (Figure 1.7) interacts with the esterase molecules 
generating a phosphorylation on the hydroxyl group of the serine in the active site 
(Costa, 2006), but when OPs interact with other molecules that are no primary 
targets, they usually bind to tyrosine residues as for albumin and tubulin (Li et al., 
2006; Grigoryan et al., 2008). In the case of the possible interaction between 
CPF,CPFO and TGase 2, it could be hypothesized that these OPs interact with 
tyrosine residues of the enzyme, but as any study has been performed it can not be 
discarded the option of the interaction with other residues. In order to get more data 
about this possible interaction, it would be interesting to perform mass spectrometry 
studies in a similar way as described by Li or Grigoryan (Li et al., 2006; Grigoryan et 
al., 2008). 
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5.4.2. Direct effects of PSP on TGase 2 
PSP is an active congener of saligenin cyclic-o-tolyl phosphate (SCOTP) which is 
the metabolite of tri-ortho-cresyl phosphate, an OP used in aviation fluids (De Nola 
et al., 2008). PSP was previously shown by our group to modulate TGase activity in 
neuronal and hepatic cell lines (Harris et al., 2009). In order to study a possible direct 
interaction between PSP and TGase 2, activity assays were performed using the 
purified TGase 2 from guinea pig liver. The results obtained from this experiment 
(Figure 5. 3.) indicate a dose dependent decrease in the activity of TGase 2 in the 
presence of PSP. These data corroborate the results obtained by our group when the 
cytosol from N2a neuroblastoma cells and HepG2 cells were exposed to PSP and 
TGase activity suffered a significant decrease (Harris et al., 2009). The data shown in 
this experiment suggest a possible direct interaction between PSP and TGase 2, 
indicating that the enzyme could be a target for different OPs. However, it is curious 
to note that, in the presence of PSP, the activity of TGase 2 suffered a decrease but in 
the presence of CPF or CPFO the activity was enhanced, thus indicating that TGase 2 
was affected in different ways depending on the OP used. Further work to determine 
whether such differences reflect distinct target sites for the CPF/CPFO and PSP 
would be worth while. 
The effects of PSP on TGase were also analysed in the ion exchange chromatography 
(IEX) fraction obtained in the porcine brain purification process (section 4.3.3.) 
because previous experiments with porcine brain cytosol extracts showed a 
stimulation dose response effect on TGase activity (Howden, 2006). This IEX 
fraction was analysed by Western blotting and showed to contain TGase 2 although 
at a very low levels (Figure 4.6). Interestingly, the results obtained (Figure 5. 4) 
indicate that PSP generated an increase in the activity of the enzyme. However, care 
should be taken when considering the effects of 25 µM PSP as this concentration 
would cause significant cell death. Previous studies by our group showed that 3 µM 
or even 6 µM PSP could be applied to the cells without causing a significant 
decrease in viability (Harris et al., 2009). At these concentrations, the data obtained 
in this thesis show that there was still a significant decrease of activity in the case of 
guinea pig liver TGase 2 and a significant increase in the case of porcine brain TGase 
activity. 
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It is curious that PSP generates different responses in the activity of the enzyme 
depending on the sample source. These differences could be due to species or tissue 
differences in the sequence, regulation of TGase or presence of other TGase 
isoforms. For example, the data obtained shows the possible presence of TGase 3 in 
the porcine brain IEX fraction (Appendix: Figure 6) and other studies have indicated 
the presence of TGase 1, TGase 3 and TGase 6 in human brain (Kim et al., 1999; 
Aeschliman and Hadjivassilliou, 2008). Therefore, they could also be present in 
porcine brain as discussed in chapter IV, as well as a yet unidentified TGase variants. 
In the case that the bands found at different molecular weights on blots probed with 
CUB-7402 were really TGase 2 isoforms, their different conformations could be 
responsible for the dissimilar response to PSP exposure, although it is just a 
hypothesis as there are no evidences to support this statement.  
It is important to bear in mind that the porcine brain IEX fraction is not a pure TGase 
2 sample and that TGase 2 isoforms differ among species, facts that make very 
difficult to draw valid conclusions about the different TGase activity responses to 
PSP exposure shown in this chapter. 
5.4.3. Direct effects of pepstatin A on TGase 2 
The protease inhibitor cocktail used in the purification process contains several 
different molecules that inhibit the effects of different types of proteases and, as 
explained in the introduction (section 5.1.3.), studies have shown that TGase activity 
can be affected by chymostatin (Egberts et al., 2004). For this reason it was 
interesting to study possible direct effects of the protease inhibitor cocktail or any of 
its compounds on TGase 2 activity. The assay was performed using the commercially 
available TGase 2 from Sigma-Aldrich purified by HIC, as it is the purest sample 
available and the results reflect a real effect on the activity. 
As TGase assays performed in the presence of protease inhibitor cocktail indicated a 
significant but small decrease in activity (Appendix: Figure 7), all of the components 
of the cocktail which includes bestatin (chemical compound), pepstatin A 
(hexapeptide), E-64 (chemical compound), leupeptin (tripeptide aldehyde), aprotinin 
(basic single chain polypeptide), AEBSF (sulfonyl fluoride molecule) and trypsin 
inhibitor (monomeric protein) were analysed individually at the same concentration 
as in the cocktail, to determine which inhibitor or inhibitors were responsible for the 
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observed reduction. The data obtained with each inhibitor compound (Figure 5. 5) 
showed a significant decrease in the activity only when the aspartic proteases 
inhibitor pepstatin A was present in the solution. Pepstatin A is a hexa-peptide 
(Figure 5. 7) that contains two residues of the unusual aminoacid 4-amino-3-
hydroxy-6-methylheptanoic acid (statine) (Marciniszyn et al., 1976a,b). It is a 
reversible inhibitor in which statine is the responsible of the inhibition effect, as the 
hydroxyl group of statine binds to the two catalytic aspartyl residues, Asp 32 and 
Asp 215 (Marciniszyn et al., 1976a,b; Polgar, 1987). 
 
 
 
 
Figure 5. 7: Pepstatin A structure 
The complete sequence of the aspartic proteases inhibitor pepstatin A is form by 
isovaleryl-L-valyl-L-valyl-statyl-L-alanyl-statine. Red arrows point to the couple of 
unusual aminoacid statine. 
 
The rest of the protease inhibitor cocktail components did not show any effect 
compared to the control, although the E-64 inhibitor promoted a slight but not 
significant decrease in the activity. E-64 (Figure 5. 8) is a potent irreversible cysteine 
proteases inhibitor that acts by binding its trans-epoxysuccinyl group to the active 
thiol group of the cysteine proteases forming a thioeter linkage (Katunuma and 
Kominami, 1995; Sreedharan et al., 1996). 
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Figure 5. 8: E-64 inhibitor structure 
The epoxysuccinyl group (active moiety) pointed by the red arrow is the responsible 
of the inhibitory effects of the molecule. 
 
TGases show similarities in the catalytic triad and reaction mechanism with papain 
(EC 3.4.22.2) and papain-like cysteines proteases (Fesus and Piacentini, 2002), thus, 
it is interesting that pepstatin A generates a high decrease in TGase activity while E-
64 or Leupeptin which inhibit cysteine proteases do not have a significant effect.   
Leupeptin does not generate any change on TGase 2 activity probably because is not 
able to recognize the active site cysteine of the enzyme and although E-64 do not 
react with cysteine residues in several other enzymes (Hanada et al., 1978; Hashida 
et al., 1980), it generates a small decrease on TGase 2 activity. 
In further experiments the effect of pepstatin A concentration on TGase 2 activity 
was also studied. The results (Figure 5. 6) showed a decrease in TGase activity as the 
concentration of the inhibitor increased. At 72.5 µM pepstatin A, the inhibition of 
TGase 2 activity was around 50 %, while recognized TGase inhibitor compounds 
such as R283 provoke a ~95 % inhibition at a similar concentration. 
Taken together the data suggest that TGase 2 could be a possible target for pepstatin 
A, which is an inhibitor of acid proteases. These effects could be due to some 
similarities between TGase 2 and the acid proteases in their conformations and in the 
sequence region that is attacked by pepstatin A. It is interesting to note that previous 
in vivo studies have shown that the exposure of keratinocyte cells to pepstatin A 
generates a decrease in TGase 1 (Egberts et al., 2004). The study suggested that the 
decrease was due to the inhibition of cathepsin D by pepstatin A, although a possible 
direct effect of this protease inhibitor on TGase 1 was not studied. Thus, after the 
suggestion of an inhibition of TGase 2 activity by pepstatin A presented in this 
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thesis, it could be hypothesized that the decreased observed in TGase 1 activity could 
be also associated to a direct attack by the inhibitor, although there are no evidences 
to help support this theory. 
It has to be remarked that the effects were studied on a pure TGase 2 sample, which 
could facilitate the attack of pepstatin A as its primary targets are not present. The 
effects of pepstatin A on TGase 2 were also studied in the IEX sample from guinea 
pig liver where the results did not show a significant change (Appendix: Figure 8), 
although there was a detectable decrease in TGase activity. The effects of pepstatin 
A on TGase activity were studied after the purification process was performed, thus 
the protocol of the purification method contains the use of the protease inhibitor 
cocktail. Taken all the data together, it has to be borne in mind a possible impact on 
TGase activity data and the potential effects in the purification process due to the 
possible direct interaction with TGase 2.    
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6.1. Introduction 
6.1.1. Externalization of TGase 2 
The externalization of TGase 2 is still an unresolved issue. It is known that TGase 2 
needs its tertiary structure in the active region to be externalized (Balklava et al., 
2002) and that it is not unspecifically released. Studies have hypothesized that the 
enzyme is released from the cells by interacting with fibronectin (FN) or passively 
through breakages present in the plasma membrane (Gaudry et al., 1999). It has also 
been suggested that the trafficking of TGase 2 to the cell surface could be performed 
by heparan sulfate proteoglycans (Scarpellini et al., 2009). 
Another way to release TGase 2 into the extracellular matrix could be through the 
exosomal pathway. This option has not yet been studied and could be an important 
step to understand the externalization process of TGase 2. 
6.1.2. Exosomes 
Exosomes, which are flat sphere vesicles with a ‘saucer-like’ morphology and 
restricted by a lipid bilayer, are generated by invagination and budding of the 
membrane from the late endosomes. Exosomes are small vesicles (30-100 nm in 
diameter) which are localized inside the late endosomes or multivesicular bodies 
(MVBs) that can fuse with either lysosomes degrading all their content or the plasma 
membrane releasing the exosomes into the extracellular area (Thery et al., 2002).  
Exosomes have an endosomic origin, which means that there are typically no 
proteins from mitochondria, nucleus or endoplasmic reticulum present in them 
(Keller et al., 2006; Mears et al., 2004). This indicates a restriction in the range of 
protein origins to mainly those from the cytosol and the plasma membrane (Keller et 
al., 2006). 
Numerous studies have shown that exosomes contain a wide diversity of proteins, for 
example cytoeskeletal proteins such as tubulin, actin and cofillin that could be 
involved in the formation of the exosomes, as well as annexins and RAB proteins, 
which are associated with the traffic of vesicles and intracellular membrane fusion 
(Thery et al., 2001). They also contain molecules involved in signal transduction 
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such as protein kinases, 14-3-3 and G proteins (Thery et al., 2001). Metabolic 
enzymes, heat shock proteins and tetraspanins have also been detected in the 
exosomes (Thery et al., 2001; Faure et al., 2006). The process by which the proteins 
are recruited into the MVBs is still not known, although in various cases some 
signals have been identified for the trafficking of MVBs (Keller et al., 2006).  
The lipid composition of exosomes has been studied in different cell types. Some 
phospholipid molecules such as phosphatidylserine (PS), phosphatidylcholine (PC), 
phosphatidyethanolamine (PE) are present in the exosomes but sphingomyelin (SM) 
is more enriched in the vesicles (Subra et al., 2007). 
Several functions have been suggested for exosomes, one of which is intercellular 
communication, via transfer of material between cells (van Niel et al., 2006). This 
function can be performed with either direct cell contact or no contact. Another 
function is the elimination of membrane proteins that are no longer required by the 
cells, thus providing an alternative for lysosomal degradation (Pan et al., 1985). 
Studies have also shown that exosomes secreted by Eppstein Barr virus transformed 
B cells can also act as immunological mediators by stimulating T cells (Raposo et al., 
1996). 
The secretion of exosomes has been described in different types of cells, such as 
reticulocytes (Johnstone et al. 1987), mast cells (Raposo et al., 1997), platelets 
(Heijnen et al., 1999), intestinal epithelial cells, tumour cells (Fevrier and Raposo, 
2004) and neural cells such as mouse N2a neuroblastoma cells (Rajendran et al., 
2006), N9 microglial cells (Potolicchio et al., 2005) and rat PC12 
pheochromocytoma cells (Yuyama et al., 2008). It is still unclear how exosome 
secretion is regulated, but recent studies have shown that p53 and the p53 regulated 
protein TSAP6 could be involved in this process (Yu et al., 2006). Given the current 
uncertainties in its mechanism of externalisation, a study of the possible presence of 
TGase 2 in the exosomes of N2a cells would help to clarify how the enzyme is 
released from the cells. 
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6.2. Aims 
The aims of this chapter were: 
a) To study the possibility of TGase 2 being exported to the extracellular matrix 
through an exosomal pathway by confirming its presence in purified 
exosomes; 
b) To determine whether the TGase 2 detected is located on the outer surface 
and/or inside the exosome vesicle. 
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6.3. Results 
6.3.1. Characterization of exosomes 
To obtain a purified exosomal fraction, the pellet obtained from growth medium 
centrifugation was applied to a sucrose density gradient. Three different sucrose 
molarity fractions were used as described in Table 6. 1. 
 
 
 
Table 6. 1: Composition of sucrose density gradient for exosome enrichment  
Table showing the different characteristics of the sucrose gradient fractions used in 
the purification of exosomes.
 
 
Previous studies have shown that exosomes are detected in the fractions with a 
density (g/cm
3
) between 1.08 and 1.2 approximately (Faure et al., 2006; Rajendran et 
al., 2006). Therefore, as in this experiment only three different sucrose gradient 
fractions were used, exosomes should be found in the middle fraction because the 
bottom fraction is too dense to contain the exosomes and the top one is very light. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molarity 
(M) 
Density 
(g/cm
3
) 
Refractive 
index 
% by 
weight 
Fractions     
Bottom 2.5 1.31 1.45 65 
middle 1.25 1.16 1.39 37 
top 0.1 1.01 1.33 3 
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The fractions obtained from the sucrose gradient were analysed by Western blotting 
in order to detect the presence of exosomal markers. For this reason, the blot was 
probed with anti-flotillin 1 antibody, which has been shown to be highly enriched in 
exosomal fractions (Rajendran et al., 2006; Lespagnol et al., 2008). 
The results present in Figure 6. 1 show an enrichment of flotillin 1 protein in the 
middle fraction of the sucrose gradient, thus indicating the possible presence of 
exosomes in this fraction, which would corroborate the above expressed idea. 
 
 
 
            Std   LYS         P             BF          MF         TF 
 
 
 
 
Figure 6. 1: Western blotting analysis of flotillin 1 in the exosomes produced by 
N2a cells 
Protein extracts (10 µg) from different fractions of the sucrose gradient and a lysate 
fraction of mitotic N2a cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown are blots probed with anti-flotillin 1 antibody for N2a cells lysate 
(LYS), sucrose gradient pellet (P), bottom fraction (BF), middle fraction (MF) and 
top fraction (TF). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 kDa 
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Transmission electronic microscopy (TEM) was used to obtain images from the 
purified exosomes, corresponding to the middle fraction of the sucrose gradient, by 
using direct negative staining with 1 % (w/v) uranyl acetate. Structures that resemble 
exosomes were visible, two of which are indicated with red arrows in Figure 6. 2.  
 
 
           A) 
  
 
 
 
 B) 
 
 
 
 
 
Figure 6. 2: Transmission electron microscopy images of negatively stained 
exosomes 
The exosomal fraction was diluted and loaded onto the grid before adding 1 % (w/v) 
uranyl acetate to negatively stain the suggested exosome membranes. The grid was 
then placed into the TEM and the analysis was performed. Shown are the images 
obtained at A) 100000x and B) 200000x magnification. Red arrows are pointing to 
two different possible exosomes. 
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The size of ten of the vesicles present in the digital image B from Figure 6. 2 was 
analysed by using the TEM software. Data were obtained from staining density 
graphs (Figure 6. 3) and the average size of the analyzed vesicles was around 85.8   
13.5 nm.  
 
 
 
Figure 6. 3: Profile showing the size of a typical vesicle selected from the images 
obtained from TEM 
The TEM software detects changes in contrast and generates an inverse peak which 
was selected by the box to obtain a measure of the longitude of the exosomes. 
 
 
 
Lipid analysis was also performed on the fraction containing the exosomes. The 
lipids present in the middle fraction were analysed by thin layer chromatography 
(TLC) and then stained by two different methods. 
Figure 6. 4A shows the results obtained from iodine staining, which only detects 
lipids containing double bonds of carbon-carbon. Molybdate reagent, which stains 
lipids containing phosphoric ester groups, was employed to corroborate the data 
obtained. Results from this second lipid staining method are shown in Figure 6. 4B. 
In both cases, an enrichment of SM in the exosome fraction was evident, which 
corresponds with data already published (Subra et al., 2007). 
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A)           PE     PS      PC     SM      M     N2a     EL         
 
 
 
 
B)           PE     PS      PC     SM      M     N2a     EL         
 
 
 
 
Figure 6. 4: Lipid analysis of N2a cells and exosomes  
Lipids from N2a cells and exosomes were extracted in a chloroform:methanol 
solution. 10 µl of each standard, N2a lipid extraction and 20 µl of exosome lipid 
extract were separated by TLC. Shown is the silica gel stained with A) iodine vapour 
and B) ammonium molybdate, showing phosphatidylethanolamine (PE), 
phosphatidylserine (PS), phosphatidylcholine (PC), sphingomyelin (SM), mixture of 
standards (M), N2a lipids (N2a) and exosome lipids (EL). Red arrows are pointing to 
the possible sphingomyelin spot in both stained silica gels. 
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6.3.2. Presence of TGase 2 in exosomes 
Once the possible presence of exosomes in the middle fraction of the sucrose 
gradient had been studied, the presence of TGase 2 in the sucrose fractions was then 
analyzed by Western blotting analysis. Different anti-TGase 2 antibodies and anti-
flotillin 1 antibody were used. 
The probed blot shown in Figure 6. 5 indicates the presence of TGase 2 in the middle 
fraction of the sucrose gradient. There is also a small presence of TGase 2 in the 
bottom fraction as there is a visible faint band. The blot probed with anti-flotillin 1 
shows a strong band in the middle fraction as well, thus indicating the possible 
presence of exosomes. It is curious the absence of flotillin 1 signal in the lysate and 
pellet fractions in Figure 6. 5B, as it has been previously described in these fractions 
in Figure 6. 1.  
 
A)           Std  LYS     P      BF     MF       TF 
 
           
 
 
B)             Std  LYS     P      BF     MF       TF 
 
 
 
 
 
Figure 6. 5: Western blotting analysis of TGase 2 and flotillin 1 proteins in the 
exosomes produced by N2a cells 
Protein extracts (10 µg) from different fractions of the sucrose gradient and a lysate 
fraction of mitotic N2a cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown are blots probed with A) TG100 (anti-TGase 2) and B) anti-flotillin 
1 antibody for N2a cells lysate (LYS), sucrose gradient pellet (P), bottom fraction 
(BF), middle fraction (MF) and top fraction (TF). 
 
 
 
 
50 kDa 
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Samples were also probed with CUB-7402 antibody as previous experiments 
performed by our group showed that a 50 kDa polypeptide was the predominant 
immunoreactive band in N2a cells (Howden, 2006). The data presented in Figure 6. 
6. show immunoreactivity with a 50 kDa band in the N2a lysate fraction (LYS) while 
the major immunoreactive band in the middle fraction (MF) corresponds to the 
normal molecular weight of full length TGase 2, indicating an enrichment.  
 
 
 
          Std  LYS          P             BF          MF       TF 
 
 
 
 
 
 
Figure 6. 6: Western blotting analysis of exosomal TGase 2 using CUB-7402 
Protein extracts (10 µg) from different fractions of the sucrose gradient and a lysate 
fraction of mitotic N2a cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown are blots probed with A) CUB-7402 (anti-TGase 2) for N2a cells 
lysate (LYS),  sucrose gradient pellet (P), bottom fraction (BF), middle fraction (MF) 
and top fraction (TF). 
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6.3.3. Trypsinization of exosomes 
In order to further study the localization of TGase 2 within the hypothetical vesicles, 
purified exosomes were incubated with 50 µg/ml of trypsin at 37C for different 
incubation times. After the incubation, the reaction was stopped by adding 0.5 mM 
phenylmethylsulphonyl fluoride (PMSF) (final concentration) to each sample. All the 
fractions were then centrifuged at 100,000 g for one hour and the resultant pellet and 
supernatant were analysed for the presence of TGase 2. Control fractions were 
incubated with TBS in the absence of trypsin. Figure 6. 7 shows the blots for the 
trypsin treated and untreated fractions. Trypsinized samples are shown in Figure 6. 
7A; this blot indicated the presence of TGase 2 in the pellet of the time 0 fraction. In 
the other two time incubations, the TGase 2 signal disappeared, indicating that it had 
been degraded by trypsin. Figure 6. 7B shows the control blot in which non 
trypsinized samples were loaded. In this case, TGase 2 was present in the pellet 
fractions at all time points, suggesting no degradation.  
 
                     A)       Stdd  SP   P         SP   P         SP   P          
 
 
 
 
  B)        Stdd   SP   P         SP   P         SP   P          
 
 
 
Figure 6. 7: Western blotting analysis of TGase 2 protein in exosomes treated in 
the absence or presence of trypsin 
Purified exosomes were incubated in the presence or absence of trypsin and analysed 
by SDS-PAGE and Western blotting. Shown are blots probed with TG100 (anti-
TGase 2) for A) trypsinized fractions and B) non trypsinized fractions containing SP) 
supernatant and P) pellet of the fractions incubated with trypsin for the period of time 
noted. 
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The effects of trypsin were also studied on antibody reactivity to tubulin, which is 
known to be present in exosomes and probably localized in the interior of them 
(Thery et al., 2001). The experiment was performed in the same way as explained 
above. 
The probed blots in Figure 6. 8A indicated the presence of tubulin protein in the 
pellet of the time 0 fraction. The tubulin signal disappeared from the exosome pellet 
fraction after incubation with trypsin (2 min and 10 min). Figure 6. 8B shows the 
control samples which were incubated with TBS only. In this case, the tubulin signal 
did not disappear from any pellet fraction. 
 
 
 
A)          Stdd  SP   P       SP   P         SP   P          
 
 
 
 
 
 
B)          Stdd    SP   P        SP   P        SP   P          
 
 
 
 
Figure 6. 8: Western blotting analysis of tubulin protein in exosomes produced 
treated in the absence or presence of trypsin 
Purified exosomes were incubated in the presence or absence of trypsin and analysed 
by SDS-PAGE and Western blotting. Shown are blots probed with B512 anti-tubulin 
for A) trypsinized fractions and B) non trypsinized fractions containing SP) 
supernatant and P) pellet of the fractions incubated with trypsin for the period of time 
noted. 
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6.4. Discussion 
As TGase 2 does not have a leader sequence to be externalized through the ER/Golgi 
route (Chen and Mehta, 1999; Lorand and Graham, 2003) the externalization of 
TGase 2 is still an enigmatic process. Some studies have shown that FN and integrin-
β1 could play a role in the transport of the enzyme to the cell surface (Scarpellini et 
al., 2009; Gaudry et al., 1999; Akimov et al., 2000). The possibility that was studied 
in this chapter is that TGase 2 could be externalised via exosomes. To perform this 
study, the mouse N2a neuroblastoma cell line was selected, as it was readily 
available but also because previous studies had shown that this cell line in the mitotic 
state produces a relatively high yield of exosomes (Rajendran et al., 2006).  
The first step of this study was to obtain data about the presence of exosomes in any 
fraction from the sucrose gradient. Each fraction obtained from the sucrose gradient 
centrifugation process (Table 6. 1) was analysed for the presence of flotillin 1 and the 
data showed (Figure 6. 1) an enrichment of this protein in the middle fraction, 
indicating the possible presence of exosomes. It is important to remark that only one 
exosomal marker and one cytosolic marker were used in this study, therefore it 
would have been interesting to use other vesicular markers such as alix (Rajendran et 
al., 2006), TSG101 (Yang et al., 2009) or CD63 (Masyuk et al., 2010) and cytosolic 
markers such as GAPDH (Ronnebaum et al., 2006) in order to obtain a more robust 
data. 
A TEM assay was performed using the middle fraction sample and, as seen in both 
images obtained (Figure 6. 2), there were some possible visible vesicles of about 80 
nm diameter (Figure 6. 3), which is in the size range of exosomes (50-100 nm) 
(Fevrier and Raposo, 200). This data has to be carefully considered as it was 
obtained analysing ten particles only, which does not give very robust information. 
The exosomal fraction was also analysed for its lipid composition and the results 
shown in Figure 6. 4  indicated the presence of different lipid components. The first 
dot seems to correspond to sphingomyelin which, together with cholesterol, is 
enriched in exosomes derived from human B cells (Wubbolts et al., 1993). The data 
obtained from the lipid analysis using two different developing methods showed an 
enrichment of the suggested lipid sphingomyelin in the exosomal fraction compared 
to the total lipid extraction from the N2a cells. Taken together the results obtained, 
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suggest the possible presence of exosomes in the middle fraction of the sucrose 
gradient. 
The second step of this study was to analyze the presence of TGase 2 in the sucrose 
gradient fractions obtained after the isolation process described above. Each fraction 
obtained from density gradient centrifugation (Table 6. 1) was analysed with two 
different anti-TGase 2 antibodies. The digital images obtained in Figure 6. 5 showed 
the strong presence of TGase 2 in the 1.25 M sucrose fraction and there were also 
some traces of the enzyme in the 2.5 M sucrose fraction. The bottom section of the 
blot was probed with anti-flotillin 1 antibody in order to detect a membrane protein 
that is used as a biomarker of exosomes (Rajendran et al., 2006; Fevrier and Raposo, 
2004). The digital image of this bottom half of the blot showed a clear signal of 
flotillin 1 in the 1.25 M sucrose fraction, indicating the potential presence of 
exosome vesicles. There was also a faint band in the fraction with a 2.5 M sucrose 
suggesting a small possible presence of exosomes in that fraction. The absence of a 
TGase 2 signal in the N2a lysate fraction is curious; it could be due to a low level of 
TGase 2 in the N2a cells that is barely detectable in 10 µg of total protein or to a high 
degradation. This observation, coupled with the strong signal in the middle fraction 
of the sucrose gradient indicates that there is an enrichment of TGase 2 in the 
exosomal fraction. Exosomal TGase 2 could be involved in communication between 
cells, in removal processes in order to avoid cytotoxicity phenomena or in the cell 
attachment process, in which it has been seen that cell surface TGase 2 plays an 
important role through its interaction with FN and syndecan-4 (Scarpellini et al., 
2009). 
The presence of TGase 2 in the exosomal fration was also studied by using the anti-
TGase 2 antibody CUB-7402. The image obtained from this blot (Figure 6. 6) 
showed the presence of the full length (75 kDa) TGase 2 in the middle fraction of the 
gradient, while in the lysate fraction a faint band appears at this position. It is 
important to note that the anti-TGase 2 antibody CUB-7402 has been raised in mouse 
and although it can interact with TGase 2 from mouse, its reactivity could be very 
poor. This fact, together with the possible low levels of TGase 2 or a possible high 
degradation in the N2a lysate fraction could explain the low reaction obtained in this 
fraction. However, it is curious that in the N2a lysate fraction, the main band 
recognized by CUB-7402 antibody is at ~45 kDa. It is unclear as to whether this 
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could be a truncated isoform of the enzyme, as the TG100 antibody used did not 
recognise it. So, in Figure 6. 6 the data also reflected the possible enrichment of 
TGase 2 in the exosomal fraction, thus corroborating the data found in the Figure 6. 5 
and increasing the evidence for the presence of TGase 2 in the possible exosomal 
fraction. 
In order to obtain a preliminary idea about the localization of TGase 2 in the 
potential exosomes, a trypsinization assay was performed. In theory by using trypsin, 
if TGase 2 is bound on the outer surface of the exosomal membrane it should be 
degraded by trypsin in a short period of time, whereas if TGase 2 is predominantly 
located in the lumen of the exosomes, the degradation should be null or should 
require a longer exposure time. The results obtained from this experiment showed 
that TGase 2 was detected only in the pellet fraction of all the samples from the 
control incubations (Figure 6. 7B) indicating that there was no appreciable loss of 
TGase 2. Its higher reactivity with 10 min incubation sample, could be due to an 
uneven transfer as all the pellet fractions contained the same amounts of TGase 2. On 
the other hand, the trypsinized samples (Figure 6. 7A), showed a clear decrease in the 
TGase 2 signal in pellet fractions after 2 minutes of exposure to trypsin, which could 
indicate that TGase 2 was present in the transmembrane or extracellular region of the 
possible exosomes. 
Western blots of trypsinized and not-trypsinized exosomal fraction were also probed 
with anti-tubulin monoclonal antibody B512, as this protein can be found in the 
exosomes. Tubulin is present in the cytosol of the cells, suggesting that it should be 
present in the lumen of the exosomes as seen in some schematic representations 
(Thery et al., 2002). The results of this experiment (Figure 6. 8) showed the same 
pattern as that seen on the anti-TGase 2 blots. This unexpected finding may have 
several possible explanations; it could be that most of the TGase 2 is present in the 
transmembrane region of the exosomes but also some in the lumen, hence the faint 
bands visible after exposure to trypsin. It could also be that some tubulin is present 
on the external side of the membrane of N2a exosomes, although tubulin has been 
described in exosomes from other cell lines as a component of the lumen that is 
involved in the regulation of the structure and functions of exosomes (Thery et al., 
2002). It could also be that exposure to trypsin may damage the exosomes, causing 
release of their contents which are then also cleaved by trypsin. Therefore, the data 
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obtained in these experiments were inconclusive and did not allow clear 
corroboration of any hypothesis about the localization of TGase 2 in the potential 
exosomes. It would have also been of value to monitor in this experiment another 
marker such as flotillin, to get more data that could help to locate TGase 2 within the 
potential exosomes. However, to determine the precise localization of TGase 2, it 
would be interesting and more accurate to perform immunogold labelling analysis 
with anti-TGase 2 antibody.  
It has to be borne in mind that during the study and due to technical restrictions, the 
exosomal fractions were frozen at – 20 ºC until needed. This step could affect the 
quality of the sample due to the formation of crystals that can break the vesicles 
structure, provoking the release of their content and generating a no representative 
reassembly of the damaged vesicles structure which could lead to a misinterpretation 
of the results. 
As further research related with the TGase 2 externalization, it would be interesting 
to study whether differentiating cells produce a good yield of exosomes, if TGase 2 
is also present and at what level. The results obtained from such a study could help to 
improve understanding of why cells are releasing TGase 2. TGase activity assays 
could also be performed in order to determine more fully the possible functions of 
the TGase 2 present in the exosomal fraction. 
In summary, the studies presented in this chapter allow to hypothesize with the 
presence of TGase 2 in exosomes and also open several investigation routes that 
could not be studied during this project due to certain limitations. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER VII 
 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                       CHAPTER VII. GENERAL DISCUSSION 
 
 205 
7. GENERAL DISCUSSION 
7.1. Effects of Chlorpyrifos and Chlorpyrifos oxon on glial cell 
transglutaminases 
Previous studies have shown that chlorpyrifos (CPF) causes developmental 
neurotoxicity in vivo (Crumpton et al., 1999) and that it also inhibits cell replication 
and increases oxidative stress in glial cells in vitro (Garcia et al., 2001; Qiao et al., 
2001). Data obtained by our group showed that CPF and chlorpyrifos oxon (CPFO) 
also inhibit the differentiation of glial cells (Sachana et al., 2008) and that other 
organophosphates (OPs) such as phenyl saligenin phosphate (PSP) affect TGase 2 in 
neuronal and hepatic cell lines (Harris et al., 2009). TGase 2 has also been identified 
as an important enzyme in the differentiation of neuronal cells (Tucholski and 
Johnson, 2003). All these facts made it of interest to analyse and obtain new data 
about the effects of CPF and CPFO on TGase 2 and other TGase isoforms present in 
the glial cell model used in the current work. The importance of TGase 2 in the 
differentiation process of the C6 glioma cells was also analysed by partially 
inhibiting the activity of the enzyme. 
Numerous studies have been performed using C6 cells as a glial model and it has 
been described that this model can differentiate into different cell types depending on 
the molecules used to induce that differentiation (Segovia et al., 1994; Gravel et al., 
2000; Lind et al., 2006). Results obtained and presented in this thesis indicate that C6 
glioma cells differentiate towards an astrocytic population when they are exposed to 
serum withdrawal and sodium butyrate (NaB) for 24 h.  
The detection of TGase 2 in C6 cells is in agreement with the data of Monsonego et 
al., (1997) who demonstrated the presence of TGase 2 in primary cultures of rat 
astrocytes. Furthermore, the results obtained in this thesis suggest that in mitotic and 
differentiating C6 cells, TGase 2 is mainly localized in the cytosolic fraction, 
although the use of more subcellular marker would have given more robust 
information. The presence of TGases 1, 2 and 3 has been reported in rat brain (Kim 
et al., 2000) but the molecular studies performed with mitotic and differentiating C6 
glioma cells suggest the presence of only TGase 1 and 2. The lack of positive 
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controls for the primers used in this PCR assay makes it very difficult to analyse the 
results obtained, which for this reason should be treated as preliminary findings.  
Results obtained from Western blotting analysis, indicated that TGase 1 suffered a 
decrease in its protein levels when cells were induced to differentiate, which may be 
due to a decrease in the levels of gene expression although the latter has not been 
quantified by real time RT-PCR. This suggests that TGase 1 does not play an 
important role in C6 cell differentiation towards the astrocyte phenotype, whereas 
Western blotting and RT-PCR analyses suggest that TGase 2 is the main isoform in 
C6 cells. 
TGase 2 has been described to play a number of roles in neuronal cells. For example, 
it is involved in the regeneration of axons (Chakraborty et al., 1987); it is able to act 
as a modulator of neuronal survival (Tucholski and Johnson, 2002) and is essential in 
neuronal differentiation in the SH-SY5Y model (Tucholski and Johnson, 2003). The 
studies performed in this thesis with C6 cells have shown an increase in TGase 
activity, TGase 2 protein levels and also an increase in the TGM2 expression when 
this glial model is induced to differentiate by NaB, thus suggesting a possible key 
role of TGase 2 in the differentiation of C6 glial cells into an astrocyte phenotype. 
However, another possibility for the increase in TGase activity could be the presence 
of NaB used in the differentiation process. The compound NaB is a noncompetitive 
inhibitor of histone deacetylase. It is known to affect cell growth, as NaB provokes 
the hyperacetylation of histones favouring the condensation of chromatin, which 
could be responsible for the arrest of cell growth. Data obtained from neuroblastoma 
cell models have shown that NaB increases the intracellular levels of cAMP (Prasad 
and Sinha, 1976), which results in the phosphorylation and activation of the cellular 
transcription factor CREB (Tucholski and Johnson, 2003) that contributes to 
neuronal differentiation (Mena et al., 1995; Heasley et al., 1991). The compound 
NaB can also affect the morphology of cells in culture, induce the synthesis of 
proteins and increase the specific activity of several enzymes (Kruh, 1982). Studies 
have indicated that the exposure of virus transformed human fibroblasts to NaB 
generates an increase in cellular transglutaminase activity due to the accumulation of 
the enzyme and to the stimulation of the synthesis of cellular transglutaminase 
mRNA (Birckbichler et al., 1983; Lee et al., 1987). Therefore, the effects of NaB on 
TGase enzyme could be the main reason for the changes observed on C6 glial cells 
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and presented in this thesis; although the possible role of TGase 2 in the 
differentiation process of C6 glial cells can not be discarded as SH-SY5Y model was 
also induced to differentiate in the presence of NaB and the results indicated that 
TGase 2 is essential for the neural differentiation (Tucholski and Johnson, 2003). It 
would have been interesting to study TGase 2 activity and protein levels in C6 glial 
cells induced to differentiate by other agents.  
It is well known from previous studies that CPF and CPFO are able to inhibit the 
NaB induced differentiation of C6 cells (Garcia et al., 2001; Sachana et al., 2008) 
and the data obtained in this project using an astrocytic marker corroborate these 
findings, as both toxins generate a significant decrease in glial fibrillary acidic 
protein (GFAP) protein levels compared to the differentiating control. 
 In neuronal cells, TGase 2 is essential in the differentiation because it activates AC 
directly or indirectly (Tucholski and Johnson, 2003) and studies in C6 cells have 
shown that CPF is able to disrupt adenylyl cyclase (AC) signalling (Garcia et al., 
2001), suggesting that this could be one of the pathways by which CPF and CPFO 
inhibit glial differentiation. More published data have also shown that when C6 cells 
are induced to differentiate, CPF inhibits the expression of the nuclear transcription 
factor Sp1, which is known to mediate cell differentiation in glial cells (Garcia et al., 
2001) and is a substrate for TGase 2 (Fesus and Piacentini, 2002). On the other hand, 
neither CPF nor CPFO generated any change in the protein levels of the 
oligodendrocytic marker 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase (CNPase), 
suggesting that they target mainly astrocytes, although this could simply be due to 
the major presence of this type of glial cells in the NaB differentiated C6 cells. It 
would be interesting to study the effects of these toxins on C6 cells induced to 
differentiate into oligodendrocytes, thus obtaining data that would indicate if 
astrocytes are a preferred target for CPF and CPFO. 
Published data by our group have indicated that PSP affects TGase 2 activity in 
neuronal and hepatic cells (Harris et al., 2009) and the work presented in this thesis 
indicates that CPF and its oxon metabolite promote an increase in the in vitro TGase 
transamidating and cross-linking activity, but have no effect on protein levels of 
TGase 2. As commented previously, TGase 1 is also present in C6 cells, and as the 
TGase activity assays are not specific for TGase 2 because they are based on 
common functions of the TGase family, it was of interest to use the R283 specific 
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TGase 2 inhibitor (Verderio et al., 2003; Maiuri et al., 2008) in an activity assay, to 
determine whether the activity detected was mainly due to TGase 2; the high level of 
inhibition obtained confirmed that the main contributor to activity measurements was 
likely to be TGase 2.  
The study of TGM2 expression in cells exposed to CPF or CPFO suggested that 
there was a decrease in the expression of the gene for both toxins. It is interesting to 
note that previous studies by Qiao et al. (2001) have described the inhibition of DNA 
synthesis by CPF which could also affect TGM2. There are no studies about CPFO 
effects on DNA synthesis but it could be possible that CPFO could generate the same 
effects than CPF.  
Immunofluorescence studies performed in this thesis also indicate that CPF and 
CPFO do not have any effect on the localization of TGase 2, as the enzyme seems to 
remain mainly present in the cytoplasm and diffusely distributed in the cell bodies 
and processes of C6 cells. 
TGase activity was only analysed in protein extracts, therefore in situ responses of 
TGase activity to the exposure of the toxins could be different. Even so, it could be 
hypothesized that the effects generated by the toxins on TGase 2 could be due to a 
response of the cells to the toxicity of both compounds in order to improve cell 
survival, as it is known that TGase 2 activity is able to ameliorate cell death 
(Tucholski and Johnson, 2002). Another hypothesis that may explain the increase in 
TGase activity is a possible disruption of metabolic pathways in the cells that make 
TGase 2 more sensitive to Ca
2+
 or GTP. Also, the cells could provoke an increase in 
TGase 2 activity to promote cell differentiation that is inhibited by the toxins, at least 
in part, due to their effects on the activity of AC and Sp1 nuclear transcription factor 
(Crumpton et al., 2000a; Kamata et al., 1996). Alternatively, it has been described 
that the exposure of neural cells to CPF and CPFO generates oxidative stress that 
leads to the accumulation of intracellular ROS (Crumpton et al., 2000b; Garcia et al., 
2001) which is known to generate an increase in TGase activity (Lesort et al., 
2000a). It has also been shown that the activation of TGase 2 due to cell stress 
depends on the type of environmental stress and also on the cell type, suggesting that 
unknown cellular factors could specifically regulate TGase 2 activity (Shin et al., 
2004). Increased TGase activity could also be due to a possible direct interaction 
between the enzyme and the toxins, suggesting that TGase 2 is a potential target for 
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some OPs. Of course, the disruption in the TGase activity could be associated with 
some or all of the processes mentioned above, thus not being dependent on only one 
phenomenon.  
As discussed above, TGase 1 was detected in C6 cells but its protein level decreased 
when cells were differentiating. When the effects of CPF and CPFO on the protein 
levels of TGase 1 were also analysed this isoform did not exhibit any change, thus 
indicating that neither CPF nor CPFO altered any pathway that regulates TGase 1 
protein levels. 
The role of TGase 2 in the differentiation of glial cells is still unclear, but it could be 
hypothesized to have a similar role to that in neuronal cell differentiation. 
Differentiation studies in the presence of R283 showed that partial inhibition of 
TGase did not inhibit the expression of the astrocyte marker GFAP. In fact, the level 
of GFAP was enhanced compared to the control. The presence of R283 during C6 
cell differentiation also generated a significant decrease in the levels of the 
oligodendrocyte protein marker compared to the control. This suggests that TGase 2 
could play a subtle regulatory role in the differentiation process.  
7.2. Purification of TGase 2 
As discussed earlier, it was of interest to study the possibility of a direct interaction 
between TGase 2 and the OPs. Since pure samples of TGase 2 were needed to 
perform these experiments and the commercially available TGase 2 from Sigma does 
not show a very high level of purity, a method was needed to purify TGase 2 to 
homogeneity.  
In this thesis, different purification methods were analysed in order to obtain TGase 
2 at the highest possible purity and yield in as short time as possible. Initial attempts 
using the one step purification processes performed with the new mixed mode 
chromatography resins were unsuccessful, as the yields obtained were very low and 
the TGase 2 purity was unsatisfactory. However, all three resins used removed 
several unwanted proteins, indicating that they could be used as part of a more 
complex purification process.  
In a purification scheme comprising ion exchange chromatography (IEX) followed 
by a chromatography step using hexylamine resin (HEA), hydrophobic interaction 
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chromatography (HIC) and finally Mono Q chromatography, a sample of higher 
purity but very low yield was obtained. Indeed, TGase 2 was not the main 
component as there were two more prominent bands detected on SDS-PAGE; these 
were identified as ferritin light chain and 10-formyltetrahydrofolate dehydrogenase 
(FDH), the latter of which was the most abundant protein. Both proteins show certain 
homologies with TGase 2 in different areas of their amino acid sequences; these 
similarities could explain the presence of these two proteins together with TGase 2 in 
the last step. Another hypothesis to explain the presence of FDH is a possible 
interaction with TGase 2 that could be beneficial for both enzymes, although none of 
them has been identified as a possible substrate for the other. However, it is known 
that FDH activates an apoptotic pathway that promotes the phosphorylation of p53 
(Ghose et al., 2009; Oleinik et al., 2007), which can be also phosphorylated by 
TGase 2 (Mishra and Murphy, 2006). This common process could involve an 
interaction between these two enzymes that might explain their co-purification, 
although more work is needed to determine whether a specific interaction exists. 
An alternative purification method, based on the process described by Folk and 
Chung (1985) was performed but with some modifications. The main difference is 
that Folk and Chung (1985) and the method improved by Leblanc and his co-workers 
(Leblanc et al., 1999) had a final size exclusion chromatography (SEC) step, whereas 
the method presented in this thesis, involves a final HIC step. In the case of TGase 2, 
it is known that in the presence of Ca
2+
 the enzyme undergoes a conformational 
change that exposes the active site (Griffin et al., 2002), increasing its 
hydrophobicity and probably facilitating its binding with the Phenyl-Sepharose
® 
CL-
4B resin, making this process very selective. However, the presence of Ca
2+
 activates 
TGase 2, which could generate the formation of cross-linked TGase 2complexes, that 
would produce a loss in the yield. The yield obtained at the end of this process was 
~42 % in both activity assays performed. The low activity levels detected in the 
homogenate material, due to the presence of possible inhibitors led to the estimation 
of a recovery >100 % which though unlikely was much higher than other reported 
yields. For this reason the yield was also determined by recovery from IEX. The data 
obtained in the method developed in this thesis and the data from other methods are 
shown in Table 7. 1.    
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It is appreciable that when the yield was determined by recovery from IEX, the 
values from most of the methods were around 40 % recovery, excepting the method 
developed by Brookhart et al., (1983), which involved an HIC step, showed a 50 % 
yield. Therefore the newly developed method generated a sample of a slightly higher 
yield than most. The purity of the fraction obtained from HIC was very high, as there 
were only two visible bands in the SDS-PAGE gel stained with the sensitive silver 
staining method. 
 
 
% Yield 
compared to homogenate compared to IEX 
Connellan et al. (1971) 20 40 
Brookhart et al. (1983) 31 50 
Folk and Chung (1985) 20 40 
Ikura et al. (1985) 83 - 
Leblanc et al. (1999) 31 40 
New method (2010) 110 42.5 
 
Table 7. 1: TGase 2 yields obtained in different purification processes 
 
Some of the previous methods, such as the one described by Folk and Chung (1985), 
did not include gel images that allow the assessment of purity. Other publications of 
methods such as those performed by Ikura et al., (1985) and Brookhart et al., (1983) 
contained gel images, but gels were stained with relatively insensitive methods, thus 
the possible contaminants present at low concentrations were not visible. On the 
other hand, Leblanc and his collaborators used a sensitive zinc staining method to 
stain the gel containing the column samples (Leblanc et al., 1999), and the image 
obtained showed the presence of several contaminants indicating that the purity of 
the enzyme was quite low. Also the fold purity compared to homogenate values 
obtained by Leblanc et al., (1999) was 300 while in the method described in the 
thesis it was over 600. 
The three step purification process was also applied to the purification of TGase 2 
from porcine brain cytosol. However, in this case the yield and the fold purity 
obtained were very low, indicating that this was not an appropriate method to purify 
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TGase 2 from porcine brain. Interestingly, when blots containing all the fractions 
from the porcine brain TGase purification were probed with two different antibodies 
for TGase 2, the results obtained were completely different. The antibody CUB-7402 
detected a band around 45 kDa that was not enriched by HIC, while the antibody 
ab10445 detected four different bands, although in the last stage of purification only 
one cross reactive band at around 25 kDa remained. Different truncated isoforms of 
TGase 2 have been identified in human cultured erythroleukemia cells (Fraij and 
Gonzales, 1996; Fraij et al., 1992) and in human brain (Citron et al., 2002; Antonyak 
et al., 2006); therefore, the cross reactive bands present in the blots could be these 
truncated isoforms, or they may represent non-specific cross reactivity. In fact, 
further analysis by MALDI-TOF mass spectrometry indicated that none of the bands 
analysed corresponded to TGase 2. 
One of the main bands detected by silver staining at around 45 kDa was identified by 
MALDI-TOF mass spectrometry as enolase 2 (gamma enolase). The ~25 kDa band 
recognized by ab10445 antibody was identified as 14-3-3 protein by MALDI-TOF 
mass spectrometry. The nonspecific crosslinking reaction, could be explained if the 
residues present in the conformational epitope recognised in the TGase 2 enzyme by 
the antibody, occur in the primary structure of the non specific protein. The similarity 
percentage data on its own, does not explain the nonspecific cross-reaction, as it has 
to be borne in mind that the antibodies recognise conformational epitopes in the 
tertiary structure of the protein, therefore the similarities in the primary sequence are 
not specifically related with the antibody recognition/binding.  
It is interesting to note that the TGase 3 isoform was detected by Western blotting 
analysis in all the porcine brain fractions, thus suggesting that the activity measured 
in the HIC fraction may in fact be due to this isoform. The presence of TGase 1 in 
the analysed porcine brain samples was not proved, but its presence at very low 
concentrations could not be discounted. Moreover, it may not have been detectable 
by the antibody available, as both TGase 1 and 3 isoforms have been found in human 
brain (Kim et al., 1999). 
Thus, it can be concluded that the new developed method to purify guinea pig liver 
TGase 2 gives a high purity and yield. However, the same approach does not work 
efficiently in the purification of TGase 2 from porcine brain. Furthermore, a single 
                                                       CHAPTER VII. GENERAL DISCUSSION 
 
 213 
step HIC clean up of commercially available TGase proved to be a very quick and 
effective way of obtaining highly purified TGase 2. 
7.3. Direct effects of esterase inhibitors on TGase 2  
It is well known that OPs have different targets such as acetylcholinesterase (AChE) 
and neuropathy target esterase (NTE), and that the effects caused on them lead to 
muscular convulsions and OPIDN, respectively (Costa et al., 2006). The data shown 
in this thesis and the results published by our group (Harris et al., 2009), indicated a 
deregulation of TGase activity in different cell types when they were exposed to 
OPs. In order to determine if TGase 2 is a possible direct target for some OPs that 
can generate a change in the activity of the enzyme in cultured cells, TGase 2 
purified in house from guinea pig liver and HIC purified Sigma TGase 2 were used.  
The data presented in this thesis suggest a possible direct interaction between 
CPF/CPFO and TGase 2 that provoked an increase in TGase 2 activity. While the 
oxon metabolite promoted a higher increase in the activity in vitro, both toxins 
generated a similar increase in TGase activity when cells were directly exposed. 
When the reducing environment characteristic of the cytosol was mimicked in the in 
vitro assay TGase activity for both toxins showed a significant increase compared to 
the untreated control, suggesting that under intracellular conditions the toxins could 
interact with the enzyme more effectively. Under the reducing conditions of the 
assay, the oxidation of TGase 2 may be prevented, thus avoiding conformational 
changes in the enzyme that could interfere with its activity. 
It was also interesting to study whether TGase 2 could be a target for other OPs, 
because previous experiments showed a disregulation in the TGase activity and 
TGase 2 protein levels in cells exposed to PSP (Harris et al., 2009). The data 
presented in this thesis indicate that, using in vitro assays, TGase 2 activity shows a 
PSP concentration related decrease. It is interesting that the OPs used in these 
experiments generate different effects on TGase 2 activity. These OPs although 
presenting the same general structure, can have very different substituent groups. 
Such differences could explain the different responses of the enzyme, due to the 
possible interaction of these OPs with different areas of the TGase 2 structure. 
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In view of the data obtained in this thesis, it would have been of interest to study if 
the possible changes suffered by TGase 2 due to the potential interaction with the 
toxins and how this might affect the binding of the enzyme with the different resins. 
It would have also been interesting to study the effects of the potential direct 
interaction with organophosphates on TGase 2 activity in the presence of other 
compounds known to alter this activity. 
Other in vitro studies using porcine brain cytosol to study the effects of PSP on 
neuronal TGase suggest an increase in the activity of the enzyme. This different 
effect compared to the effect on guinea pig liver TGase could be explained by the 
possible presence of other isoforms of TGase 2 in porcine brain as they have been 
identified in HEL cells (Fraij and Gonzales, 1996; Fraij et al., 1992) and human brain 
(Citron et al., 2002; Antonyak et al., 2006).  
Several studies have been focused in the potential inhibition of TGase activity by 
different compounds such as primary amines, TGase 2 cofactors, chemical inhibitors 
(Siegel and Khosla, 2007) and protease inhibitors such as pepstatin A (Egberts et al., 
2004). The fact that pepstatin A is able to inhibit TGase 1 activity and that this 
aspartyl protease inhibitor in present in the protease inhibitor cocktail used in the 
purification process, made it of interest to study a possible effect on TGase 2 activity. 
The data reported in this thesis show that pepstatin A is also able to inhibit in vitro 
TGase 2 activity in a concentration dependent manner. This information should be 
studied together with the structures of TGase 2 and the enzymes inhibited by 
pepstatin A. Similarities in the structure and in the localization of aspartyl residues 
could explain why pepstatin A is able to produce a decrease in the TGase 2 activity, 
as this inhibitor binds to the two catalytic aspartyl residues in the active site cleft of 
the aspartic proteases (Polgar, 1987). 
Although previous studies have shown that chymostatin is able to inhibit TGase 2 
activity induced by the tumour promoter 12-O-tetradecanoylphorbol-13-acetate 
(TPA) in epidermal cells (Kawamura et al., 1983), the fact that TGase 2 is not the 
main target for pepstatin A and that in IEX samples the inhibition of TGase activity 
is relatively low argues against the use of this compound to inhibit TGase activity in 
complex environments. 
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7.4. Externalization of TGase 2 from the cells 
The presence of TGase 2 in the extracellular matrix (ECM) is well established 
(Griffin et al., 2002); TGase 2 is thought to regulate interaction between cells and the 
ECM and to be associated with the stabilization of the ECM (Aeschlimann and 
Thomazy, 2000). However, it is still unclear how TGase 2 is externalised from cells. 
The results presented in this thesis support the view that TGase 2 may be 
externalised through an exosome mediated pathway. Although previous studies have 
indicated that TGase 2 could be released through splits in the membrane (Gaudry et 
al., 1999), through N-acetylation of the enzyme (Chen and Mehta, 1999) or by 
interacting with fibronectin (FN) containing vesicles (Gaudry et al., 1999), the data 
obtained in this project indicate the presence of TGase 2 in the exosomes produced 
by N2a cells, suggesting that this could be an important pathway for the 
externalisation of TGase 2. On the other hand, the results do not explain if TGase 2 is 
externalised inside the exosomes or if it is present on the surface of these membrane 
vesicles.  
Proteomic studies of exosomes from dendritic cells have indicated the presence of 
several proteins such as tubulin, actin or 14-3-3 (Thery et al., 2001) which can act as 
substrates for TGase 2 (Fesus and Piacentini, 2002; Mishra and Murphy, 2006). This 
fact could favour the presence of TGase 2 inside the exosomes, as the enzyme could 
be bound to a substrate during the formation of the vesicles. 
A hypothetical pathway to explain the presence of TGase 2 in the exosomes is 
described in Figure 7. 1. To clarify the localization of TGase 2, it would be 
interesting to perform further analysis by immunogold electron microscopy using 
anti-TGase 2 antibodies which would indicate whether TGase 2 was present on the 
exosomes surface on not.  
Further studies on TGase activity and on molecular interactions of TGase 2 in 
exosomes might help to clarify the role or roles of this externalized form of TGase 2. 
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Figure 7. 1: Overview of the possible incorporation of TGase 2 into exosomes 
Different processes are involved in the formation and fates of MVBs. The MVBs can 
fuse with the plasma membrane releasing the exosomes, or they can fuse with the 
lysosomes, degrading their content. 
 
 
 
 
 
 
 
 
 
 
7.5. Conclusions 
In conclusion, this thesis provides information about TGase 2 present in C6 glial 
cells and how the enzyme is affected by the differentiation of this type of cell into 
astrocytes, and by the presence of OPs. It also shows a new method to purify TGase 
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2 from guinea pig liver and reveals a possible direct interaction between the enzyme 
and several esterase inhibitors. Finally, it explores an externalization pathway for 
TGase 2. 
The findings showed in this thesis can be summarised as follows: 
 In the presence of NaB, C6 cells differentiate into astrocytes.  
 TGase 2 activity, protein levels and gene expression are up-regulated during 
C6 cell differentiation. 
 In the presence of CPF or CPFO, TGase 2 activity in differentiating C6 cells 
increases while the protein levels remain constant and gene expression is 
lower than the corresponding control. 
 A new purification procedure that generates a high yield and high purity 
TGase 2 from guinea pig liver was developed. However, the purification 
method cannot be applied for the purification of TGase 2 from porcine brain. 
 A possible direct interaction between guinea pig liver TGase 2 and 
CPF/CPFO in vitro generates an increase in TGase activity, while in the 
presence of PSP, TGase activity decreases. 
 The acid protease inhibitor pepstatin A is also able to partially inhibit TGase 
2 activity in a purified enzyme sample. 
 Neuronal TGase 2 could be externalized from the cells by the exosomal 
pathway. 
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1. TGM2 expression values in the different treatments 
 
 
A) 
 
 
 
 B) 
 
 
 
 
 
 
Figure 1: TGM2 relative expression values in mitotic, differentiating control 
and CPF/CPFO treated differentiating C6 cells 
Shown are the average value expression ± SEM normalized against A) GAPDH 
values or against B) normalizer values for three independent assays. For the 
statistical analysis, ANOVA analysis was performed with a Dunnett’s multiple 
comparison post test (n = 3, *p < 0.05, **p < 0.01, ***p < 0.001). 
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2. Melting curve graph obtained in a real time RT-PCR 
 
 
 
 
 
Figure 2: Melting curve analysis for real time PCR for TGM2 samples  
Three replicates for mitotic, differentiating, CPF/CPFO treated C6 cells were 
analysed by real time PCR using SYBR green chemistry. Each colour represents a 
different sample. 
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3. Reactivity of a 33 kDa band with anti-TGase 1 in mitotic and differentiating 
C6 cells 
 
i) BLOT 
 
            Std      mit      diff           
 
 
 
 
ii) QUANTIFICATION 
 
 
 
Figure 3: Western blotting analysis of a 33 kDa reactive band with anti-TGase 1  
Protein extracts (20 µg) for cytosolic fractions of mitotic and differentiating C6 cells 
were separated by SDS-PAGE and analysed by Western blotting. Shown is blot 
probed with anti-TGase 1 antibody for mitotic control (mit) and differentiating C6 
cells (diff). Densitometry of each band of ~33 kDa present in the blot was analysed 
using AIDA software. GAPDH from a re-probed blot was used as an internal control. 
Values are expressed as a percentage average ± SEM of the protein levels of the 
control (100 %), after being corrected against GAPDH values for three independent 
experiments. For the statistical analysis, a paired t-test was performed. Std represents 
molecular weight standards. 
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4. TGase 2 protein levels in lysates from mitotic, differentiating and 
CPF/CPFO treated differentiating C6 cells 
 
 
i) BLOT 
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ii) QUANTIFICATION 
 
 
 
 
 
Figure 4: Western blotting analysis of TGase 2 in C6 cell lysates 
Protein extracts (10 µg) of protein from lysate fractions of mitotic, differentiating 
and treated C6 cells were separated by SDS-PAGE and analysed by Western 
blotting. Shown is blot probed with TG100 anti-TGase 2 antibody for a) mitotic 
control (CON), untreated differentiating (DIFF), CPF treated (CPF) and CPFO 
(CPFO) treated C6 cells. Densitometry of each band present in the blot was analysed 
using AIDA software. GAPDH was used as an internal control. Values are expressed 
as a percentage average ± SEM of the protein levels of the control (100 %), after 
being corrected against GAPDH values for three independent experiments. For the 
statistical analysis, paired t-test was performed (n = 3, *p < 0.05). Std represents 
molecular weight standards. 
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5. Purification of TGase 2 from guinea pig liver in four steps 
 
 Volume 
Total 
Protein 
Activity  
Fold 
purity 
Yield 
Yield 
compared 
to IEX 
Step ml mg 
Total 
activity 
(units) 
SA 
(units/mg) 
 % % 
Homogenate 210 15246 2268 0.15 1 100  
Supernatant 175 10377 1771 0.17 1 78  
IEX 490 1327 6247.5 4.7 32 275 100 
Protamine 
sulfate 
245 196 400 2 14 18 6.4 
HIC 235.2 28.2 2658 94.2 633 117 42.5 
Mono Q 9.3 2.3 351.1 152 1017 15.5 5.6 
 
 
 
Figure 5: Purification of guinea pig liver TGase using a four step purification 
process  
Table showing the volume, protein amount, activity, specific activity, fold purity and 
yield for every step of the purification. TGase activity was analysed by the biotin 
cadaverine assay and the protein concentration was evaluated using the BCA assay. 
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6. Presence of TGase 1 and 3 in the porcine brain purification process 
 
 
A) 
 
 Std     HOM  IEX    PS      HIC        TG1 
 
 
 
 
  B) 
 
 Std    HOM  IEX    PS      HIC       TG3 
 
 
 
 
Figure 6: Western blotting analysis of TGase 1 and 3 from different steps of the 
purification process of the porcine brain 
Protein extracts (10 µg) from the different steps of the purification process and 2 µg 
from TGase 1/3 were separated by SDS-PAGE and analysed by Western blotting. 
Shown are A) blot probed with anti-TGase 1 antibody and B) blot probed anti-TGase 
3 antibody for homogenate (HOM), IEX fraction (IEX), protamine sulphate (PS) and 
HIC fraction (HIC). Std represents molecular weight standards. 
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7. Effects of protease inhibitor cocktail on commercially available TGase 2 
purified by HIC 
 
 
 
 
Figure 7: In vitro effects of protease inhibitor cocktail on the activity of 
commercially available TGase 2 purified by HIC 
Samples of the commercially available Sigma TGase 2 purified by HIC were pre-
incubated at 37˚C for 20 min with the appropriated dilution of protease inhibitor 
cocktail (1/200) or DMSO (control) before performing the biotin cadaverine assay to 
elucidate TGase 2 activity. Values are shown as mean in % activity compared to 
control ± SEM for four independent experiments. For the statistical analysis, paired 
t-test was performed (n = 4, *p < 0.05). 
 
8. Effects of pepstatin A on TGase activity of IEX sample from guinea pig liver 
 
 
 
Figure 8: In vitro effects of pepstatin A on the activity of IEX sample from 
guinea pig liver 
Samples obtained from IEX from guinea pig liver were pre-incubated at 37˚C for 20 
min with 7.5 µM pepstatin A or DMSO (control) before performing the biotin 
cadaverine assay to elucidate TGase 2 activity. Values are shown as mean in % 
activity compared to control ± SEM for four independent experiments. For the 
statistical analysis, paired t-test was performed (n = 4). 
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The organophosphorothioate compound chlorpyrifos (CPF) is a widely used pesticide, which is known to
inhibit the differentiation of mouse N2a neuroblastoma and rat C6 glioma cells. This study in focused on
the possible effects of CPF in the activity and expression of tissue transglutaminase (TGase 2) in differen-
tiating C6 cells. Cells exposed for 24 h to 10 lM CPF, which had no effect on cell viability, exhibited a sig-
niﬁcant increase in cytosolic TGase 2 activity. Western blotting analysis indicated that there was no
change in the cytosolic TGase 2 protein levels, suggesting that the enzyme was activated under these con-
ditions. When commercially available TGase 2 was incubated with CPF in vitro, an increase in activity was
also observed, suggesting that CPF might interact directly with TGase 2.
 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Organophosphate (OP) compounds are widely used as pesti-
cides in agriculture and the home. OPs are able to induce several
types of delayed neurotoxicity such as organophosphate-induced
neuropathy (OPIDN), which is still not understood at a molecular
level although some events such as inhibition of neuropathy target
esterase (NTE) (Glynn, 2003) and Ca2+ homeostasis disruption (El-
Fawal and Ehrich, 1993) have been described.
Chlorpyrifos (CPF) [O,O-diethyl O-(3,5,6-trichloro-2-pyridi-
nyl)phosphorothioate] is a very common OP, used mainly as a po-
tent insecticide due to its inhibitory effect on acetylcholinesterase
(AChE). In vivo studies have shown the ability of CPF to produce
acute toxicity (Nolan et al., 1984) and delayed neuropathy in rats
(Kaplan et al., 1993). At sub-cytotoxic levels, CPF inhibits DNA syn-
thesis (Qiao et al., 2001), cell differentiation, cell replication, en-
hances the formation of reactive oxygen species (ROS) (Garcia
et al., 2001; Slotkin, 1999) and disrupts cytoskeletal proteins
(Sachana et al., 2008) in differentiating C6 glioma cells.
Glial cells are the most abundant cells in the brain, with a range
of neuronal support functions, such as formation of the myelin
sheath and the maintenance of brain homeostasis, etc. (Allen and
Barres, 2009). Both neurons and glial cells are very sensitive to
the attack by reactive oxygen species (ROS) (Gilgun-Sherki et al.,
2001) which are overproduced in a range of neurodegenerative
diseases such as Alzheimer’s disease, Huntington’s disease and
Parkinson’s disease (Emerit et al., 2004). ROS have a number of ef-
fects at the protein level but of particular interest to the current
work is their ability to disrupt the activity of tissue transglutamin-
ase (TGase 2) (Ientile et al., 2007) which is up regulated in the
above mentioned neurodegenerative conditions (Cooper et al.,
2002). In our recent work we found that it was also disrupted when
neuronal (N2a) and hepatic cells lines (HepG2) were treated in situ
with the OP phenyl saligenin phosphate (PSP) (Harris et al., 2009).
TGase 2 is a widely expressed Ca2+ dependent enzyme that
catalyses post translational modiﬁcations, such as protein: protein
cross-linking, protein deamidation and amine incorporation into
proteins. It plays an important role in other functions, such as
wound healing, matrix stabilization, cell signalling, apoptosis and
cell adhesion (Piacentini et al., 2002). The fact that TGase 2 activity
can be disrupted by both ROS formation and the disruption of Ca2+
homeostasis, and that both of these phenomena are associated
with exposure to OPs, suggests that this enzyme could be a poten-
tial target of CPF. Thus, the main aims of the present work were to
determine the effects of CPF exposure on TGase 2 activity in CPT-
treated differentiating C6 cells and on puriﬁed TGase 2.
2. Materials and methods
2.1. Chemicals
All reagents were purchased from Sigma Aldrich, Co., Ltd (Poole,
UK) unless otherwise stated in the text. Cell culture consumables
were obtained from Sarstedt (Leicester, UK). Mouse monoclonal
anti-GAPDH (ab8245) and goat polyclonal anti-transglutaminase
2 (ab10445) were supplied by Abcam (Cambridge, UK). Horserad-
0887-2333/$ - see front matter  2010 Elsevier Ltd. All rights reserved.
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ish peroxidase conjugated anti-goat and anti-mouse immunoglob-
ulins were obtained from DakoCytomation (Ely, UK). Guinea pig li-
ver TGase 2 was purchased from Sigma–Aldrich Co, Ltd (Poole, UK).
2.2. Cell maintenance and treatment
Rat C6 glioma cells were cultured in growth medium, compris-
ing Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10%
v/v foetal bovine serum, 2 mM glutamine, penicillin (100 Units/
ml) and streptomycin (100 lg/ml) and maintained in a humidiﬁed
environment of 5% CO2 and 95% air at 37 C in a Sanyo MCO18AIC
CO2 incubator. Prior to CPF treatment, cells were seeded in T75
ﬂasks in 40 ml of growth medium at a density of 50,000 cells/ml.
After 24 h, the growth medium was carefully removed and re-
placed by serum free medium containing 2 mM sodium butyrate
in the presence and absence of 10 lM CPF. Control cells were incu-
bated with vehicle only (0.5% v/v dimethyl sulphoxide). Cells were
incubated for another 24 h before being lysed for Western blotting
analysis or harvested for enzyme assays. C6 cell differentiation and
its inhibition by CPF were monitored by the outgrowth of neurites,
as described previously (Sachana et al., 2008).
2.3. Preparation of cytosolic fractions from C6 cells
After the incubation in presence or absence of 10 lM CPF, cell
monolayers were washed and detached with ice-cold Tris buffered
saline (TBS) and harvested by centrifugation at 300g for 5 min 4 C.
Cell pellets were resuspended and washed with ice-cold TBS before
centrifugation as above. The resultant pellets were homogenised in
500 ll of ice-cold TBS containing 20 lM PMSF using a hand-held
ground glass homogeniser. Homogenates were centrifuged at
100,000g for 45 min at 4 C, after which pellets were discarded
and supernatants were retained for use in TGase 2 assays and wes-
tern blotting analysis, as described below.
2.4. TGase 2 activity assay
TGase 2 activity was monitored by amine incorporation using
the method of Slaughter et al. (1992) with some modiﬁcations. A
96-well microtitre plate (Nunc, UK) was coated overnight with
N0, N0-dimethylcasein (10 mg/ml in 100 mM Tris buffer, pH 8.5)
at 4 C. Wells were washed twice with washing buffer (150 mM
phosphate buffered saline with 0.05% v/v Tween-80) and twice
with distilled water before being blocked with 3% w/v bovine ser-
um albumin (BSA) in 100 mM Tris buffer for 1 h at room tempera-
ture. The plate was washed as described above, and 50 ll of cytosol
extract were applied to 150 ll of reaction buffer (100 mM Tris,
13.3 mM dithiothreitol and 0.9 mM biotin-cadaverine at pH 8.5)
containing either 6.7 mM CaCl2 or 1.3 mM EDTA. Incubation of
the samples for 60 min at 37 C was followed by another wash step
prior to the addition of 200 ll per well of 1% w/v BSA in 100 mM
Tris buffer containing ExtrAvidin Peroxidase (1:5000). Samples
were incubated for another 60 min before being washed, after
which 200 ll of developing buffer (100 mM sodium acetate pH 6
containing 0.31 mM 3, 30, 5, 50-tetramethyl benzidine and 0.004%
v/v H2O2) were added to each well. Colour development was
stopped after 1 min by the addition of 50 ll of 5 M sulphuric acid.
Absorbance was read at 450 nm in an AYSA Expert plate reader
(Scientiﬁc Laboratory Supplies, Nottingham, UK). A unit of activity
was deﬁned as a change in absorbance of 1.0 per hour.
2.5. Western blotting analysis
Cytosolic cell fractions were analyzed using the Bicinchoninic
Acid assay (BCA) to elucidate the protein concentration (Smith
et al., 1985). Equal amounts of protein were loaded into 10% w/v
polyacrylamide resolving gels overlaid with a 4% stacking gel for
electrophoretic separation in the presence of sodium dodecyl sul-
phate (SDS–PAGE) (Laemmli, 1970). Proteins were then transferred
onto nitrocellulose membrane ﬁlters (Towbin et al., 1979), blocked
in 3% w/v BSA in TBS and probed overnight at 4 C with primary
antibodies (anti-TGase 2 or anti-GAPDH) diluted in 3% BSA. Blots
were then incubated in 3% w/v BSA/TBS containing an appropriate
dilution of HRP-conjugated secondary antibody and developed by
enhanced chemiluminescence (Sachana et al., 2008). Intensity of
the bands was analysed using AIDA software (Fuji). Changes in
expression were normalised against reactivity with GAPDH, which
was unaffected by the toxin.
2.6. Statistical analysis
Values obtained were analysed by paired Student’s t-test to
determine the signiﬁcant differences between both treatments.
The signiﬁcance criterion was set as p 6 0.05.
3. Results
To study the possible effect of CFP on glial TGase 2, differentiat-
ing C6 cell monolayers were treated with 10 lM CPF, a sub-lethal
concentration that was previously shown to inhibit C6 cell differ-
entiation (Sachana et al., 2008). Cytosolic fractions from CPF-trea-
ted and control cells were assayed for TGase activity by the amine
incorporation assay described in Section 2 Transglutaminase spe-
ciﬁc activity in the CPF-treated cells showed a signiﬁcant increase
of approximately 50% compared to the control (Fig. 1a).
The possibility that CPF might have a direct effect on TGase 2
activity was investigated using puriﬁed guinea pig liver TGase 2 in
thebiotin-cadaverine assay. For this, pure TGase 2waspreincubated
for 4 h at 37 C in the presence of 14 mM b-mercaptoethanol, and in
the presence or absence of 10 lMCPFprior to carrying out the assay.
Under these conditions, TGase 2 activity showed a signiﬁcant in-
crease of approximately 60% compared to the control (Fig. 1b).
In order to determine whether these changes in enzyme activity
reﬂected altered levels of TGase protein expression, cytosolic ex-
tracts from control and CPF-treated cells were analysed by western
blotting. A typical digital image of probed blots is shown in Fig. 2a.
As shown in Fig. 2b, reactivity with anti-transglutaminase 2 and
anti-GAPDH was quantiﬁed densitometrically, showing no signiﬁ-
cant change in the levels of TGase 2 in the CPF-treated cells com-
pared to the control (106 ± 8.5%). Protein levels of TGase 2 were
normalised against GAPDH protein expression, which was not af-
fected by CPF exposure (97.1 ± 5.8% of control values).
4. Discussion
Previous studies have shown that, at sub-lethal concentrations
of CPF, differentiating C6 cells present cytoskeletal changes and a
decrease in the outgrowth of extensions (Sachana et al., 2008).
The fact that the CPF concentrations used in our work are signiﬁ-
cantly lower than those used to demonstrate developmental toxic-
ity of CPF in a number of other in vivo and in vitro studies (Slotkin,
1999; Garcia et al., 2001; Qiao et al., 2001) suggests that the ob-
served effect of this OP on TGase may represent an important bio-
marker of its developmental neurotoxicity. Our data obtained in
the transglutaminase activity assay of cell extracts suggested an in-
crease of 50% in the amine incorporation activity due to the effects
of CPF. Although the ability of OPs to disrupt Ca2+ homeostasis and
induce the formation of ROS could have contributed to the increase
in TGase activity, other options could not be eliminated.
Western blotting analysis indicated that TGase 2 protein
expression levels in the cytosol were unaffected by the toxin.
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Previous studies have shown a downregulation in TGase 2 activity
and protein levels in a neural cell line and upregulation of both
phenomena in HepG2 cells treated with PSP (Harris et al., 2009).
However, in the present work the observed increase in TGase 2
activity in CPF-treated cell extracts would appear to be unrelated
to altered expression levels of the protein.
Further experiments were performed to study the possibility of
a direct interaction between CPF and TGase 2. The fact that pre-
incubation of guinea pig liver TGase 2 with 10 lM CPF resulted
in an increase in activity compared to the non-CPF treated control,
gives a clear indication that CPF is capable of interacting directly
with the enzyme, resulting in its activation. Indeed, it has been
suggested before that OPs may interact directly with molecules
other than AChE or NTE (Pope, 1999). The enhancement of TGase
2 activity by CPF is consistent with the possibility that this OP
binds to a location away from the active site in a manner that en-
hances its response to activators such as Ca2+. Work underway will
help to determine whether the interaction between CPF and TGase
2 is covalent (as is the case for AChE and NTE), and to establish the
nature of the binding site(s) and biochemical properties affected.
The exact role of the increased TGase 2 activity in the cellular
response to CPF is not yet known. For example, increased TGase-
mediated cross linking may have a damaging or protective effect
on the proteins modiﬁed, a problem which is still under debate
with respect to a number of neurodegenerative diseases in which
TGase activity is up-regulated (Cooper et al., 2002). It may be that
TGase plays an important role in C6 cell differentiation and that its
over-activation is detrimental to glial development. Further study
of the role of TGase and its substrates affected by exposure to
CPF in this cellular model should help to address this question. In
summary, the data presented in this study suggested that the inhi-
bition of C6 cell differentiation by CPF is associated with increased
TGase activity caused by a direct interaction between CPF and the
enzyme, supporting the view that TGase is a novel OP target.
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50 kDa (b) Graph showing the densitometric peak areas TGase 2 and GAPDH in
treated cells expressed as a percentage of the corresponding control (n = 10).
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E-mail address: alan.hargreaves@ntu.ac.uk (A.J. HaThe main aim of this study was to determine whether sub-lethal concentrations of the organophosphate
compound phenyl saligenin phosphate (PSP) could disrupt the activity of the Ca2+-activated enzyme tis-
sue transglutaminase (TGase 2) from cultured cell lines of neuronal (N2a) and hepatic (HepG2) origin.
The results indicated that PSP added directly to cytosol extracts from healthy cells was able to inhibit
TGase 2 activity by 40–60% of control levels at sub-lethal concentrations (P0.1 lM) that were approxi-
mately 100-fold lower than their IC50 values in cytotoxicity assays. Following 24 h exposure of N2a cells
to 0.3 and 3 lM PSP in situ, a similar reduction in activity was observed in subsequent assays of TGase 2
activity. However, signiﬁcantly increased activity was observed following in situ exposure of HepG2 cells
to PSP (ca. 4-fold at 3 lM). Western blotting analysis indicated slightly reduced levels of TGase 2 in N2a
cells compared to the control, whereas an increase was observed in the level of TGase 2 in HepG2 cells.
We suggest that TGase 2 represents a potential target of organophosphate toxicity and that its response
may vary in different cellular environments, possibly affected by its expression pattern.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Apart from their ability to induce acute toxicity by the inhibi-
tion of acetylcholinesterase, many organophosphate compounds
(OPs) have been found to induce sub-cholinergic effects associated
with a range of clinical conditions including cognitive impairment,
intermediate syndrome, dippers ﬂu and delayed neuropathy
(Abou-Donia and Lapadula, 1990; HSE, 2002; Eaton et al., 2008).
Of particular interest to the present work is the condition known
as organophosphate-induced delayed neuropathy (OPIDN), the
symptoms of which appear 2–3 weeks following exposure to cer-
tain OPs, such as tri-ortho-cresyl phosphate (Abou-Donia and Lap-
adula, 1990). Little is known about the precise molecular basis of
this condition, although inhibition and aging of the enzyme neu-
ropathy target esterase (NTE – Glynn, 2003), cytoskeletal reorgani-
sation and the disruption of Ca2+ homeostasis (El-Fawal and Ehrich,
1993) are known to be early events that precede the onset ofll rights reserved.
vine serum albumin; DMSO,
m; NTE, neuropathy target
, organophosphate-induced
te; PBS, phosphate buffered
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he presence of SDS; TGase,
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rgreaves).OPIDN. Since the disruption of Ca2+ homeostasis is likely to affect
the activity of a number of Ca2+-dependent enzyme activities and
cell functions, further investigation of such potential targets would
be worthwhile.
In this respect, chemically-induced neuropathies such as
OPIDN, share a number of common features with neurodegenera-
tive disorders, such as Alzheimer’s disease (AZD), including disrup-
tion of calcium homeostasis (Thibault et al., 2007) and
disorganisation of the neuronal cytoskeleton (Selkoe et al., 1982;
Tucholski et al., 1999). Given that one consequence of disrupted
Ca2+ homeostasis in AZD and other neurodegenerative conditions
is increased activation of the Ca2+ dependent enzyme tissue trans-
glutaminase (TGase 2), and that cytoskeletal proteins forming
insoluble aggregates in AZD are known substrates for this enzyme
(Tucholski et al., 1999), it was of interest to determine whether
TGase might also be affected by exposure to OPs that induce
OPIDN.
TGase 2, also termed tissue transglutaminase (EC 2.3.2.13), is
the most abundant and ubiquitous member of a family of multiple
TGases that exhibit a range of physiological functions in different
tissues. It is a multifunctional calcium-activated enzyme that catal-
yses a number of posttranslational modiﬁcations, such as the cova-
lent cross-linking of amines into proteins and protein–protein
cross-linking, and it is implicated in the regulation of diverse phys-
iological processes such as wound healing, apoptosis, extracellular
matrix stabilisation, insulin secretion and neurite outgrowth
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2002). The latter is of particular interest here, since up-regulation
of TGase 2 activity is implicated in the pathogenesis of neurode-
generative diseases such as Alzheimer’s disease and Huntington’s
disease, due at least in part to disruption of calcium homeostasis
(Cooper et al., 2002).
A compound used for the induction of OPIDN in animal models
is tri-ortho-cresyl phosphate, which, in terms of neurodegenerative
effects, is converted into the active metabolite saligenin cyclic-o-
tolyl phosphate (SCOTP) (Eto et al., 1962; Nomeir and Abou-Donia,
1986). Phenyl saligenin phosphate (PSP), an active congener of this
metabolite, has been shown to act identically to SCOTP in its ability
to induce OPIDN in animal models (Nomeir and Abou-Donia, 1986;
El-Fawal and Ehrich, 1993) and has been found to inhibit neurite
outgrowth by the disruption of cytoskeletal proteins that are
known substrates of TGase 2 (Hargreaves et al., 2006). Given the
fact that PSP is able to disrupt calcium homeostasis (El-Fawal
and Ehrich, 1993), that the neurotoxic metabolite is produced
mainly in the liver (Nomeir and Abou-Donia, 1986), and that some
organophosphates have been reported to have hepatotoxic effects
(Kalendar et al., 2005), a comparative study of the effects of orga-
nophosphates on neural and liver cell TGase 2 would be of value.
The main aims of the present work were to study the effects of
PSP on cell viability and TGase 2 activity in cultured neuronal
(N2a) and liver (Hep G2) cell lines.2. Materials and methods
2.1. Materials and reagents
Unless otherwise speciﬁed, all reagents were purchased from
Sigma Aldrich, Co., Ltd (Poole, UK). Goat polyclonal antibody to
TGase 2 (ab10445) and mouse anti-GAPDH (ab8245) were supplied
by Abcam plc (Cambridge, UK). Horse radish peroxidase-conju-
gated secondary antibodies to goat and mouse immunoglobulins
were obtained from DakoCytomation (Ely, UK). Enhanced chemilu-
minescence (ECL) reagent was purchased from Santa Cruz Biotech-
nology via Autogen Bioclear (Calne, UK). Cell culture plastic ware
was purchased from Scientiﬁc Laboratory Supplies (SLS: Notting-
ham, UK).
2.2. Maintenance and seeding of cultured cell lines
Mouse N2a neuroblastoma and human HepG2 hepatoma cells
were cultured in growth medium, consisting of Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal
calf serum, 2 mM glutamine, penicillin (100 units/ml) and strepto-
mycin (100 lg/ml). This was carried out in a Sanyo MCO-18AIC CO2
incubator with a humidiﬁed atmosphere of 5% CO2 and 95% air.
Sub-conﬂuent cell monolayers were seeded into 24-well culture
dishes, T25 or T75 culture ﬂasks, as indicated below and incubated
for 24 h, after which the medium was changed for medium lacking
or containing a range of PSP concentrations up to a maximum of
25 lM, as indicated in Results. Stock solutions of PSP were diluted
in dimethyl sulphoxide (DMSO), which was present in all samples
including the control at a ﬁnal concentration of 0.5% (v/v).
2.3. Measurement of cell growth and viability
Cell growth and viability were assessed in 24-well culture
dishes seeded with 25,000 cells per well (in 0.5 ml growth med-
ium) by methyl blue tetrazolium (MTT) reduction assays (Mos-
mann, 1983), which were performed following 24 h incubation in
the presence and absence of PSP. A volume of 50 ll MTT (5 mg/
ml in PBS) was added to each well for the ﬁnal 30 min of incuba-tion, after which the growth medium was carefully removed and
the reduced formazan product in the cell monolayer was solubi-
lised in DMSO. The extent of the reduction reaction was deter-
mined by measurement of the absorbance of the solubilised
reaction product at 570 nm in an ASYA Expert 90 microtitre plate
reader (Scientiﬁc Laboratory Supplies, Nottingham, UK). Individual
experimental values were an average of the absorbance for 4 cul-
ture wells and each experiment was carried out on at least 3 inde-
pendent occasions (n = 3). Data were calculated as mean
absorbance expressed as a percentage of the corresponding control
value ± SEM.
2.4. Isolation of cytosol fractions from N2a and Hep G2 cells
For determination of the direct effects of PSP on TGase 2 activity
in isolated cytosol extracts, 60–80% conﬂuent cell monolayers,
grown in 40 ml growth medium, were pooled from ﬁve T75 cell
culture ﬂasks prior to homogenisation. In order to determine the
effects of in situ exposure of cells to PSP, cells were seeded at a den-
sity of 50,000 cells/ml in 40 ml growth medium. After 24 h incuba-
tion, the medium was carefully removed and replaced with fresh
medium containing sub-lethal concentrations of PSP for a further
24 h, as indicated in Results.
Following incubation in the presence or absence of PSP as de-
scribed above, monolayers were detached with ice-cold versene
and cells collected by centrifugation at 300 g for 5 min. The pellet
was then resuspended and washed by recentrifugation in ice-cold
PBS. Pellets were homogenised on ice using a hand-held ground
glass homogeniser and the homogenate centrifuged at 80,000 g
for 45 min at 4 C, after which the supernatant was immediately
used in TGase 2 assays, as described below.
2.5. Measurement of TGase 2 activity
TGase 2-mediated amine incorporation into N’N’-dimethyl
casein was monitored by the assay of Slaughter et al. (1992) with
minor modiﬁcations. Brieﬂy, 96-well Maxisorb microtitre plates
(Nunc, UK) were pre-coated overnight at 4 C with N0, N0-dimethyl
casein (10 mg/ml in 100 mM Tris buffer – pH 8.5). Four replicates
wells were prepared for each data point and each assay was re-
peated on extracts from at least 3 independent cell cultures. Wells
were blocked by incubation with 3% (w/v) BSA in Tris buffer. The
reaction mixture contained 150 ll reaction buffer (100 mM Tris
pH 8.5, 13.3 mM dithiothreitol, and 0.9 mM biotin-cadaverine)
containing either 6.7 mM CaCl2 or 1.3 mM EDTA, to which a vol-
ume of 50 ll of cytosol extract was applied. Samples were incu-
bated for 90 min at 37 C, before the labelled substrate was
probed with ExtrAvidin peroxidase (diluted 1:5000 in 1% (w/v)
BSA in Tris buffer) for a further 45 min before colour development
using 200 ll of a solution containing 3, 30,5,50-tetramethyl benzi-
dine, 0.004% (v/v) H2O2 in 100 mM sodium acetate pH 6.0. Colour
development was terminated by the addition of 50 ll 5 N H2SO4
and the absorbance read at 450 nm in an ASYA Expert 90 ll plate
reader (Scientiﬁc Laboratory Supplies, Nottingham, UK). A unit of
activity was deﬁned as a change in absorbance (450 nm) of
1.0 per h. Speciﬁc activity was expressed as units per mg protein.
2.6. Western blotting analysis of cell lysates
For this 500,000 exponentially growing cells in 10 ml growth
medium were seeded into T25 cell culture ﬂasks. After 24 h recov-
ery, they were incubated for a further 24 h in the presence or ab-
sence of sub-lethal concentrations of PSP in fresh growth
medium, as indicated in Results. Culture medium was carefully re-
moved, the cells gently rinsed with PBS and then lysed by the di-
rect application of 0.5% (w/v) SDS pre-heated to 100 C. Lysates
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incubated for a further 5 min in a heating block set at 100 C. Pro-
tein content was determined by the bicinchoninic acid assay, using
BSA as the standard (Brown et al., 1989).
Equal protein amounts (25–30 lg) were separated by polyacryl-
amide gel electrophoresis in the presence of sodium dodecyl sul-
phate (SDS–PAGE) in a 10% (w/v) polyacrylamide resolving gel
overlaid with a 4% (w/v) polyacrylamide stacking gel (Laemmli,
1970), after which they were electrophoretically transferred onto
nitrocellulose membrane ﬁlters (Towbin et al., 1979). The resultant
blots were blocked, probed with primary antibodies (CUB7402 or
B512), then incubated with HRP-conjugated secondary antibody
and ﬁnally developed using ECL reagent, as described previously
(Sachana et al., 2008). Band intensities were quantiﬁed using AIDA
software (Fuji) and expressed as a percentage of corresponding
control values. All changes were normalised to the reactivity with
B512, which is unaffected by the concentrations of PSP used in this
work (Hargreaves et al., 2006).
2.7. Statistical analysis of data
The signiﬁcance of differences from control values was deter-
mined by ANOVA and the Tukey post test, using 95% conﬁdence
limits.Fig. 1. Effects of PSP on MTT reduction in cell monolayers and TGase activity in cell
extracts. (a) N2a cells (dark) and HepG2 cells were seeded and incubated with or
without PSP, and assayed for their ability to reduce MTT as indicated in Section 2.
Shown are the mean absorbance values ± SEM for at least 4 independent experi-
ments. Asterisks indicate signiﬁcant difference compared to the corresponding
control (p < 0.05). (b) Cytosol extracts from sub-conﬂuent N2a (dark) and HepG2
(light) cells were prepared, incubated in the presence and absence of PSP and
assayed for TGase-mediated incorporation of biotin-cadaverine into N0 ,N0-dimethyl
casein, as described in Section 2. Speciﬁc activities in U/mg protein were expressed
as mean% control ± SEM for at least 3 independent experiments. Typical control
activity values were 1.1 ± 0.2 and 2.4 ± 0.2 U/mg for N2a and HepG2 cell extracts,
respectively. Asterisks indicate a signiﬁcant difference from corresponding control
(p < 0.05).3. Results
In order to determine the cytotoxic range of PSP, MTT reduc-
tion assays were performed on N2a and Hep G2 cell monolayers
as described in Section 2. As can be seen in Fig. 1, PSP inhibited
the reduction of MTT by both cell lines to a similar extent with
IC50 values of approximately 10–15 lM. In initial experiment to
determine whether PSP might act directly on TGase in cytosol ex-
tracts isolated from normal cells, dose response experiments indi-
cated that a range of sub-cytotoxic concentrations of PSP (i.e.
those showing no effect on MTT reduction) caused signiﬁcant
inhibition of TGase activity in vitro, which levelled off at approx-
imately 40% and 60% of control values at a PSP concentration of
0.1 lM for N2a and Hep G2 cells, respectively. Activity remained
relatively low and constant at higher PSP concentrations (up to
25 lM – not shown). A similar effect was observed in the TGase
2 activity of cytosol extracts from N2a cells treated for 24 h with
0.3 and 3 lM PSP in situ. However, by contrast the cytosol iso-
lated from PSP- treated Hep G2 cells exhibited increased TGase
activity by up to 4-fold at 3 lM, compared to the non PSP-treated
control (Fig. 2a).
Western blotting analysis was then carried out to determine the
effects of the same concentrations of PSP on the levels of TGase
protein in N2a and HepG2 cell lysates. As indicated in Fig. 2b, a sin-
gle major band of approximately 75 kDa molecular weight was de-
tected in blots of all cell lysates when probed with a goat
polyclonal anti-TGase 2. Densitometric analysis suggested a slight
but not signiﬁcant decrease in the levels of TGase 2 in lysates of
PSP-treated N2a cell lysates to 72 ± 13% of control values, whereas
a slight but not signiﬁcant increase in reactivity to 183 ± 70% of
control levels was observed in the case of PSP-treated HepG2 cell
lysates.4. Discussion
The data obtained from MTT reduction assays suggested that
PSP exhibited similar levels of basal cytotoxicity towards both
cell lines with signiﬁcant decreases in cell viability in the micro-
molar concentration range, N2a cells being slightly more sensi-
tive than HepG2 cells. In agreement with previous studies ofthe cellular effects of PSP (Hargreaves et al., 2006), no toxicity
was observed at concentrations of 3 lM or lower. Comparison
of IC50 values for basal toxicity and maximal TGase inhibition
following direct addition of PSP to isolated cytosol extracts indi-
cated that sub-lethal concentrations of PSP were able to directly
inhibit TGase approximately 100-fold more effectively than their
ability to inhibit MTT reduction by 50%, consistent with the
notion that sub-lethal levels of PSP are capable of inhibiting
intracellular TGase activity in both cell lines. The ability of these
concentrations of PSP to inhibit TGase, together with the known
involvement of TGase activity in neurite outgrowth (Mahoney
et al., 2000), is consistent with the possibility that modulation
of TGase 2 activity by PSP might play a role in the inhibition
of neurite outgrowth described in our previous work (Hargreaves
et al., 2006).
However, the fact that in situ exposure to selected sub-lethal
concentrations of PSP revealed a distinct pattern of TGase disrup-
tion for the two cell lines suggested that there were some differ-
ences between the molecular events involved in the cellular
responses of the two cell types in vivo. Such differences might re-
ﬂect the disruption of distinct TGase-related functions in neurons
and hepatocytes and/or the interference of PSP with different
molecular pathways that inﬂuence TGase 2 and its substrates in
the two cell types. However, another possible reason for the differ-
ent in situ exposure effects is suggested by the different trends ob-
served in the levels of reactivity of Western blots of lysates from
Fig. 2. Effects of PSP on TGase in HepG2 and N2a cells. (a) N2a (dark) and HepG2
(light) cells were seeded, incubated for 24 h in the presence and absence of PSP
prior to the extraction of cytosol, then assayed for TGase-mediated incorporation of
biotin-cadaverine into N0 ,N0-dimethyl casein, as indicated in Section 2. Data are
expressed as mean speciﬁc activity ± SEM for 3 independent experiments. Panel (b)
shows western blots of cell lysates prepared from N2a (upper panel) and HepG2
(lower panel) cell monolayers incubated in the presence and absence of selected
sub-lethal concentrations of PSP as described above. Blots were probed with a goat
polyclonal antibody to identify the major forms of TGase 2 and the positions of
molecular weight markers are indicated by arrows.
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which is consistent with the notion that altered levels of TGase 2
may account at least in part for the alterations in activity observed.
Further work will help to determine if the observed changes in
TGase levels are the result of PSP-induced alterations to the syn-
thesis and/or degradation of this enzyme. Whether or not these ef-
fects relate to the modulation of Ca2+-activated proteases such as
calpain, as previously suggested by El-Fawal and Ehrich (1993), re-
mains to be determined.
Interestingly, it has been suggested that the full length form of
TGase 2 can have a protective role against apoptotic cell death that
is associated with its transamidation activity (Antonyak et al.,
2006), whereas a C-terminally truncated splice variant of TGase 2
(TG-s) is capable of promoting apoptotic cell death independently
of this activity. Thus, it may be that different TGase 2 isoforms are
able to respond differently to PSP exposure and that the loss of
TGase 2 in N2a cells increases their sensitivity to the cytotoxic ef-
fects of PSP.
However, we cannot at this stage rule out the possibility that
other forms of TGase (e.g. TGases 1 and 3 or splice variants of
TGase 2), which are not detected using the antibody in the pres-
ent study, might also be present at different levels in the two
cell lines, and contribute to the differences observed. Nor can
we rule out the possibility that other posttranslational events,such as altered phosphorylation, oxidation, etc., of TGase or its
substrates might directly or indirectly affect the response of
TGase to PSP in situ. Furthermore, given that several OPs have
now been shown to have multiple targets in addition to acetyl-
cholinesterase and NTE (Pope, 1999), the possibility that this
compound might interact directly with TGase 2 also warrants
investigation. In summary, the results presented in this study
suggest for the ﬁrst time that TGase 2 represents a potential tar-
get of PSP toxicity in both hepatic and neuronal cell types. Fur-
ther work will help to establish the precise molecular basis of
these effects and their role in the neurotoxic and/or hepatotoxic
effects of PSP.References
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